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ABSTRACT 
Mood disorders were initially recognized as a legitimate illness in Hippocrates’ 
Aphorisms. Two of the most prevalent and debilitating mood disorders are major 
depressive disorder (MDD) and bipolar disorder (BP). While a number of studies have 
established a genetic component to these illnesses, the genomic architecture remains 
less than clear. Recently, microRNAs—small, non-coding RNAs that act as post-
transcriptional regulators of gene expression—have demonstrated dysregulation in 
psychiatric disease state. Given these data, we hypothesized that miRNAs may exhibit 
mood-disorder-dependent differential expression in the anterior cingulate cortex (AnCg), 
a brain region heavily involved in the regulation of mood. In our first set of studies we 
employed qPCR analyses of 29 miRNAs implicated in psychiatric illness in AnCg of 
patients with MDD and BP versus controls. We validated a number of miRNAs as 
dysregulated in these illnesses and subsequently identified (and validated) several 
mRNA targets of miRNAs dysregulated in disease. Finally, we demonstrated alterations 
in the steady-state levels of two of these mRNA targets.  
In a second set of studies we examined the impact of chronic stress on the 
transcriptomic network in medial prefrontal cortex (mPFC). Chronic stress is a major 
precipitant of neuropsychiatric illness and induces a number of physiological and 
genetic changes in a highly brain-region-dependent fashion. Due to this, we 
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hypothesized that chronic stress would have a significant impact on gene expression in 
mPFC, a brain region centrally involved in stress responses and regulating HPA axis 
activity. Furthermore, given that mPFC hypofunction is one of the most commonly 
observed stress-induced deficits, we hypothesized these gene changes would be 
consistent with mPFC hypofunction. By employing RNA sequencing and high-
throughput qPCR analyses, we validated a number of mRNA and miRNA transcripts as 
stress-regulated. We finally constructed a biochemical “interactome” of stress-regulated 
mRNAs using bioinformatics tools and literature screens that is consistent with chronic-
stress-induced glutamatergic hypofunction in mPFC. The work outlined in this thesis 
sheds light on transcriptomic events that occur in in human mood disorders or in animal 
models of chronic stress, which could be of clinical relevance in understanding the 
molecular architecture of mood disorders. 
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Chapter I: Introduction 
Section 1: Depression – its history, descriptions and current impact 
 
“Grief and fear, when lingering, promote melancholia.” 
-Hippocrates 
 
History and background of depression 
While depression has been recognized throughout much of human history, it was first 
classified as a distinct illness by the Greek physician Hippocrates in either the 4th or 5th 
century BC. In his Aphorisms, Hippocrates claimed depression arose from a 
preponderance of black bile based upon the four humors (the name of the illness, 
‘melancholia’, translates literally to ‘black bile’). While this characterization of a mental 
illness as having a physical basis was in many ways ahead of its time, one of its failures 
was in classifying depression as a single illness. “Depression,” or a “low” mood, is an 
imprecise term and encompasses components of multiple different illnesses. Major 
depressive disorder, seasonal affective disorder and bipolar disorder, for instance, all 
present with “low” mood as a symptom but each presents with a unique symptomatic 
profile and is treated in different ways. For the purposes of this thesis I will be focusing 
on two major types of depression: major depressive (MDD) and bipolar (BP) disorder.
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Definition of major depressive disorder 
According to the DSM-5 (American Psychiatric, American Psychiatric, & Force, 
2013), MDD is diagnosed when a patient has a collection of at least five of 
symptoms (listed below) that: 
 Co-occur for a minimum of two weeks, 
 Include either a low/“depressed” mood or anhedonia (reduced interest in nearly 
all activities), 
 “Cause clinically significant distress or impairment in social, occupational, or 
other important areas of functioning,” (American Psychiatric et al., 2013) and 
 Is not better explained by either another medical condition or substance. 
Symptoms indicative of MDD include: 
1. Depressed mood most of the day, nearly every day, as indicated by either 
subjective report (e.g. feels sad, empty, hopeless) or observation made by others 
(e.g. appears tearful). (Note: In children or adolescents, can be irritable mood.) 
2. Markedly diminished interest or pleasure in all, or almost all, activities most of the 
day, nearly every day (as indicated by either subjective account or observation). 
3. Significant weight loss when not dieting or weight gain (e.g. a change of more 
than 5% of body weight in a month), or decrease or increase in appetite nearly 
every day. 
4. Insomnia or hypersomnia every day. 
5. Psychomotor agitation or retardation nearly every day (observable by others, not 
merely subjective feelings of restlessness or being slowed down). 
6. Fatigue or loss of energy nearly every day. 
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7. Feelings of worthlessness or inappropriate guilt (which may be delusional) nearly 
every day (not merely self-reproach or guilt about being sick). 
8. Diminished ability to think or concentrate, or indecisiveness, nearly every day 
(either by subjective account or as observed by others). 
9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation 
without a specific plan, or a suicide attempt or a specific plan for committing 
suicide. 
Additionally MDD is often described in terms of “episodes”, or periods of time in which 
these symptoms are present. The duration of these episodes is highly variable, from as 
little as two weeks to multiple years in length, and their length may be inconsistent even 
within the same patient. Finally, while a diagnosis of MDD requires only a single 
episode in a patient’s life, it tends to be a recurrent illness with multiple depressive 
episodes occurring over the life of a patient. 
 
Definition of bipolar disorder 
Bipolar disorder (BP)—classically termed “manic-depressive disorder”—is another 
mood disorder that presents with major depressive episodes. The symptoms and 
diagnostic criteria are very similar to those for MDD and, in fact, BP may initially be 
mistaken for MDD due to this. A diagnosis of BP requires the presence of manic or 
hypomanic episodes--while MDD is often termed unipolar depression, a characteristic of 
BP is the oscillation between depressive and either manic or hypomanic episodes. The 
DSM-5 (American Psychiatric et al., 2013) defines a manic episode as follows: 
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1. A distinct period of abnormally and persistently elevated, expansive, or irritable 
mood and abnormally and persistently increased goal-directed activity or energy, 
lasting at least 1 week and present most of the day, nearly every day (or any 
duration if hospitalization is necessary). 
2. During the period of mood disturbance and increased energy or activity, three (or 
more) of the following symptoms (four if the mood is only irritable) are present to 
a significant degree and represent a noticeable change from usual behavior: 
a. Inflated self-esteem or grandiosity. 
b. Decreased need for sleep (e.g. feels rested after only 3 hours of sleep). 
c. More talkative than usual or pressure to keep talking. 
d. Flights of ideas or subjective experience that thoughts are racing. 
e. Distractibility (i.e., attention too easily drawn to unimportant or irrelevant 
external stimuli), as reported or observed. 
f. Increase in goal-directed activity (either socially, at work or school, or 
sexually) or psychomotor agitation (i.e., purposeless non-goal-directed 
activity). 
g. Excessive involvement in activities that have a high potential for painful 
consequences (e.g. engaging in unrestrained buying sprees, sexual 
indiscretions, or foolish business investments). 
3. The mood disturbance is sufficiently severe to cause marked impairment in social 
or occupational functioning or to necessitate hospitalization to prevent harm to self 
or others, or there are psychotic features. 
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4. The episode is not attributable to the physiological effects of a substance (e.g. a 
drug of abuse, a medication, other treatment) or to another medical condition. 
The diagnostic criteria between manic and hypomanic episodes are very similar, with 
the key distinctions that 1) elevated mood and energy must last for only 4 days (as 
compared to 1 week for a manic episode) and 2) the episode is not sufficiently severe to 
necessitate hospitalization or cause impairment. These distinctions are key, as BP is 
divided into two disorders--Bipolar I Disorder (which presents with depressive, 
hypomanic and manic episodes) and Bipolar II Disorder (which presents with 
depressive and hypomanic episodes only). 
 
Prevalence and co-morbidity of MDD and BP 
Although MDD and BP are clinically distinct and separate disorders, these illnesses 
share several unfortunate features. Chief amongst these is their high prevalence—in the 
USA, MDD and BP have a lifetime prevalence of 16.6% and 3.9%, respectively (Kessler 
et al., 2005). These illnesses are also often debilitating—while MDD and BP have a 
lower 12 month prevalence (6.7% and 2.7%, respectively), a high proportion of patients 
(30.4% and 44.8%, respectively) were classified as “serious” due to (but not limited to) 
the following: a suicide attempt with lethal intention, work disability and/or 30 or more 
days out of the year where the patient was completely unable to work and/or carry out 
normal function (Kessler et al., 2005). 
It is important to note that, while a diagnosis of MDD or BP requires only an individual 
episode over the course of a patient’s life (a fact that is reflected in the statistics listed 
above), both MDD and BP have a strong likelihood of being recurrent. Those who 
6 
 
experience a single depressive episode have a >50% chance of experience additional 
episodes, while two depressive episodes raises the chance of experiencing another to 
80% (Burcusa & Iacono, 2007). Similarly, patients diagnosed with BP are highly likely to 
experience a relapse (a recurrence of symptoms), with 40-50% experience a relapse 
within one year and between 70 and 90% experiencing relapse within five years (Gitlin, 
Swendsen, Heller, & Hammen, 1995; Lobban et al., 2010). Another potentially 
concerning observation is that the incidence of these disorders appears to be increasing 
over time (Kessler, Avenevoli, & Ries Merikangas, 2001; Kessler & Walters, 1998; 
Moreno et al., 2007), though this apparent trend may be explained by other factors such 
as greater recognition (and subsequent diagnoses) than in prior years. 
In addition to their high prevalence, patients diagnosed with these disorders often 
demonstrate co-morbidity: that is, they are likely to have one (or more) illnesses or 
conditions that co-occur with these illnesses. These comorbidities span a wide range of 
maladies and include (but are not limited to) chronic pain, migraines, cardiovascular 
illness, metabolic disorders, diabetes and stroke (Arnow et al., 2006; Horrobin & 
Bennett, 1999; Krishnan et al., 2002; Merikangas & Stevens, 1997; Van der Kooy et al., 
2007). It should be noted that, while these illnesses co-occur, whether they are 
causative (e.g. whether depression may cause stroke, or vice versa) is much less well 
understood. 
Perhaps unsurprisingly, some of the most common conditions that present as comorbid 
with MDD and BP are other psychiatric illnesses. Both MDD and BP have high 
comorbidity with anxiety disorders (Hirschfeld, 2001; Keller, 2006). Patients with either 
of these disorders are significantly more likely to abuse drugs and/or alcohol as those 
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without illness (Cassidy, Ahearn, & Carroll, 2001; Grant, 1995; Olfson et al., 1997). 
Perhaps most alarming of all are the correlations between these disorders and suicide. 
While the average suicide rate of the general population has hovered around 0.01%, the 
suicide rate of patients with mood disorders is much higher: up to 15% for patients with 
MDD, and up to 20% for patients with BP. Over two-thirds of the 30,000 reported 
suicides in the USA in 1999 were due to depression (White House Conference on 
Mental Health, 1999). Combined, this data indicates a reduction in both lifespan and in 
quality of life for patients suffering from these disorders. 
 
The economic and societal impact of depression 
In addition to their great impact on the individual suffering from these illnesses, 
depression—here used to encompass both MDD and BP—represents a sizable public 
health concern. Currently, MDD (e.g. “unipolar” depression) represents a leading cause 
of illness with over 350 million people affected and is the leading cause of disability 
worldwide (reviewed in (Ferrari et al., 2013; Reddy, 2010). The incidence of depression 
is increasing over time while the average age of onset is decreasing (Hidaka, 2012) 
revealing a concerning trend in the potential societal and economic impacts of 
depression in the coming years (see Chapter I, Clinical Connections).  
Given the prevalence and nature of these disorders, MDD and BP impose a rather large 
economic burden on society in the form of increased health care costs and reduced 
work productivity. Prior work indicates that, even after accounting for medical services 
due to non-depressive comorbid illness, patients presenting with depressive symptoms 
incur an increase of 50 to 75% in healthcare costs (Simon, VonKorff, & Barlow, 1995; 
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Unutzer et al., 1997). For BP patients this cost is projected to be even higher, with one 
study indicating an increase of 250% in healthcare costs over a sample 6-month time 
period (Simon & Unutzer, 1999). Strikingly, less than 10% of these increased costs 
were attributable to the direct treatment of depression (Unutzer et al., 1997), indicating a 
sizable drain on general medical services due to illness.  
MDD and BP also heavily impact both work productivity and likelihood of employment: 
previous studies have indicated a 2- and 7-fold increase (in MDD and BP, respectively, 
compared to age- and sex-matched general outpatient controls) in working days missed 
due to illness, while patients with BP were 40% less likely to have paid employment 
(Akiskal et al., 2000; Kessler et al., 1999; Olfson et al., 1997; Ormel et al., 1994; 
Zwerling et al., 2002). Putting numbers to the combined costs of healthcare and lost 
productivity, it is estimated that depression (in all its forms) resulted in an annual cost of 
$83 billion dollars in 2000 the USA alone (Greenberg et al., 2003). 
Finally, in addition to the economic burden these illnesses impose, these disorders 
come with a high societal cost. A remarkably high number of people with mental illness 
(both proportionally and in total numbers) are incarcerated, with incarcerated patients 
outnumbering those in hospitals three-to-one (Kramer, 2006). Unlike many other highly 
prevalent diseases, mood disorders still carry a strong social stigma—rather than being 
recognized as a legitimate illness, there is a pervasive belief that mental illness 
(depression in particular) represents a failure of character rather than a treatable 
disorder. Dovetailing with this, the majority of health insurance plans (at least in the 
USA) cover mental illness to a far lesser extent than non-mental illnesses, making 
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treatment difficult or expensive for a large proportion of patients with these illnesses 
("Health Policy Brief: Mental Health Parity," 2014). 
 
Current Treatments for MDD and BP 
Due to their extremely high prevalence, personal impact and heavy economic cost, 
treating depressive illness is imperative. Treatments can be separated into two major 
groups, psychological (cognitobehavioral therapy, social rhythm therapy, etc.) and 
pharmacological treatments. While both psychotherapy and pharmacological 
approaches may be effective on their own, greater therapeutic efficacy is typically 
achieved with treatment regimens that incorporate both (Thase et al., 1997). 
One of the longest-lasting hypotheses of depression, the monoaminergic hypothesis, 
was formulated in large part due the mechanisms of action of the first generations of 
antidepressants. Serotonergic reuptake inhibition (tricyclic antidepressants (TCA)) and 
inhibition of monoamine breakdown (monoamine oxidase inhibitors (MAO-I)) led to the 
notion that the underlying pathophysiological mechanism of mood disorders was a 
deficit of serotonin at the synapse. Even today, the majority of first-line pharmacological 
treatments for MDD still target the monoaminergic system. In addition to the TCA and 
MOA-I classes of antidepressants, selective serotonin reuptake inhibitors (SSRI), 
serotonin and norepinephrine reuptake inhibitors (SNRIs), and noradrenergic and 
specific serotonergic antidepressants (NaSSAs) are all used in the treatment of MDD. 
In spite of their depressive symptomatic similarity, pharmacological treatment 
paradigms for MDD and BP differ greatly. This is, in large part, due to the fact that 
antidepressants may trigger either a manic or a hypomanic episode in a significant 
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fraction of BP patients (Henry, Sorbara, Lacoste, Gindre, & Leboyer, 2001; Preda, 
MacLean, Mazure, & Bowers, 2001; Yildiz & Sachs, 2003). In lieu of antidepressants, 
patients with BP are often treated with one or more mood stabilizers (such as lithium or 
valproic acid) or the glutamate-based anticonvulsant lamotrigine. In contrast to 
pharmacological treatment paradigms, however, psychological treatment options are 
fairly similar between the illnesses. 
Additional parallels between treatment strategies for both MDD and BP can be drawn 
between treatment efficacy and pharmacological “lag”. A major difficulty in treating 
these illnesses is the rate of patients who do not respond to the initial pharmacological 
treatment plan: a large-scale study of depressive patients using monoamine-based 
antidepressants revealed that a minority (less than a third) of patients entered remission 
(Trivedi et al., 2006). Furthermore, multiple studies indicate that up to 50% of patients 
will not respond to the first treatment plan prescribed (a statistic that holds true for BP 
as well as MDD patients). 
Another major difficulty in treating these illnesses is the “lag” time experienced between 
beginning medication and seeing therapeutic benefit. While the pharmacological 
mechanisms of both mood stabilizers and serotonin-based drugs occur extremely 
rapidly, it takes an average of six weeks for patients to experience therapeutic benefits. 
In addition to this initial lag, if the patient fails to respond to this initial medication there 
may a “wind-down” period where the patient is weaned off the medication to avoid 
withdrawal symptoms (particularly with serotonin-based medications). This represents 
another massive hurdle in treating these illnesses, as patient non-compliance increases 
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significantly following the therapeutic failure (or occurrence of undesirable side effects) 
of one or more pharmacological treatments (Demyttenaere, 2001). 
While these medications are invaluable in the treatment of MDD and BP, they also 
underscore that our understanding of these disorders are far from complete. While we 
understand the pharmacological mechanisms of these compounds, how they exert their 
therapeutic effects is still unclear. Recent work in animal models has also revealed that 
our assumptions for the therapeutic mechanism of action in TCA antidepressants may 
be incomplete. mRNA and surface protein levels of Adra2a are increased in prefrontal 
cortex in both human depressive patients and animal chronic stress models, with 
increased signaling from these receptors thought to be a causal component of 
dysfunction in MDD (reviewed in (Cottingham & Wang, 2012)). The therapeutic effects 
of TCA are often attributed to increased norepinephrine. However, a study by 
Cottingham et al. involving desipramine (DI, a TCA-class antidepressant that inhibits 
serotonin and norepinephrine uptake) revealed that DI also induced the internalization 
of adrenergic receptors (Cottingham, Chen, Jiao, & Wang, 2011). Furthermore, they 
demonstrated that this receptor internalization—and not the physiological concentration 
of norepinephrine achieved following reuptake inhibition—was sufficient to induce 
Adra2a receptor internalization, consistent with prior work by Gilsbach et al. that 
showed elevated norepinephrine levels were insufficient to reduce Adra2a receptor 
levels (Gilsbach et al., 2006). Considering that many of our pharmacological treatments 
for depressive illness are focused on a relatively limited biological scope, and that we 
know comparatively little of the biological systems impacted by these illnesses, 
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understanding the molecular architecture of depressive illness would greatly aid us in 
developing new treatment strategies. 
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Section 2: Stress responses, glucocorticoid signaling and its impact on the CNS. 
 
“Stress, in addition to being itself, can also be the cause of itself and the result of itself.” 
-Dr. Paul Rosch, Founder, American Institute of Stress 
 
Definitions and purposes of stress 
Much like the word “depression”, “stress” is an extremely nebulous term whose 
definition depends heavily on context. Although he regretted his choice of the word 
“stress” to define this concept, a straightforward (if somewhat simplistic) definition was 
put forth by Dr. Hans Selye in 1936: “(Stress is) the non-specific response of the body to 
any demand for change.” A more recent definition of stress characterizes it as, “…a real 
or interpreted threat to the physiological and psychological integrity of an individual that 
results in physiological and/or behavioral responses.” (McEwen, 2000)These threats, 
termed “stressors”, comprise a wide variety of physical (excess cold or heat, pain, etc.) 
and psychological (dangerous situations, fear, etc.) stimuli that threaten to disrupt an 
organism’s internal stability in the face of changing external conditions. This process is 
termed “homeostasis” (Cannon, 1926) (from the Greek ‘homeo’ (similar/same) and 
‘stasis’ (still). 
A “stress response,” then, is the reaction of one or more system(s) that act to minimize, 
mitigate and/or prevent deviations from this equilibrium due to one or more stressor(s). 
While this terminology is applicable at the cellular level, this thesis will focus primarily on 
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the physiological and genetic responses to stress at the organismal level (specifically, in 
the mouse (Mus musculus) and humans (Homo sapiens)). 
 
Stress responses: the autonomic system, HPA axis and glucocorticoid release 
There are two main intertwined systems that underlie the central stress response: the 
autonomic nervous system (ANS) (specifically, the sympatho-adrenomedullary axis) 
and the hypothalamic-pituitary-adrenocortical (HPA) axis (reviewed in (Ulrich-Lai & 
Herman, 2009)). The first of these systems, the ANS, has two major components: the 
sympathetic (responsible for the “fight-or-flight” response) and the parasympathetic 
(responsible for “rest-and-digest”) divisions. Following the presentation of a stressor, the 
sympatho-adrenomedullary axis is engaged. Axonal projections from spinal cord 
indirectly innervate the cardiovascular system (amid other organs) and adrenal medulla. 
The brainstem modulates these pathways, leading to increased cardiovascular activity 
(heightened blood pressure and heart rate), decreased gut motility, and increased 
circulating levels of adrenaline (epinephrine) and noradrenaline (norepinephrine). This 
pathway simultaneously informs and engages so-called “higher order” components of 
the limbic system (including the medial prefrontal cortex (mPFC) (Figure 1.1) and 
anterior cingulate cortex (AnCg)) that regulate the duration and intensity of the ANS 
response. Of note is that this sympathetic response canonically has a short duration 
due to opposing effects of the parasympathetic division of the ANS. 
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The HPA axis, in contrast to the ANS response, may be much longer in duration (which 
may be on the order of hours). The HPA axis does however, share several key points 
with the ANS response: it is quite rapid in its onset, and it directly innervates the 
paraventricular nucleus of the hypothalamus (PVN) which serves as the initiation point 
for the canonical CRH → ACTH → Glucocorticoid (GC) loop in the HPA axis response. 
After the initiation of the HPA axis response, the PVN secretes several stress-linked 
hormones including corticotropin releasing hormone (CRH). These hormones travel to 
the pituitary gland via the hypophyseal portal system, a network of blood vessels 
directly linking the hypothalamus to the pituitary. Following the arrival of these 
hormones, CRH stimulates the anterior pituitary to release adrenocotricotropic hormone 
(ACTH) into the general circulation. ACTH then acts upon the adrenal glands to 
stimulate the release of glucocorticoids, the main effectors of the HPA axis. The release 
of ACTH is fairly rapid, with glucocorticoids circulating throughout the body and reaching 
Figure 1.1: Linkages between mPFC, HPA axis, ANS and behavior. 
Reprinted with permission from (McKlveen, Myers, & Herman, 2015), 
Journal of Neuroendocrinology, under Wiley Publishing © 2015. 
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peak circulating concentration within a matter of minutes following the stressor. 
Intriguingly, under conditions of moderate stress, glucocorticoids also serve to rapidly 
and efficiently terminate HPA axis activity via direct actions on the PVN, anterior 
pituitary and limbic system (particularly mPFC and anterior cingulate cortex (AnCg)) in a 
classic negative feedback loop. 
As the primary effectors of stress responses, glucocorticoids trigger a large variety of 
responses that minimize the immediate impacts of the stressor and assist in the 
mounting of the stress response. Unlike the ANS response, however, the HPA axis is 
an adaptive response, capable of making changes in anticipation of immediate or future 
stressors. One of the key ways it accomplishes this is through the glucocorticoid-
receptor-mediated regulation of gene expression, which will be covered in depth in the 
following section. 
 
Impacts of stress on transcriptional control and gene expression 
Glucocorticoids play a key role in gene expression across nearly every cell type in every 
major organ system and tissue (reviewed in (Chrousos, 2009)). In spite of the diverse 
array of processes and regulatory pathways they oversee, glucocorticoids share a basic 
mechanism of action when exerting their effects. Following their release, the vast 
majority of glucocorticoids are sequestered by glucocorticoid binding proteins in 
circulation. Only ~10% of the released glucocorticoids are unbound (“free”) and this 
form is able to easily permeate through the cell membrane where it binds to two major 
receptors, the mineralocorticoid receptor (MR) and the glucocorticoid receptor (GR). 
Following their binding to glucocorticoids, these receptors then translocate to the 
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nucleus where they bind to specific sequences of DNA (termed glucocorticoid response 
elements, or GREs) and mediate gene transcription. 
While conceptually straightforward, a number of molecular and cellular phenomena add 
further layers of complexity and rigid regulatory control. The first is the relative binding 
affinity of these receptors, with MR notable for having a high binding affinity for its 
glucocorticoid and GR, in contrast, having a low binding affinity. These initial 
observations led to the notion that these receptors may play markedly different roles. 
This notion was later proven true, with MR currently thought to be predominantly 
responsive to processes involving low concentrations of glucocorticoids (e.g. 
endogenous glucocorticoid rhythmicity, initiation of the stress response, etc.) while GR 
is responsive to those involving relatively high concentrations (such as HPA axis output) 
(Rupprecht et al., 1993). Adding further complexities, heteromeric (e.g. GR/MR) 
receptor complexes may form as well, effectively adding a third “type” of glucocorticoid 
receptor with distinct pharmacological and functional properties. 
Glucocorticoids, as well as affecting nearly every cell, have an extremely context-
sensitive impact. In addition to the various receptor types, the specific anatomy--e.g. 
tissue, tissue sub-region and individual cell type--can have a profound effect on the 
expression (and complement) of genes subject to glucocorticoid regulation. In the CNS, 
for instance, MR is found primarily in the brainstem and hippocampus (HC), while GR is 
more broadly expressed throughout the brain (Patel et al., 2000). In addition, though GR 
mRNA tends to have an overall higher expression level than MR mRNA the relative 
enrichment is highly brain-region-dependent, leading to the observation that different 
stoichiometries of these receptors yields unique signatures of gene regulation (de Kloet, 
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Fitzsimons, Datson, Meijer, & Vreugdenhil, 2009). Glucocorticoids and their receptors 
may also have their activity either inhibited or potentiated by a variety of factors 
endemic to a given cell type or tissue. In parotid, colon and kidney the relatively high 
expression of 11β-hydroxysteroid dehydrogenase 2 (11βHSD2) catalyzes the 
conversion of glucocorticoids (which bind to both GR and MR) into aldosterone (which 
binds only to MR), severely limiting the impact of GR in these tissues (Edwards et al., 
1988). 
A variety of binding partners or other co-factors are also capable of modulating the 
transcriptional activity of glucocorticoid receptors (reviewed in (Rosenfeld & Glass, 
2001) and (Zalachoras, Houtman, & Meijer, 2013)). Two specific examples, discussed 
further in Chapter 2, are the Nuclear Co-Activator 1 (NCOA1) and Nuclear Co-
Repressor 2 (NCOR2) genes. Both genes are GR co-factors and are capable of not 
only altering the GR-mediated transcriptional response of individual genes (of particular 
note, CRH) via protein-protein interactions with GR but are also necessary for 
homeostatic control of the HPA axis. Glucocorticoid receptors may also exert regulatory 
control over gene transcription by regulating access of the transcriptional machinery to 
its target. A large variety of enzymes, collectively termed histone acetylases and histone 
deacetylases, catalyze the addition or removal of acetyl groups within nucleosomes (a 
nucleic acid organizational structure, consisting of DNA wrapped around several histone 
protein cores) which are, respectively, linked to an increase or a decrease in 
transcriptional activity (reviewed in (Zentner & Henikoff, 2013)). Not only is the 
transcriptional activity of GRs themselves affected by the acetylation status of histones, 
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but GRs are capable of recruiting (de)acetylases and thereby directly affect chromatin 
remodeling (Ito, Barnes, & Adcock, 2000). 
Perhaps most intriguingly, stress has extremely far-reaching impacts on both gene 
expression and physiology in the brain. Chronic exposure to cortisol, for instance, 
induced the differential expression of over 1500 transcripts in fetal human brain 
aggregates (Salaria et al., 2006). Several hundred genes were identified as regulated 
by corticosterone in hippocampus at the mRNA level in rats (Datson, van der Perk, de 
Kloet, & Vreugdenhil, 2001), while mice implanted with a corticosterone pellet 
demonstrated changes in expression at the protein level in 150 genes across multiple 
brain regions (Skynner et al., 2006). Speaking to the wide variety of processes 
influenced by stress, these transcripts are linked to a wide variety of processes and 
systems within CNS—including neurogenesis, neurodevelopment, metabolism and 
vascular tone—in a highly brain region- and cell-type-specific fashion. 
One striking effect of stress on gene expression is its impacts on processes underlying 
synaptic function. The fundamental unit of connectivity within the CNS, synapses and 
synaptic function represent the summation of a staggering variety of proteins from 
divergent biological, cellular and mechanistic processes. These include growth and 
neurotrophic factors (e.g. neuronal growth factor (NGF), brain-derived neurotrophic 
factor (BDNF)), signaling peptides (e.g. proenkephalin (PENK), vasopressin (AVP), 
adenylate cyclase activating polypeptide 1 (Adcyap1)) second messengers (cyclic 
adenosine monophosphate (cAMP), calcium (Ca2+), etc), and—of major relevance to 
this thesis—neurotransmitters. Intriguingly, stress has been demonstrated to have 
significant effects on much of the machinery underlying neurotransmission in the limbic 
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system, particularly within the PFC. Sustained stress (as well as depressive illness) has 
been observed to increase activity within the locus coeruleus (LC), resulting in not only 
local increased noradrenergic (NA) tone but increased sensitivity to NA in mPFC via 
upregulating NA receptor expression and sensitivity (specifically, ADRA2A) (Mana & 
Grace, 1997; Nakane, Shimizu, & Hori, 1994; Pavcovich, Cancela, Volosin, Molina, & 
Ramirez, 1990; Wilson et al., 1998). More recently, stress has been shown to 
significantly alter GABAergic neurotransmission in a mPFC (Perrine et al., 2014).  
In addition to these systems, the glutamatergic system has also been widely studied in 
the context of stress, revealing not only regional but also stress-specific alterations in 
response to chronic stress. For instance, following chronic immobilization stress, Vyas 
et al. reported dendritic spine retraction and neuronal atrophy in the hippocampus (HC), 
contrasting with their observation of dendritic arborization in the amygdala (Vyas, Mitra, 
Shankaranarayana Rao, & Chattarji, 2002). In this same study, the authors observed no 
significant changes in hippocampus but observed atrophy in amygdalar bipolar neurons 
following a different stressor (chronic unpredictable stress), demonstrating a stressor-
specific effect. Deficits in glutamate neurotransmission have also been observed in the 
mPFC. Yuen et al. demonstrated stress-induced reductions in glutamate-mediated 
neurotransmission, caused by both significant reductions in cell surface specific AMPA 
and NMDA receptor subunit expression as well as reductions in total protein expression 
(Yuen et al., 2012). Pointing to a possible mechanistic role underlying the physiological 
impacts of stress in the mPFC, neuronal atrophy, mEPSCs, spine loss and shrinkage in 
glutamatergic neurons (specifically, pyramidal cells) has also been observed following 
chronic stress in mPFC (Cook & Wellman, 2004; Radley, Arias, & Sawchenko, 2006; 
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Radley et al., 2004). Of further note, these changes appear to be brain-region-specific: 
while prior work has identified similar reductions in spine size in hippocampus, Yuen et 
al. identified no commensurate alterations in mEPSCs in other limbic structures (e.g. 
hippocampus) or in striatum (Yuen et al., 2012).  
In summary, stress has far-reaching effects on gene expression. Its regulation of gene 
expression and physiological events is highly context-specific, dependent on not only 
the organ itself but also individual cell type(s). This regulation is particularly important to 
consider within the brain, where stress heavily influences synaptic physiology and 
function, potentially via modulation of neurotransmission across a variety of 
neurotransmitter systems within the mPFC. This is of key relevance given that a major 
goal of this thesis is to identify 1) the effect of chronic stress on gene expression 
changes at the RNA level in mPFC, and 2) elucidate the prospective cell type(s) these 
changes may be occurring in. 
Finally, while this thesis has devoted substantial space to the impact of stress on gene 
expression, we have so far focused solely on protein-coding (e.g. mRNA) transcripts. 
Given the common transcriptional machinery employed by various RNA species, 
stress—via glucocorticoids—is capable of regulating a variety of non-coding transcripts. 
This includes microRNAs (miRNAs), the subject of the following section. 
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Section 3: Gene expression and the role of microRNAs. 
 
“Certainly, microRNAs are important regulators inside of the cell.” 
-Dr. Craig C. Mello 
 
Gene expression: a background 
Central to the continued survival of a biological organism is the ability to maintain 
homeostasis. As previously described in Chapter 1.2, homeostasis is a central feature 
to the continued survival of an organism. This process occurs on not only the 
physiological and psychological levels previously described, but also on the molecular 
and cellular level within organisms. One key tool with which organisms maintain 
biochemical homeostasis is through the modulation of gene expression. 
Gene expression can be defined as the flow of genetic information from DNA to a 
functional gene product (either RNA or protein). This process was described as the 
central dogma of molecular biology and can be summarized as follows: DNA is 
transcribed into RNA, which is subsequently translated into protein (Crick, 1970). 
Information may not flow from protein to protein, or from protein to nucleic acid. Implicit 
in this, however, is the notion that RNA may alter the flow of genetic information through 
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interactions with RNA—one example of which is the interaction of microRNAs (miRNAs) 
with mRNAs, discovered in the late 20th century (Lee, Feinbaum, & Ambros, 1993). 
 
MicroRNAs: history, definition and mechanism of action 
Originally discovered in 1993, miRNAs were initially thought to be a biological quirk of 
the nematode C. elegans—a single small RNA (the lin-4 miRNA) was identified as 
capable of repressing a single target (the lin-14 messenger RNA (mRNA)) (Lee et al., 
1993). Seven years later, a second miRNA—termed let-7—was identified in C. elegans 
and found to be capable of repressing the lin-41 mRNA (Reinhart et al., 2000). Shortly 
after this study, screens identified a large number of similar RNA species not only within 
C. elegans but also evolutionarily conserved orthologues of these RNAs in multiple 
species (including humans), indicating a much broader role than previously described 
(Lagos-Quintana, Rauhut, Lendeckel, & Tuschl, 2001). 
 
Figure 1.2: Overview of 
miRNA biogenesis. 
Following transcription by 
RNA polymerase II/III, 
miRNAs undergo a 
sequence of cleavages to 
generate the mature 
miRNA duplex. Reprinted 
by permission from 
Macmillan Publishers Ltd: 
Nat. Cell Biol. ((Winter, 
Jung, Keller, Gregory, & 
Diederichs, 2009)), ©2009. 
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So what are miRNAs? Collectively, the term ‘miRNA’ refers to any member of a family 
of endogenous small RNA molecules (18-22 nucleotides in length) that act as 
sequence-specific post-transcriptional regulators of gene expression. While miRNAs are 
subject to many of the same transcriptional controls as mRNAs, one key distinction is 
that miRNAs are non-coding transcripts (though they may be present in intronic regions 
of protein-coding mRNA transcripts (Zhu, Kalbfleisch, Brennan, & Li, 2009)). Also unlike 
other RNA species, miRNAs undergo a unique biogenesis (Figure 1.2) (reviewed in (Ha 
& Kim, 2014)). miRNAs are initially transcribed as a long (80 to several hundred 
nucleotides) primary miRNA transcript, termed a pri-miRNA, containing a stem-loop 
secondary structure (Figure 1.2). Prior to being exported from the nucleus the DGCR8 
enzyme cleaves the pri-miRNA, leaving only the stem-loop structure (now termed a pre-
miRNA). Once in the cytoplasm, the pre-miRNA undergoes further processing by the 
DICER1 enzyme (a component of the RNA-induced silencing complex (RISC)), which 
cleaves the “loop” structure and reduces the pre-miRNA to a 22-nt dsRNA. Following 
this, the “passenger” strand is usually degraded while the remaining strand of the 
dsRNA duplex is loaded into the RISC machinery and guided to the mRNA target. 
Following this, the mature miRNA will exert its effect by binding to the 3’ UTR of mRNA 
targets. While this binding occurs in a sequence-specific fashion, miRNA/mRNA 
interactions are not perfectly complementary (the exception being nucleotides 2-8, 
termed the “seed sequence”, which guides miRNAs within the RISC complex to their 
mRNA targets). As such, while identifying prospective miRNA/mRNA interactions can 
be accomplished using bioinformatics approaches (Agarwal, Bell, Nam, & Bartel, 2015), 
validating these interactions requires an empirical approach. miRNA interactions with 
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mRNAs subsequently impact gene expression via either degradation of mRNA 
transcripts or inhibition of protein translation (reviewed in (Eulalio, Huntzinger, & 
Izaurralde, 2008)). Of particular interest given this property is the “one-to-many” 
relationship miRNAs have with their targets: a single miRNA species may target 
anywhere from several dozen to several hundred individual mRNA targets (Selbach et 
al., 2008). Coupled with the observation that a majority of protein-coding mRNA 
transcripts are predicted to be subject to regulation by miRNAs and that a high degree 
of evolutionary conservation is observed in miRNAs expressed between species 
(Friedman, Farh, Burge, & Bartel, 2009), this evidence provides solid footing for the 
notion that miRNAs are important regulators of gene expression. 
 
Expression of miRNAs within the central nervous system: biological roles within human 
disease and disease-like states 
While relatively few miRNAs are uniquely expressed and/or enriched in the brain, a 
majority of miRNAs are expressed within brain tissue (Kosik & Krichevsky, 2005). 
miRNAs have been characterized as key mediators in a number of CNS processes and 
functions. Two seminal studies by Krichevsky et al. and Giraldez et al. revealed the 
widespread regulation of brain development by miRNAs and demonstrated their central 
role in regulating morphogenesis of the brain (Giraldez et al., 2005; Krichevsky, King, 
Donahue, Khrapko, & Kosik, 2003). Further work by Schratt et al. demonstrated the 
temporally sensitive pattern of expression of the brain-specific miR-134 in developing 
mouse brain (Schratt et al., 2006), while a growing body of work has revealed the role of 
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multiple miRNAs and miRNA clusters in regulating the development of specific brain 
structures (reviewed in (Petri, Malmevik, Fasching, Akerblom, & Jakobsson, 2014). 
In addition to temporal regulation, miRNAs also exhibit several levels of spatial 
regulation. At the organ level, miRNAs may be enriched not only within the brain but 
localized to specific subregions and/or specific cell type(s). Both miR-124 and miR-219 
are CNS-specific miRNAs that demonstrate extraordinarily robust expression. miR-124, 
however, exhibits a pan-neuronal expression while miR-219 is expressed specifically 
within oligodendrocytes (Jovicic et al., 2013). This type of spatial regulation extends 
further, with multiple miRNAs demonstrating enrichment and/or specificity to cells with 
particular neurochemical phenotype(s) (such as glutamatergic vs GABAergic 
interneurons) (He et al., 2012).  
Consistent with this tight spatiotemporal control of miRNA expression, miRNAs play key 
roles in a staggering array of biological processes within the CNS including (but not 
limited to) development, cell fate and synaptic plasticity (reviewed in (Salta & De 
Strooper, 2012)) (Figure 1.3). Dicer1 is a key component of the miRNA biogenesis 
pathway, with its knockout sufficient to ablate mature miRNA expression and result in 
embryonic lethality (Bernstein et al., 2003). While not embryonically lethal, ablation of 
miRNA expression via Dicer1 deletion specifically in the CNS in mice resulted in low 
numbers of Dicer1-null embryos with no post-natal survivors (Kawase-Koga, Otaegi, & 
Sun, 2009). In the same study, mice rendered null for Dicer1 specifically in the cerebral 
cortex were viable and survived until postnatal day 30 but exhibited gross defects in 
cortical morphology, cell proliferation and neuronal migration, demonstrating an 
indispensable role for miRNAs in CNS development and migration. 
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In addition to regulating development and neuronal migration, miRNAs are also key 
modulators of neuronal morphology and synaptic plasticity. miR-134 was identified as 
the first miRNA capable of regulating neuronal morphology via negatively regulating 
dendritic spine size and prospectively synaptic plasticity via BDNF interactions (Schratt 
et al., 2006). More recent work, however, has revealed a litany of miRNA regulatory 
events involved in altering synaptic plasticity (reviewed in (Aksoy-Aksel, Zampa, & 
Schratt, 2014; Bicker, Lackinger, Weiss, & Schratt, 2014)). An example of this is miR-
132’s interaction with Mecp2: miR-132 targets and represses Mecp2 which, in turn, 
inhibits brain-derived neurotrophic factor (Bdnf) (Klein et al., 2007). As Bdnf is 
Figure 1.3: A sample subset of miRNA roles in the CNS. Reprinted from The Lancet, 
Volume 11, Issue 2, (Salta & De Strooper, 2012), Non-coding RNAs with essential roles in 
neurodegenerative disorders, p. 189-200, © 2012, with permission from Elsevier. 
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necessary for adult synaptic plasticity and LTP (Andero, Choi, & Ressler, 2014), miR-
132 is able to indirectly modulate changes in synaptic plasticity via modulation of Bdnf 
levels. Congruous with this role in regulating synaptic plasticity the expression, turnover 
and biogenesis of a subset of miRNAs has been shown to be tightly coupled to neuronal 
activity (Sim, Bakes, & Kaang, 2014), implying an important role for miRNAs in basal 
CNS function. 
miRNAs are also capable of regulating a variety of behaviors across a variety of 
organisms. In the fruit fly Drosophila melanogaster ablation of miR-124 resulted in 
increased time spent climbing and a drastically reduced percentage of flight in males (C. 
Wang, Feng, Wan, Kong, & Yuan, 2014). Knockdown of one of several miRNAs in 
zebrafish is capable of inducing hyperactivity similar to that observed in zebrafish 
exposed to ethanol during larval development (Tal et al., 2012). One study of particular 
clinical interest was performed by Stark et al. employing a mouse model of the 22q11 
microdeletion syndrome (Stark et al., 2008). This model replicates a chromosomal 
microdeletion carried by ~2% of patients with schizophrenia and disrupts expression of 
the Dgcr8 gene, a key component of the miRNA biogenesis machinery (Bassett & 
Chow, 1999; Gregory et al., 2004). Mice carrying this deletion demonstrated not only 
structural and functional neural abnormalities but also impaired prepulse inhibition, a 
features that demonstrates clinical parallels in human schizophrenic patients (reviewed 
in (Larrauri & Schmajuk, 2006)). 
Given the number of biological processes that miRNAs regulate, coupled with the 
capability of one miRNA species to regulate a large number of mRNA targets, it is 
perhaps unsurprising that a growing body of literature implicates miRNAs as both 
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effectors and signatures of diseases within the CNS. Likely due to the wide variety of 
cellular processes they oversee, disruptions in the miRNA regulatory network have 
been tightly linked with various forms of cancer and tumor suppression (reviewed in 
(Jansson & Lund, 2012)). In the CNS, miRNA “clusters” have been associated with a 
variety of illnesses including (but not limited to) epilepsy, stroke, Alzheimer’s, and 
Huntington’s disease (Cogswell et al., 2008; C. Liu, Zhao, Han, Li, & Li, 2015; Maciotta, 
Meregalli, & Torrente, 2013).  
Of particular interest to this thesis, however, is the growing number of studies that have 
identified differential miRNA expression in human patients with a variety of 
neuropsychiatric illnesses. Seminal work in 2007 identified differential expression of 
miRNAs within the dorsolateral prefrontal cortex (DLPFC) in patients with schizophrenia 
(SZ) and schizoaffective disorder (Perkins et al., 2007). In the intervening years a 
growing body of literature has demonstrated differential miRNA expression across a 
range of mood and affective disorders including major depressive disorder (MDD), 
bipolar disorder (BP) and SZ (Bavamian et al., 2015; A. H. Kim et al., 2010; Miller et al., 
2012; Moreau, Bruse, David-Rus, Buyske, & Brzustowicz, 2011). To date this body of 
work has largely focused on schizophrenic patients with an emphasis on examining 
miRNA expression within DLPFC and cerebellum. Absent from these studies, however, 
has been the anterior cingulate cortex (AnCg), a brain region centrally involved in the 
regulation of mood, affect and cognition (Drevets, Savitz, & Trimble, 2008; Ebert & 
Ebmeier, 1996; Mayberg et al., 1999; Posner & DiGirolamo, 1998). A growing body of 
literature has also demonstrated further connections between AnCg dysfunction and 
mood disorders, with altered AnCg activity differentiating MDD versus BP patients and 
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predicting successful therapeutic responses to pharmaceutical and cognitive treatments 
(Diler et al., 2014; Fujino et al., 2015; Mulert et al., 2007; Pizzagalli et al., 2001; 
Salvadore et al., 2009). Neuropsychiatric illnesses likely comprise, at least in part, the 
dysregulation of multiple brain regions, and an understanding of how each of these 
regions may be affected is key to understanding the whole. As such, a major goal of this 
thesis is to identify miRNAs differentially expressed within anterior cingulate cortex 
(AnCg) of patients with unipolar and bipolar depression and to characterize putative 
mRNA targets of these miRNAs. 
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Section 4: Clinical Connections -- Linking Chronic Stress, microRNAs and Depression 
 
“Depression isn’t a straightforward response to a bad situation; (it) just is, like the 
weather.” 
-Stephen Fry 
 
As described in previous sections, MDD and BP are debilitating illnesses and each have 
an extremely high prevalence. While this background has focused on the diagnoses, 
prevalence and societal impact of these illnesses it has not yet touched on our current 
understanding of their respective causes and treatments. The purpose of this section 
will be to describe the etiology of MDD and BP, identify the linkages between chronic 
stress and these illnesses, and provide context for the work described within this thesis. 
 
Linkages between HPA axis dysfunction and mood and affective disorders 
As may be inferred from the litany of various symptoms that may (or may not) present 
within MDD and BP (see Chapter 1.1), mood disorders are extraordinarily 
heterogeneous. One of the major difficulties in developing diagnostic criteria has been 
that this heterogeneity extends from the symptomatic to the cellular, molecular and 
systems level. Due in large part to this, diagnoses based solely on biomarkers remain 
problematic.
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While there is, as of the time of this writing, no definitive biomarker for mood disorders, 
a series of intriguing studies were published beginning in 1956. Several groups 
independently observed increased levels of plasma cortisol (hypercortisolemia) in 
patients presenting with anxiety, schizophrenia and major depression compared to 
controls (Basowitz et al., 1956; Bliss, Migeon, Branch, & Samuels, 1956; Board, Persky, 
& Hamburg, 1956; Board, Wadeson, & Persky, 1957), providing the first linkage of these 
illnesses to the HPA axis.  
Although these studies were acute examinations of cortisol level (e.g. taking place over 
several hours), a later study examined chronic levels of cortisol in major depressive 
patients versus controls (Gibbons & Mc, 1962). The authors recorded chronic elevations 
in cortisol in a majority of depressed patients. More intriguingly, they observed two 
striking correlations: 1) plasma cortisol concentration tended to positively correlate with 
the severity of a patient’s depressive symptoms, and 2) plasma cortisol concentration 
tended to negatively correlate with the likelihood a patient would improve. Combined, 
these early studies provided compelling evidence that the HPA axis—via cortisol—may 
play a role in mood disorders. This finding has since only been strengthened, as 
hypercortisolemia is one of the most consistently observed pathophysiology in both 
MDD and BP patients (Axelson et al., 1993). 
Another key piece of evidence linking MDD and BP to HPA axis dysfunction is the 
dysregulation of the circadian clock (loosely defined as the collection of biochemical 
events that enable the ~24 hour rhythmicity observed in many biological processes) and 
its impact on these illnesses (reviewed in (Bunney et al., 2015)). Similar to the linkage 
between glucocorticoid levels and depressive symptoms, prior studies have established 
33 
 
1) a positive correlation between the degree of circadian dysfunction and depressive 
severity and 2) patient improvement correlating with resynchronization of the circadian 
clock (Bunney & Bunney, 2013; B. P. Hasler, Buysse, Kupfer, & Germain, 2010). The 
circadian clock is also responsible for the diurnal variation in circulating glucocorticoids: 
glucocorticoid concentrations peak during sleep and are highest at waking, with levels 
tapering off during the day and rising again during sleep.  
This linkage between the circadian clock, HPA axis function and mood disorders is 
intriguing for several reasons. The first is that a diurnal rhythmicity in mood and mood 
disorders has been observed (Wirz-Justice, 2008). Additionally, while MDD patients 
maintain this glucocorticoid rhythmicity, the dynamic range of these oscillations is 
frequently smaller than those of control patients (remaining high throughout the day) 
and they are also more likely to exhibit temporal desynchronization of glucocorticoid 
levels (Holsboer, 2000; Scharnholz et al., 2010). Furthermore, dysregulation and/or 
differential expression of genes linked to the biochemical regulation of the circadian 
clock have been strongly associated with both MDD and BP (Edgar & McClung, 2013; 
Soreca, 2014). The disruption of rhythmic processes under the control of the circadian 
clock and/or glucocorticoids are also often observed in MDD and BP, particularly sleep 
disturbances. 
Finally, the targeting of HPA axis dysregulation has been successfully employed in both 
the diagnosis and treatment of depression. The dexamethasone suppression test (DST) 
is one such example, whereby patients are administered dexamethasone and 
monitored for changes in plasma cortisol and ACTH. As dexamethasone binds to the 
glucocorticoid receptor this should (under normal conditions) mediate significant 
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reductions in both plasma cortisol and ACTH following administration. If these 
reductions are not observed, glucocorticoid receptor function is assumed to be blunted 
(potentially due to the physiological effects of persistently elevated glucocorticoid levels, 
explored in the following section). Furthermore, consistent with hypercortisolemia 
playing a presumptive causative role in depression, several studies have demonstrated 
therapeutic success via treatment with several HPA axis inhibitors. Examples of these 
have included GR receptor antagonists (prospectively blocking the negative impacts of 
high cortisol levels) and CRH receptor antagonists (presumptively blunting the CRH 
cascade) (Belanoff, Flores, Kalezhan, Sund, & Schatzberg, 2001; Holsboer & Ising, 
2008). However, as these diagnostics and treatments have proven less consistent than 
ideal, research is ongoing. 
In summary, the strong associations of HPA axis dysfunction and elevated 
glucocorticoid levels with mood disorders provides a compelling rationale for further 
examining their roles in the molecular architecture of MDD and BP. 
 
Physiological and behavioral impacts of stress in the context of mood disorders  
While the stress response was covered in an earlier section (see Chapter 1.2), it must 
be noted that this ‘idealized’ response (and subsequent rapid return to homeostasis) is 
more characteristic of short-term—or acute—stress. These demands, in isolation, are 
not harmful: while they add to the allostatic load (e.g. the natural “wearing out” of the 
body and its subsequent susceptibility to disease), their negative impact is miniscule 
compared to their adaptive benefits. Under conditions of prolonged and/or heavy stress, 
the allostatic load may become too great with the excessive release of glucocorticoids 
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becoming damaging to the brain. Multiple lines of evidence support this idea, with 
chronic stress (via hypercortisolemia) representing a prospective ‘trigger’ which 
contributes to the precipitation of depressive illnesses (Holsboer, 2000). 
At present, however, there are several caveats in the current approaches to 
understanding chronic stress and its linkages to mood disorders. There is no clear 
consensus in the field at what point stress becomes “chronic.” Researchers using 
animal models to examine chronic stress, for instance, may employ behavioral 
paradigms lasting anywhere from 10 days to 6 or more weeks. Further complicating the 
ability to translate findings between animal models of chronic stress and humans is the 
diverse array of behavioral paradigms (and their temporal duration) employed by 
researchers: chronic unpredictable/variable stress (CUS/CVS), chronic mild stress 
(CMS), chronic social defeat stress (CSDS), chronic restraint stress (CRS) and learned 
helplessness are all accepted models of chronic stress (Barlow, Morrison, & Sullivan, 
1975; Herman, Adams, & Prewitt, 1995; Kudryavtseva, Bakshtanovskaya, & Koryakina, 
1991; Willner, Muscat, & Papp, 1992). However, these models may not only exhibit 
inter-model variability but also temporal variability: researchers employing the CUS 
model for 10 days observed an increase in local GABA concentrations in mPFC, while 
those employing CMS for a longer duration (6 weeks) observed a concomitant decrease 
(Perrine et al., 2014; Venzala, Garcia-Garcia, Elizalde, & Tordera, 2013). Finally, it is 
important to note that animal models do not directly represent “depression” but rather 
multiple physiological, behavioral and/or genetic deficits representing adaptive brain 
responses that resemble depression. 
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In spite of these limitations we have gained a great deal of insight regarding the 
physiological and behavioral impacts of chronic stress and their prospective role in the 
etiology of MDD and BP. These models of chronic stress all induce sustained elevations 
in circulating glucocorticoids. As stated in the prior section, hypercortisolemia 
(measured in circulating, cerebrospinal and urinary glucocorticoid levels) is one of the 
most commonly observed pathophysiologies in patients with MDD and BP. Keeping with 
this, both animal models of chronic stress and human MDD and BP patients often 
present with adrenal hyperplasia (e.g. increased size of the adrenal glands)—consistent 
with the notion of chronic-stress-induced hypercortisolemia. 
Further consistent with increased glucocorticoid levels is the observation that multiple 
brain regions demonstrate altered glucocorticoid receptor expression both in response 
to chronic stress and in human MDD and BP patients. These observations are of note 
for several reasons. The first is that manipulating glucocorticoid receptor levels within 
notable stress-sensitive regions of brain (particularly forebrain) has been shown to 
precipitate depressive-like symptoms in mice (M. P. Boyle et al., 2005; Wei et al., 2004). 
Additionally, reductions of glucocorticoid receptor specifically in the forebrain resulted in 
not only depressive-like symptoms but also HPA axis dysregulation within mice, with 
these symptoms following a temporal profile similar to that of depression (M. P. Boyle et 
al., 2005). A 2012 study by Guidotti et al. not only observed these chronic-stress-
induced reductions in glucocorticoid receptor expression, but demonstrated that 
antidepressant treatment was sufficient to normalize GR expression levels (Guidotti et 
al., 2013). 
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The hypothesis these data support, whereby prolonged elevations of glucocorticoids 
suppress glucocorticoid receptor expression, is a particularly attractive mechanistic 
explanation for depression. This is due in part to the observation that multiple brain 
regions exhibiting suppressed glucocorticoid receptor expression in chronic stress and 
depressive illness also exhibit morphological abnormalities. Chief amongst these is the 
PFC: MDD and BP patients both present with significant reductions in the steady-state 
levels of glucocorticoid receptor in PFC (Webster, Knable, O'Grady, Orthmann, & 
Weickert, 2002).  While depressive patients tend to display reduced gray matter volume 
in multiple brain regions, the prefrontal cortex (and its multiple sub-regions) 
demonstrates the largest and most significant reductions observed. The anterior 
cingulate cortex (AnCg), for instance, demonstrates a ~10% reduction in volume 
depressive patients compared to controls, while the DLPFC demonstrates a ~25% 
reduction (Grieve, Korgaonkar, Koslow, Gordon, & Williams, 2013). These findings are 
also compelling due to the observation that alterations in mPFC and AnCg activity may 
be predictive of not only depressive illness but also response to pharmacological 
treatments (Fujino et al., 2015; Mulert et al., 2007). Consistent with these observations 
(e.g. reductions in total AnCg volume indicating reduced activity), deep brain stimulation 
targeting the cingulate cortex (resulting in increased phasic neuronal activity) resulted in 
a high proportion of patients with treatment-resistant depression experiencing 
antidepressant-like effects (~66%) (Mayberg et al., 2005). 
Prior studies have also demonstrated chronic stress- and glucocorticoid-induced 
reductions in spine size and neuronal activity. Specifically, both chronic stress and 
artificially induced elevations in glucocorticoid levels resulted in neuronal atrophy, cell 
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loss, reduced dendritic arborization and dendritic spine size shrinkage in not only PFC 
but in other limbic structures (including hippocampus and nucleus accumbens) (Cook & 
Wellman, 2004; Radley et al., 2006; Radley et al., 2004). In contrast to these 
observations, other groups observed increased dendritic arborization and activity in the 
amygdala (Vyas et al., 2002) as well as increased activity in the locus coeruleus (Mana 
& Grace, 1997; Nakane et al., 1994; Pavcovich et al., 1990; Wilson et al., 1998). 
Intriguingly, these opposing effects are highly consistent with stress-induced mPFC 
hypofunction given that 1) the locus coeruleus is activated in stress and inhibits mPFC 
activity, and 2) the mPFC acts as a “brake” on amygdalar activity.  
These physiological observations are also noteworthy for their prospective behavioral 
effects. Many maladaptive behavioral responses induced by chronic stress mirror those 
observed in patients with psychiatric illness. Anxiety, for instance, is not only one of the 
default emotional states of the stress response but is highly co-morbid with those 
suffering from depressive illnesses (Hirschfeld, 2001; Keller, 2006). Depressive illness 
is also often accompanied by increased emotionality and decreased control over 
emotions, which—together with anxiety—may be a behavioral result of the 
aforementioned amygdalar hyperactivity. This is consistent with the mPFC’s role as a 
“brake” on amygdalar activity, particularly in light of the fact that the mPFC exerts 
higher-order (e.g. cognitive) control over dysphoria and general emotionality (Joormann 
& Gotlib, 2010). Combined, this would represent not only a chronic-stress-induced 
increase in emotionality (via amygdalar hyperfunction) but, due to stress-induced 
prefrontal cortical hypofunction, one would have reduced cognitive control over 
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emotional state (making it increasingly difficult to “think” one’s way out of the dysphoria  
experienced in depression). 
Another behavioral impact of chronic stress that mirrors that observed in depressive 
patients is a reduction in the ability to feel pleasure (specifically, anhedonia). Stress 
exerts a measure of control over the reward system and reduces the ability to perceive 
pleasure during the stress response (Gold, 2015). One can see how this would be a 
beneficial adaptation: acutely reducing the ability to feel pleasure in a stressful situation 
would, in theory, minimize the likelihood of distraction and thus maximize the odds of an 
effective response. Chronic stress, however, impairs pleasure via inhibiting the NAc, the 
central component of the reward pathway. In addition to the previous observations of 
reduced NAc volume and activity in depressive patients, prior studies have identified 
direct innervation of the NAc by the mPFC and established it acts as a positive regulator 
of NAc activity (Murase, Grenhoff, Chouvet, Gonon, & Svensson, 1993). Given that 
anhedonia and a ‘blunting’ of the ability to feel pleasure is a central feature of 
depression, this provides further evidence of 1) the linkage of chronic stress to 
precipitation of depressive illness and 2) the mPFC—specifically, via prospective PFC 
hypofunction negatively influencing NAc activity—may be a central player in the 
mechanistic underpinnings of MDD and BP. 
In summary, as many of the physiological and behavioral alterations observed in MDD 
and BP patients are mirrored in the effects of chronic stress, these data provide a 
compelling case for a causative role of chronic stress in these illnesses. Additionally, 
given their particularly stress-sensitive natures and linkages to many brain regions 
impacted by chronic stress and mental illness, the mPFC and AnCg have been cast as 
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areas of intense interest in understanding these conditions. Due in part to these 
observations, the work outlined in this thesis has focused on examining gene 
expression changes in AnCg (Chapter II) and mPFC (Chapter III) in human depressive 
patients and an animal model of stress, respectively. 
 
The molecular architecture of MDD, BP and chronic stress: glutamate and GABA 
Traditional genetic approaches to characterizing MDD and BP have been fraught with 
difficulty. For perspective, a recent genome-wide association study (GWS) employing 
11,974 patients with bipolar disorder and 51,792 control patients yielded only two 
statistically significant single-nucleotide polymorphisms (SNPs): CACNA1C and ODZ4 
("Large-scale genome-wide association analysis of bipolar disorder identifies a new 
susceptibility locus near ODZ4," 2011).  Similarly, another study employing 6,783 
patients with MDD and 50,695 patients observed no statistically significant SNPs in 
MDD versus control patients (Ripke et al., 2013).  
In spite of these findings, however, both MDD and BP have significant heritability, 
estimated at >40% for each disorder (Craddock & Jones, 1999; Lohoff, 2010) and 
indicating a strong genetic component. Similar to that observed in the physiology of 
these illnesses, the molecular and genetic architectures of these diseases are 
extraordinarily complex, involving a truly staggering array of prospective genes of 
interest. As such, Chapters II and III will focus on two major hypotheses of particular 
relevance to the work outlined in this thesis. It is important to note, however, that these 
hypotheses are not mutually exclusive (either of themselves or other hypotheses, such 
as the monoaminergic hypothesis of depression (reviewed in (Delgado, 2000)). 
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The Glutamatergic Hypothesis of Depression: Given the large body of literature 
identifying brain regions with differential activity in MDD, BP and chronic stress, a 
necessary next step was identifying components of the neural circuitry that may 
underlay these disruptions. Given that many brain regions present with either 
hyperactivity (e.g. amygdala, subgenual cingulate cortex, orbitofrontal cortex) or 
hypoactivity (PFC, hippocampus, nucleus accumbens) in stress and depressive illness, 
a logical starting point was examining excitatory and inhibitory components of the neural 
circuitry. 
Excitatory neurotransmission in the CNS is largely mediated by glutamate. Glutamate is 
the most prevalent neurotransmitter in the brain, with an overwhelming proportion of 
neurons (>80% in some areas, notably neocortex) being glutamatergic (Orrego & 
Villanueva, 1993). Glutamatergic neurons also serve as the primary excitatory outputs 
for virtually all neurotransmitter systems (particularly monoaminergic neurotransmission) 
and brain regions. Glutamatergic pyramidal cells, for instance, are the major output of 
the PFC and receive heavy (inhibitory) monoaminergic innervation from the locus 
coeruleus. A current hypothesis is that this prefrontal cortical hypofunction observed 
following chronic stress and in depressive illness may be 1) causative in nature and 2) 
the result of impaired glutamatergic output. 
Several lines of inquiry have yielded evidence that bolsters this hypothesis. As 
mentioned previously, chronic stress induces neuronal atrophy and dendritic spine 
retraction in the mPFC. A recent study identified that chronic stress significantly reduced 
glutamatergic synaptic transmission via reductions in surface levels of AMPA and 
NMDA glutamatergic receptors and that this effect was glucocorticoid receptor-
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dependent (Yuen et al., 2012). These findings of reduced NMDA and AMPA receptor 
expression in mPFC have been replicated in human MDD patients, although data in BP 
patients is less consistent (Choudary et al., 2005; Feyissa, Chandran, Stockmeier, & 
Karolewicz, 2009). Evidence outlining glutamatergic hypofunction in mPFC is also in 
line with the aforementioned 1) increased post-synaptic expression of inhibitory 
adrenergic receptors (particularly Adra2a) in mPFC and 2) increased adrenergic and 
noradrenergic drive onto mPFC via stress-induced locus coeruleus hyperactivity. This 
body of literature is also consistent with evidence demonstrating reduced expression of 
genes responsible for glutamate reuptake and recycling in the mPFC of depressive 
patients (Choudary et al., 2005; Miguel-Hidalgo et al., 2010). Furthermore, specific 
optogenetic activation of layer V pyramidal cells in mPFC was sufficient to induce an 
antidepressant-like phenotype in mice subjected to a forced-swim test (Kumar et al., 
2013) 
Finally, reductions of glutamate (and glutamate metabolites) have been observed in 
mPFC and AnCg in MDD and following chronic stress (Auer et al., 2000; Chiba et al., 
2012; G. Hasler et al., 2007; Mirza et al., 2004; Rosenberg et al., 2004). Once again, 
however, the data is less clear for BP, with various studies showing increases, 
decreases and no change in glutamate and its metabolites in PFC for various cohorts of 
BP patients (Bhagwagar et al., 2007; Davanzo et al., 2003; Michael et al., 2003; Ongur 
et al., 2008; Port, Unal, Mrazek, & Marcus, 2008). 
Finally, a major strength of the glutamatergic hypothesis is the success observed in its 
use as a therapeutic target. In recent years, ketamine (an NMDA receptor antagonist) 
has come under intense investigation due to its effects as an extremely rapid and 
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efficacious antidepressant (Park, Niciu, & Zarate, 2015). Multiple other drugs targeting 
the glutamatergic system have also come under scrutiny for their prospective use in 
treating depression (reviewed in (Dutta, McKie, & Deakin, 2015)). Riluzole, a drug that 
acts to inhibit presynaptic glutamate release and facilitate its uptake, has exhibited 
antidepressant properties (Banasr et al., 2010). Lamotrigine, which acts to inhibit 
glutamate release, has also shown efficacy as an antidepressant specifically in BP 
patients (though not in MDD patients) (Amann, Born, Crespo, Pomarol-Clotet, & 
McKenna, 2011; Geddes, Calabrese, & Goodwin, 2009; Reid, Gitlin, & Altshuler, 2013). 
Given the dysregulation of glutamate signaling in MDD, BP and chronic stress 
(components of which are reviewed in Figure 1.4), and the antidepressant efficacy of 
agents targeting the glutamatergic system, glutamate may play an important role in the 
pathophysiology of depressive illness. 
The GABAergic hypothesis of depression: In contrast to glutamate’s role in the CNS, 
gamma aminobutyric acid (GABA) is the predominant inhibitory neurotransmitter in the 
CNS. While representing a smaller total number of cells, GABAergic neurons make up a 
sizable minority of neurons (ranging between 20 and 40% of total neurons, depending 
on brain region) and are noted for their extreme diversity of neurochemical cell types 
(reviewed in (Rudy, Fishell, Lee, & Hjerling-Leffler, 2011)). 
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The GABAergic hypothesis of depression is a more recent one, but a growing body of 
evidence has placed it squarely alongside that of the glutamatergic hypothesis. In part 
this is due to the conceptual model of neural activity in the brain as a glutamatergic 
“push” with a GABAergic “pull” counteracting it. In the context of depressive illness, this 
raises the possibility that GABAergic hyperfunction (rather than, or in addition to, 
glutamatergic hypofunction) plays a mechanistic role in mPFC and AnCg hypofunction. 
Figure 1.4: Schematic demonstrating components of glutamatergic 
neurotransmission impacted by stress. Red circles indicate components of the 
neural and glial machinery impacted by stress such as glutamate release (1), 
AMPA/NMDA glutamate receptors in postsynaptic cells (2), and glutamate 
clearance/recycling (3 and 4).  Reprinted from Anxiety and Depression, Vol. 62, 
Issue 1, (Sanacora, Treccani, & Popoli, 2012), "Towards a glutamate hypothesis of 
depression: an emerging fronteir of neuropsychopharmacology for mood 
disorders," pp. 63-77, ©2012, with permission from Elsevier. Figure adapted from 
(and reprinted by permission from) Macmillan Publishers Ltd: Nat. Rev. Drug 
Discov., (Sanacora, Zarate, Krystal, & Manji, 2008), ©2008. 
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A growing body of literature has identified the differential expression of multiple 
ionotropic and metabotropic GABA receptor genes in both MDD and BP, particularly in 
the mPFC and AnCg (reviewed in (Luscher, Shen, & Sahir, 2011)). Additional studies 
have been performed on several of these genes using animal models with relevance to 
chronic stress and depression. Mice rendered heterozygously null for the gamma 
ionotropic GABA receptor subunit Gabrg2 have been characterized as an animal model 
of depression, demonstrating HPA axis dysregulation as well as an anxious/depressive 
phenotype and exhibiting synaptic and dendritic defects (Ren et al., 2015). These 
findings are in line with prior anatomical data demonstrating that paraventricular nucleus 
of the hypothalamus (PVN)—a major component of the final neuronal pathway involved 
in the mammalian stress response—is regulated by GABAergic inhibition via the frontal 
cortex (Radley, Gosselink, & Sawchenko, 2009).  
In addition to these studies, mouse knockout models of the metabotropic GABA 
receptors GABBR1 and GABBR2 exhibit an antidepressant-like phenotype (decreased 
immobility in the forced swim test), while rats subjected to chronic unpredictable stress 
demonstrate increased basal GABA release in PFC compared to non-stressed controls 
(Mombereau et al., 2004; Mombereau et al., 2005; Perrine et al., 2014). Finally, more 
recent electrophysiological data reveals a chronic-stress-induced increase in inhibitory 
tone on mPFC pyramidal cells (Herman, University of Cincinnati, unpublished). 
Several studies have also revealed antidepressant effects in targeting the GABAergic 
system. Mice treated with GABBR antagonists have demonstrated an antidepressant- 
and anxiolytic-like phenotype (Mombereau et al., 2004). While canonically used in the 
treatment of anxiety disorders, the antidepressant efficacy of benzodiazepenes (BZ)--
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which act as positive allosteric modulators of ionotropic GABA receptors--is still largely 
unclear, though at least one BZ (specifically, alprazolam) has been demonstrated to 
possess antidepressant effects (Warner, Peabody, Whiteford, & Hollister, 1988). These 
findings are of note due to the primary use of BZs in treating anxiety and the 
aforementioned strong comorbidity between anxiety and depressive illness. 
 
The epigenetic architecture of MDD, BP and chronic stress: microRNAs 
As previously described (see Section 1.3), miRNAs are noteworthy primarily for 1) the 
high proportion of mRNA transcripts they regulate and 2) the ability for one miRNA 
species to regulate anywhere from several dozen to several hundred individual mRNA 
targets. Given the significant genetic complexity of MDD, BP, and maladaptive 
responses to chronic stress, miRNAs are uniquely positioned to play a key role in the 
regulation of these conditions. 
Perhaps the strongest evidence is that a growing body of literature has identified the 
dysregulation of numerous miRNAs across a variety of brain regions in not only MDD 
and BP but also in SZ and schizoaffective cohorts (Bavamian et al., 2015; A. H. Kim et 
al., 2010; Miller et al., 2012; Moreau et al., 2011). Intriguingly there appears to be a 
strong directional trend, with miRNAs dysregulated in patients with mental illnesses 
tending towards repression. Finally, in addition to mental illness, miRNA expression 
levels may be modulated by chronic and acute stress in a region specific manner 
(Haramati et al., 2011; Rinaldi et al., 2010; Shaltiel et al., 2013). 
Prior work has also established miRNAs regulating key components of HPA axis activity 
and genes of relevance to the aforementioned hypotheses of depressive illness. miR-18 
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and miR-124, for instance, are able to negatively regulate the glucocorticoid receptor as 
well as the glucocorticoid-induced GILZ gene (Vreugdenhil et al., 2009). Additionally, 
inhibition of miR-124 in hippocampus induced antidepressant-like effects (Bahi, 
Chandrasekar, & Dreyer, 2014). A number of miRNAs were found to be regulated in rat 
hippocampus by chronic treatment with the mood stabilizers lithium and valproic acid 
(Zhou et al., 2009). One of these miRNAs, miR-34a, was also found to negatively 
regulate metabotropic glutamate receptor 7 (GRM7), a gene previously linked to BP 
(Zhou et al., 2009). 
In addition to genetic linkages, miRNAs have been linked to behavioral alterations. A 
2008 study by Uchida et al. identified that Fisher 344 rats, but not Sprague-Dawley rats, 
are susceptible to repeated restraint stress (Uchida et al., 2008). In this same study, the 
authors identified miRNA-mediated repression of the glucocorticoid receptor in PVN 
specifically in stress-susceptible Fisher 344 rats and postulated this behavioral 
difference could be due to miRNA overexpression (Uchida et al., 2008). Haramati et al. 
demonstrated the regulation of miR-34c by both acute and chronic stress regulation in 
amygdala and that overexpression conferred an anxiolytic-like phenotype (Haramati et 
al., 2011). Shaltiel et al. also demonstrated that miR-132—a miRNA strongly linked to 
schizophrenia (Miller et al., 2012)—was elevated in the hippocampus of mice subjected 
to predator-scent-induced anxiety and that modulation of miR-132 expression induced 
an anxiety-like phenotype via targeting of acetylcholinesterase (Shaltiel et al., 2013).  
In summary, we know that miRNAs are dysregulated in chronic stress and mental 
illnesses across a variety of brain regions. Two points that are currently unclear, 
however, is 1) whether miRNAs are dysregulated in AnCg of MDD and/or BP cohorts 
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versus controls and 2) what miRNAs are regulated by chronic stress in mPFC. 
Investigating these points will be the major goals of chapters II and III, respectively. 
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Section 1.5: Hypothesis and Experimental Design 
 
"A hypothesis is a novel suggestion that no one wants to believe. It’s guilty until found 
effective." -Edward Teller 
 
Due to the established links between chronic stress and mood disorders, shedding 
further light on the genetic architecture of each of these conditions may provide key 
insights into their pathophysiological mechanisms and prospective therapeutic targets. 
Given the strong linkage between these conditions, the aim of this thesis is to examine 
the following two hypotheses: 
1. MicroRNAs are dysregulated in various brain regions of patients with various 
mental illnesses, including MDD and BP. Given its central role in the regulation of 
mood and affect, miRNAs are likely to a) be differentially expressed in the AnCg 
of patients with MDD and BP and b) target genes of relevance to 
pathophysiological processes. 
2. Chronic stress is a major precipitant of mental illness and is a powerful modulator 
of gene expression. Given the mPFC is a central regulator of stress responses 
(and is a particularly stress-sensitive brain region), chronic stress will result in 
widespread gene expression changes consistent with inhibited mPFC function.
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These hypotheses will be explored in Chapters II and III, respectively. I have elected to 
interrogate these hypotheses using the following methods: 
Hypothesis 1 
 Employ high-throughput quantitative real-time PCR (qPCR) assays to measure 
steady-state levels of miRNAs in AnCg of MDD and BP patient cohorts versus 
controls. 
 Utilize in silico miRNA target prediction algorithms, molecular cloning and in vitro 
luciferase assay methodologies to identify and validate mRNAs of interest that 
are regulated by disease-linked miRNAs. 
 Test whether steady-state levels of validated mRNAs change in MDD and/or BP 
cohorts versus controls using qPCR. 
Hypothesis 2 
 Following a 14-day chronic variable stress (CVS) paradigm that induces 
depressive-like behavior in mice, obtain total RNA samples from medial PFC 
(mPFC) of mice subjected to CVS or non-stressed controls. 
 Use next-generation RNA sequencing to generate expression profiles within 
mPFC. 
 Employ high-throughput qPCR assays to 1) validate next-generation sequencing 
data and 2) identify stress-regulated miRNAs. 
 Utilize in silico miRNA target prediction algorithms, molecular cloning and in vitro 
luciferase assay methodologies to identify and validate mRNAs of interest that 
are regulated by stress-regulated miRNAs. 
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 Utilize laser-capture microdissection (LCM) to generate material from prelimbic 
and infralimbic subregions of mPFC from CVS and non-stressed control animals. 
 Employ qPCR methodologies to identify subregion specificity of stress-regulated 
mRNAs. 
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Chapter II: The microRNA network is altered in anterior cingulate cortex of 
patients with unipolar and bipolar depression 
 
A version of this chapter has been submitted to the Journal of Psychiatric Research and 
is awaiting a response. 
 
 
ABSTRACT 
MicroRNAs (miRNAs) are small, non-coding RNAs acting as post-transcriptional 
regulators of gene expression. Though implicated in multiple CNS disorders, miRNAs 
have not been examined in any psychiatric disease state in anterior cingulate cortex 
(AnCg), a brain region centrally involved in regulating mood. We performed qPCR 
analyses of 29 miRNAs previously implicated in psychiatric illness (major depressive 
disorder (MDD), bipolar disorder (BP) and/or schizophrenia (SZ)) in AnCg of patients 
with MDD and BP versus controls. miR-132, miR-133a and miR-212 were differentially 
expressed in BP, miR-184 in MDD and miR-34a in both MDD and BP. In silico target 
prediction algorithms identified putative targets of differentially expressed miRNAs. 
Nuclear Co-Activator 1 (NCOA1), Nuclear Co-Repressor 2 (NCOR2) and 
Phosphodiesterase 4B (PDE4B) were selected based upon predicted targeting by miR-
34a (with NCOR2 and PDE4B both targeted by miR-184) and published relevance to 
psychiatric illness. Luciferase assays identified PDE4B as a target of miR-34a and miR-
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184, while NCOA1 and NCOR2 were targeted by miR-34a and 184, respectively. qPCR 
analyses were performed to determine whether changes in miRNA levels correlated 
with mRNA levels of validated targets. NCOA1 showed an inverse correlation with miR-
34a in BP, while NCOR2 demonstrated a positive correlation. In sum, this is the first 
study to 1) demonstrate miRNA changes in AnCg in psychiatric illness and 2) validate 
miR-34a as differentially expressed in CNS in MDD. These findings support a 
mechanistic role for miRNAs in the regulation of stress-responsive genes disrupted in 
psychiatric illness. 
 
INTRODUCTION 
Known as melancholia at the time of Hippocrates, ‘depression’ is a general term that 
encompasses a large number of mood disorders. Two of these particularly debilitating 
disorders—major depressive disorder (MDD, or unipolar depression) and bipolar 
disorder (BP; bipolar depression)—are also extremely common, with a lifetime 
prevalence of 16.6% and 3.9%, respectively (Kessler et al., 2005). Though a genetic 
component has been established (due in part to a high degree of heritability (Bierut et 
al., 1999; Lohoff, 2010; McGuffin et al., 2003; Smoller & Finn, 2003)), the genomic 
architecture of these disorders remains poorly understood. 
In recent years, however, microRNAs (miRNAs)—small, 21-23 nt RNAs that canonically 
act as post-transcriptional regulators of gene expression—have become an increasing 
focus for understanding CNS processes. Greater than 40% of all protein-coding 
transcripts are predicted to be regulated by miRNAs (Tan et al., 2009; Xie et al., 2005). 
MiRNAs are also highly enriched within the CNS, with greater than two-thirds of 
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identified miRNAs expressed in brain (Bak et al., 2008; Cao, Yeo, Muotri, Kuwabara, & 
Gage, 2006; Sempere et al., 2004). MiRNAs are also key governors of CNS processes 
at both the cellular level (e.g. synaptic plasticity, neuronal differentiation and neuronal 
migration (Cui et al., 2012; Makeyev, Zhang, Carrasco, & Maniatis, 2007; Morgado et 
al., 2014; Schratt et al., 2006)) and the systems level, with miRNAs linked to the 
regulation of HPA axis glucocorticoid negative feedback and complex behaviors such as 
responses to both acute and chronic stress as well as mood and anxiety (Bahi et al., 
2014; Haramati et al., 2011; Honda et al., 2013; Katsuura et al., 2012; Muinos-Gimeno 
et al., 2011; Vreugdenhil et al., 2009).  
The role of miRNAs in the regulation of stress responses is of particular interest given 
that chronic stress is not only a precipitant of mood and affective disorders (Breslau & 
Davis, 1986; Ilgen & Hutchison, 2005) but HPA axis disruption is one of the most 
commonly observed pathophysiologies in MDD patients, with symptomatic severity 
correlating with extent of hypercortisolemia (Gibbons & Mc, 1962; Vythilingam et al., 
2004). Intriguingly, a number of studies have directly demonstrated dysregulation of the 
miRNA regulatory network in patients with a variety of mood and affective disorders, 
with the vast majority focusing on schizophrenia (SZ) (Beveridge, Gardiner, Carroll, 
Tooney, & Cairns, 2010; Beveridge et al., 2008; A. H. Kim et al., 2010; Miller et al., 
2012; Moreau et al., 2011; Perkins et al., 2007; Santarelli, Beveridge, Tooney, & Cairns, 
2011; Shi et al., 2012; Smalheiser et al., 2014; Wan et al., 2015). Absent from these 
studies, however, has been analysis of the anterior cingulate cortex (AnCg), a brain 
region centrally involved in the regulation of mood, affect and cognition (Drevets et al., 
2008; Ebert & Ebmeier, 1996; Mayberg et al., 1999; Posner & DiGirolamo, 1998). 
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Alterations in AnCg function have been increasingly linked to mood disorders with AnCg 
activity previously demonstrated to differentiate patients with unipolar versus bipolar 
depression (Diler et al., 2014) and also to predict successful pharmaceutical and 
cognitive treatment response (Fujino et al., 2015; Mulert et al., 2007; Pizzagalli et al., 
2001; Salvadore et al., 2009). Further work has also established alterations in various 
systems within AnCg in MDD and BP disorders, including dysregulation in the fibroblast 
growth factor (FGF) system and clock genes (Bunney et al., 2015; Cheng et al., 2007; 
Evans et al., 2004). 
In the present study we assessed miRNA expression in the AnCg of both MDD and BP 
patients compared to controls. As miRNAs exert their regulatory effects by targeting 
mRNA transcripts, we employed bioinformatics approaches to identify mRNA targets of 
miRNAs whose expression varied due to disease and validated several mRNAs as 
direct targets. Finally, we examined the steady-state levels of a subset of validated 
mRNA targets and identified two that vary as a function of affective disease. 
 
MATERIALS AND METHODS 
Postmortem brain tissue and RNA extraction 
RNA samples derived from human post-mortem AnCg tissue were provided by the 
Pritzker Neuropsychiatric Research Consortium. The initial acquisition of tissue, 
microdissection of AnCg and subsequent RNA extraction that generated these samples 
is described in detail in (Evans et al., 2003). Briefly, brains were extracted during 
autopsy and sliced into coronal slabs approximately 0.75 cm thick. Slabs were then 
snap-frozen and stored at -80 degrees C until subsequent dissections. Anterior 
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cingulate cortex (AnCg, corresponding to Brodmann’s Area 24) was identified and 
dissected from left hemisphere, with all dissections being performed with tissue slabs on 
dry ice. Following dissection, total RNA was extracted from each sample using TRIzol 
(Invitrogen).  
Patient demographics and information—including gender, brain pH, post-mortem 
interval, medication history and agonal factor status—are listed in Supplementary 
Table 2.1. A total of 37 patients (n=8, BP; n=15, MDD; n=14, Control) were used for all 
miRNA and mRNA qPCR experiments. Patient diagnoses were based on criteria from 
the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, and were 
obtained from medical examiners, medical records and a family member. Patient 
samples were matched on two primary criteria, brain pH and agonal factor score. Given 
that our group has previously observed the significant impact of low brain pH on gene 
expression (Li et al., 2004) all patients were noted to have a brain pH > 6.55 to mitigate 
gene expression variance. Additionally, as a prolonged agonal state (e.g. coma, multiple 
organ system failures, respiratory arrest, etc.) tended to be associated with lower brain 
pH, all patients included in this study had no agonal factors. 
 
MicroRNA selection, reverse transcription and detection 
29 MicroRNAs (Supplementary Table 2) were selected for qPCR analyses. These 
miRNAs were based upon several criteria including prior published association with 
psychiatric illness(es) at the time of miRNA selection, shared dysregulation between 
multiple psychiatric illnesses (e.g. SZ, BP and/or MDD), abundant expression and prior 
literature validating interactions with mRNAs previously implicated in mental illness 
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(outlined in Supplementary Table 2). Total human RNA (7.5 ng) was reverse 
transcribed with the High Capacity RNA to cDNA Kit (Applied Biosystems Inc., 
Carlsbad, CA) as per manufacturer’s instructions using custom pooled RT primers 
corresponding to miRNAs selected for analysis. Following reverse transcription, first-
strand cDNA was subjected to preamplification per manufacturer’s instructions (Applied 
Biosystems Inc., Carlsbad, CA) using custom pooled preamplification primers. The 
resulting preamplified material was diluted 1:4 in 0.1x TE buffer before being subjected 
to qPCR. qPCR was performed using custom TaqMan Low-Density Array (TLDA) cards 
(Applied Biosystems Inc., Carlsbad, CA). Each TLDA card accommodated 4 biological 
samples and measured 29 miRNAs, as well as RNU48 as a control, in technical 
triplicate. RNU48 showed no significant variability between patient cohorts (CTRL, MDD 
and/or BP). qPCR reactions were run and measured on a ViiA7 thermocycler (Applied 
Biosystems Inc., Carlsbad, CA) using the following conditions: 2 minutes at 50 C, 10 
minutes at 95 C (1 repeat); 15 seconds at 95 C, 1 minute at 60 C (40 repeats). 
Following detection, miRNAs were analyzed for differential expression using the 2-ᇞᇞCT 
method (Livak & Schmittgen, 2001). miRNAs with a raw p-value < 0.05 in this initial 
screen were subjected to additional validation via individual assay qPCR. miRNAs in 
these subsequent validations were considered significantly differentially expressed with 
a two-tailed Student’s t-test result of p<0.05). 
 
In silico target prediction and vector construction 
Putative mRNA targets of dysregulated miRNAs were identified based on predicted 
targeting in  miRanda (Betel, Koppal, Agius, Sander, & Leslie, 2010) (August 2010 
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Release) and/or TargetScan (Lewis, Burge, & Bartel, 2005) (Release 6.2) in silico target 
prediction algorithms using default parameters. A gene ontology analysis of predicted 
targets of miR-34a was performed using DAVID Bioinformatics (Huang da, Sherman, & 
Lempicki, 2009a, 2009b) using default parameters (Supplementary Table 3). Following 
this, candidate mRNA targets were narrowed to those associated with terms in the top-
scoring functional clusters. Targets were subsequently selected for validation based 
upon 1) a direct association (based upon prior literature) with neuropsychiatric illness 
and/or 2) function in a biological process implicated in the pathophysiology of mental 
illness (e.g. glucocorticoid signaling, synaptic plasticity, transcriptional regulation). 
Target genes were amplified via end-point PCR (Supplementary Table 4) and 
subsequently cloned into a previously described US2 plasmid expression vector 
encoding firefly luciferase driven by the human UBC promoter (US2-Luc) (Yu et al., 
2008). Putative miRNA binding sites were identified via the aforementioned prediction 
algorithms and subsequently mutagenized using the QuikChange XL kit (Agilent 
Technologies, Santa Clara, CA) following manufacturer’s protocol. Mutagenesis primers 
(Supplementary Table 4) were designed using the web-based QuikChange Primer 
Design software (Agilent Technologies, Santa Clara, CA). 
 
Cell culture, transfection and luciferase assays 
96-well plates were coated for 15 minutes in 0.1 mg/mL poly-L-lysine (ThermoFisher 
Scientific, Waltham, MA) and washed with 1X PBS to aid in cell adherence. HEK293 
cells were plated at 70-90% confluence in 75 ul DMEM media (Invitrogen, Carlsbad, 
CA) containing Pen-Strep (Life Technologies, Carlsbad, CA) and 10% FBS 
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(ThermoFisher Scientific, Waltham, MA) per well. Cells were maintained at 37 C at 5% 
CO2. 
24 hours following plating HEK293 cells were transfected with 0.5 ul Lipofectamine 
2000 (Invitrogen, Carlsbad, CA), 300 ng US2-Firefly Luciferase (US2-Luc) plasmid 
containing the 3’ UTR of a gene of interest, 300 ng US2-Renilla Luciferase (US2-RL) 
plasmid and either 0.5 pmol miRNA mimic (MISSION MicroRNA Mimic) (Sigma-Aldrich, 
St. Louis, MO) (miRNA treated) or 1 ul sterile saline (vehicle treated) in 50 ul OPTI-
MEM media (Life Technologies, Carlsbad, CA) per well (n=6 per treatment group). Cells 
were allowed to incubate for 24 hours before proceeding to luciferase assays. 
Immediately prior to luciferase assays, OPTI-MEM media was aspirated and replaced 
with 75 ul of DMEM media per well. Protein lysates were prepared by adding 75 l of 
Dual-Glo Luciferase Assay Reagent (Promega, Madison, WI) per well and transferring 
the resulting lysate to a 96-well microassay plate (Sigma-Aldrich, St. Louis, MO). 
Luciferase assays were then performed following manufacturer’s instructions (Dual-
Glo® Luciferase Assay System (Promega, Madison, WI)). Luminescence was 
measured on a FluoStarOptima (BMG Labtech, Germany) with renilla luciferase serving 
as a transfection efficiency control.  
 
Messenger RNA reverse transcription and qPCR detection 
The same RNA samples used for the miRNA expression analyses were used for 
messenger RNA studies. Briefly, RNA samples (25 ng per sample) were converted to 
cDNA with random hexamer priming using SuperScript II Reverse Transcriptase 
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(Invitrogen, Carlsbad, CA) following manufacturer’s instructions. The resulting cDNA 
was diluted 1:4 in sterile water before use in subsequent qPCR studies. 
Individual TaqMan gene expression assays (Applied Biosystems Inc., Carlsbad, CA) 
were used to measure gene expression for NCOA1 (Assay ID# HS00186661_m1), 
NCOR2 (Assay ID# HS00196955_m1) and PDE4B (Assay ID# HS00963643_m1) with 
beta actin (Assay ID# HS99999903_m1) serving as a reference control. Messenger 
RNA qPCR detections were run on a ViiA7 thermocycler (Applied Biosystems Inc., 
Carlsbad, CA) using the previously described thermocycler conditions.  All samples 
were run in technical triplicate and were analyzed for differential expression using the 2-
ᇞᇞCT method (Livak & Schmittgen, 2001) and were considered significant with a two-
tailed Student’s t-test result of p<0.05. 
 
RESULTS 
Differential expression of a subset of miRNAs in AnCg of patients with MDD or BP 
disorder. 
Following qPCR detection 3 miRNAs—miR-33a, miR-144 and miR-431*—were 
excluded from analysis due to high variability among technical replicates and cycle 
threshold values >30. After exclusion, 26 miRNAs were examined for differential 
expression in BP and MDD cohorts versus controls (Table 2.1). Of these, 5 miRNAs—
miR-132, miR-133a and miR-212 in the BP cohort; miR-184 in the MDD cohort, and 
miR-34a shared between cohorts—exhibited raw p-values < 0.05 (Table 2.2) (although 
none passed multiple correction testing, e.g. FDR<0.15).To validate the differential 
expression of this subset of five miRNAs we performed an additional round of qPCR 
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validations employing individual miRNA assays. Analysis of this subsequent round of 
qPCR data identified all 5 miRNAs as differentially expressed with consistent 
directionality, magnitude of fold-change and disease specificity to the initial screen 
(Figure 2.1). 
Intriguingly, these miRNAs were dysregulated in a unidirectional fashion: all 
dysregulated miRNAs were repressed compared to control patients. While it did not  
achieve significance, miR-195—previously linked to regulation of brain-derived 
fneurotrophic factor (BDNF) (Mellios, Huang, Grigorenko, Rogaev, & Akbarian, 2008)—
exhibited a strong trend towards repression in both BP and MDD cohorts (p=0.10 and 
p=0.09, respectively). We note that three of these miRNAs—miR-132, miR-212 and 
miR-34a—have previously been shown to be dysregulated in PFC of SZ patients (A. H. 
Kim et al., 2010; Miller et al., 2012). These results suggest the shared dysregulation of 
Figure 2.1: A subset of miRNAs validate as differentially expressed in AnCg of BP 
and/or MDD patients. Vertical axis represents linear fold change in BP or MDD cohorts 
versus control patients (BP: n=8; MDD: n=15; Control: n=14). Expression levels were 
measured using Taqman-chemistry-based qPCR using individual assays. Three miRNAs 
(miR-132, 133a and 212) were dysregulated in BP, one (miR-184) was dysregulated in 
MDD and one miRNA—miR-34a, previously linked to schizophrenia—was dysregulated in 
both groups. All samples were run in technical triplicate with the snoRNA RNU48 serving 
as a reference control. (*: P < 0.05, #: P < 0.10; error bars represent SEM.) 
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several miRNAs across several neuropsychiatric conditions, with miR-34a serving as a 
consistently dysregulated miRNA in MDD, BP and SZ. Given this, along with the large 
number of validated miR-34a targets previously linked to multiple mood and affective 
disorders (Table 2), we elected to focus primarily on miR-34a for subsequent analyses. 
 
 
In silico target prediction analyses of dysregulated miRNAs 
Following our validation of miR-34a’s differential expression we performed a gene 
ontology analysis on the 655 putative miR-34a targets identified by the TargetScan 
algorithm (Lewis et al., 2005). Based upon the enriched terms in the two most 
significant GO clusters—specifically, ‘Synapse’ (Cluster 1) and ‘Transcription Regulator 
Activity’ (Cluster 2) (Supplementary Table 3)—we were able to identify 3 putative 
targets of miR-34a based upon our previously described selection criteria. Prior work 
has shown that two of these genes (NCOA1 and NCOR2) modulate the transcriptional 
activity of the glucocorticoid receptor (van der Laan, Lachize, Vreugdenhil, de Kloet, & 
Meijer, 2008), while PDE4B—a genetic risk factor for mental illness (Fatemi et al., 2008; 
Millar et al., 2005; Numata et al., 2009; Pickard et al., 2007)—regulates cAMP signaling 
and is enriched at the synapse (Bradshaw et al., 2008; Millar et al., 2005). Further 
sequence analysis indicated that, in addition to putative miR-34a binding sites, both 
NCOR2 and PDE4B possess putative miR-184 binding sites, potentially indicating 
common regulatory targets for both miRNAs disrupted in MDD patients. 
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Target validations of dysregulated miRNAs 
Following the identification of NCOA1, NCOR2 and PDE4B as putative mRNA targets of 
dysregulated miRNAs, luciferase vectors containing their respective 3’ UTRs were 
generated as previously described (Yu et al., 2008). HEK293 cells transfected with 
US2-Luc plasmids containing a wild-type 3’ UTR from PDE4B (PDE4B WT 3’ UTR) and 
either a miR-34a mimic or a miR-184 mimic yielded reduced luciferase values relative to 
control (Fig. 2.2A) (n=6 per treatment group). Similarly, HEK293 cells transfected with 
NCOA1 or NCOR2 WT 3’ UTR yielded reduced luciferase activity when transfected with 
miR-34a or miR-184 mimics, respectively (Fig. 2.2b and 2.2c). Though it exhibited a 
strong trend, treatment of HEK293 cells transfected with NCOR2 WT 3’ UTR and miR-
34a did not result in a statistically significant repression of luciferase activity (Fig. 2.2c). 
The specificity of these mRNA/miRNA interactions were demonstrated when mutating 
predicted miR-34a or miR-184 binding sites (34a-MUT or 184-MUT, respectively) was 
sufficient to relieve repression in the presence of miRNA mimics (Fig. 2. 2a-c). These 
findings demonstrate the direct regulation of these genes of interest by miRNAs 
dysregulated in BP and MDD patients. 
 
qPCR of validated miRNA targets 
As one way that miRNAs can exert their regulatory influence is via the degradation of 
mRNA transcripts, we employed qPCR methodologies to examine steady-state levels of 
our validated targets of miR-34a and/or miR-184 (Fig. 2.3). Consistent with miRNAs’ 
canonical role as negative regulators of gene expression, we observed a significant 
increase in NCOA1 mRNA levels in the BP cohort but not the MDD cohort. In contrast, 
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we observed a significant decrease in NCOR2 mRNA levels specific to the MDD cohort. 
Neither BP nor MDD cohorts showed significant alterations in PDE4B mRNA 
expression. Taken together, these results suggest the possibility that the reduction in 
miR-34a levels may influence steady-state levels of NCOA1 in BP patients. 
 
 
  
Figure 2.2: PDE4B, NCOA1 and NCOR2 are targets of miRNAs dysregulated in psychiatric 
illness. HEK293 cell cultures were plated and cotransfected with a miRNA mimic (either miR-34a or miR-184) 
and a firefly luciferase vector (Yu, Chung, Deo, Thompson, & Turner, 2008) containing either a wild-type 3’ 
UTR (WT 3’ UTR) or a 3’ UTR mutagenized at a predicted miRNA binding site (34a-MUT or 184-MUT 3’ UTR) 
(n=6/group). A vector encoding renilla luciferase was used to normalize luciferase activity. Significant 
reductions in luciferase activity were observed for PDE4B when cotransfected with either miR-34a or miR-184 
(Fig. 2a), NCOA1 when cotransfected with miR-34a (Fig. 2b) and NCOR2 when cotransfected with miR-184 
(Fig. 2c). Mutagenesis of the predicted binding sites was sufficient to relieve these 3’ UTR constructs of 
miRNA-induced inhibition.Mutagenesis of sites in the NCOR2 3’ UTR was not performed since this UTR 
showed no significant repression by miR-34a. (*: P < 0.05, #: P < 0.10 ; error bars represent SEM.) 
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DISCUSSION 
Given their enrichment in the brain, their regulation of key CNS processes, their 
widespread regulation of protein-coding transcripts and their dysregulation in a number 
of illnesses, miRNAs are uniquely positioned to play a key role in the pathology of 
psychiatric illness. In this study we examined the expression of 26 miRNAs in the AnCg 
of MDD and BP patients versus controls. From this, we identified 5 miRNAs—3 in BP, 1 
in MDD and 1 shared across both cohorts—that were differentially expressed in patients 
with psychiatric illness. Intriguingly, fold changes were unidirectional with all 
differentially expressed miRNAs reduced in MDD or BP versus controls. Additionally, we 
Figure 2.3: Steady-state mRNA levels of validated targets are altered in BP and 
MDD patients. The mRNA levels of NCOA1 and NCOR2 were dysregulated 
specifically in the BP and MDD cohorts, respectively. The same patient cohorts were 
used in both miRNA and mRNA expression analyses (BP: n=8; MDD: n=15 ; Control: 
n=14). Vertical axis represents linear fold change in BP or MDD patients versus 
controls. mRNA expression levels were analyzed using single-tube TaqMan qPCR 
assays specific to the genes of interest. Bars represent linear fold changes in BP and 
MDD cohorts compared to control patients with error bars representing SEM. (*: P < 
0.05, #: P < 0.10) 
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examined a subset of putative targets for differentially expressed miRNAs, and were 
able to validate NCOA1 as a target of miR-34a, NCOR2 as a target of miR-184 and 
PDE4B as a target of both miR-34a and miR-184. mRNA levels of NCOA1 showed an 
inverse correlation with miR-34a in the BP cohort, while mRNA levels of NCOR2 
showed a positive correlation with miR-34a and miR-184 in the MDD cohort (with 
PDE4B showing no expression change in either). While we note that it is possible that 
repression may occur at the level of translation rather than transcription (Wilczynska & 
Bushell, 2015), patient samples were not initially processed for protein examination; as 
such, we were unable to investigate this line of inquiry. While we recognize that the 
observed changes in miRNA expression levels are relatively modest, we feel it 
important to note that cooperative repression by a miRNA in combination with other 
miRNAs or RNA-binding proteins allows a non-linear relationship between miRNA 
expression and extent of mRNA target repression (Broderick, Salomon, Ryder, Aronin, 
& Zamore, 2011; Jacobsen, Wen, Marks, & Krogh, 2010; Mukherji et al., 2011), 
potentially allowing even minor changes in miRNA levels to act as ‘switches’ rather than 
simply fine-tuning gene expression.  
 
These data add to our understanding of potential mechanisms underlying psychiatric 
disorders. While miRNA expression has been examined across a multitude of 
psychiatric illnesses, encompassing several brain regions, cell types and blood 
(Bavamian et al., 2015; Fan et al., 2014; A. H. Kim et al., 2010; Miller et al., 2012; 
Moreau et al., 2011; Sun et al., 2015; Walker et al., 2015), to our knowledge this is the 
first work to examine miRNAs dysregulated as a function of psychiatric illness in AnCg. 
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Additionally, comparing prior work examining miRNA dysregulation in the DLPFC—
another brain region of intense interest in the pathology of mental illness—of BP and 
MDD patients to our results in AnCg, we see little overlap in the specific miRNA species 
dysregulated as a function of brain region. Potential explanations for this lack of overlap 
across studies include the usage of different cohorts of patients and the heterogeneity 
of neuropsychiatric illness. However, given prior work revealing that the complement of 
transcripts dysregulated in mental illness is highly dependent on brain region, the notion 
of region-specific patterns in miRNA disruption is consistent with current knowledge. 
Of further note is that this specificity extends not only to miRNA species (e.g. miR-34a 
versus miR-132) but also to individual miRNA isoforms. In a prior study, miR-133b was 
differentially expressed in DLPFC of BP patients (A. H. Kim et al., 2010). In contrast, 
while miR-133b levels were not significantly different in our cohort of MDD and BP 
patients versus controls, miR-133a (encoded by a different gene than miR-133b) was 
significantly repressed in the AnCg of our cohort of BP patients (Fig. 2.1). As the mature 
forms of miR-133a and b differ in only one nucleotide (a U versus a G, respectively, at 
the final 3’ residue), this single-nucleotide difference could represent a more subtle (but 
potentially significant) shift in target recognition between the two isoforms.  
While miR-132 and miR-212 have been previously identified as differentially expressed 
in the DLPFC of SZ patients (A. H. Kim et al., 2010; Miller et al., 2012), we have 
identified these miRNAs—which are co-transcribed in the same primary transcript—as 
differentially expressed in a cohort of BP patients; an intriguing finding given that BP 
and SZ may share familial and genetic risk factors (Berrettini, 2003; D. Kim, Kim, Koo, 
Yun, & Won, 2015; Purcell et al., 2009; Shepherd et al., 2015), including miRNAs (A. H. 
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Kim et al., 2010; Miller et al., 2012; Walker et al., 2015). Additionally, as miR-34a 
expression levels are dysregulated in cohorts of both SZ and BP patients (in DLPFC 
and cerebellum, respectively) (Bavamian et al., 2015; A. H. Kim et al., 2010), our finding 
that miR-34a is significantly differentially expressed in a cohort of patients with MDD 
identifies miR-34a as the first miRNA to be differentially expressed in the CNS across 3 
psychiatric illnesses—BP, MDD and SZ. Unfortunately, the lack of SZ patients in the 
present study precludes the possibility of identifying whether miR-34a is regulated 
across BP, MDD and SZ specifically in AnCg: an intriguing possibility given the 
postulated linkage between BP and SZ (Berrettini, 2003; Purcell et al., 2009) and 
several shared symptoms of BP and MDD. 
Given prior evidence that suicide may be a strong factor in influencing miRNA 
expression (Smalheiser et al., 2014) we also performed miRNA expression analyses 
specifically in the suicide subgroups of our MDD and BP cohorts. Analyses of miRNA 
expression in the suicide subgroups of MDD and BP mirrored the directionality, 
magnitude of fold-change and disease specificity compared to entire patient populations 
(data not shown). Additional miRNA expression analyses using only non-suicide 
patients revealed strong trends in directionality of fold change and disease specificity 
identical to both suicide-subgroup and whole-group analyses, but these changes were 
not statistically significant. We note, however, that the total number of patients in the 
non-suicide groups are extremely small (n=2, BP; n=5, MDD) and, as such, we are 
unable to definitively conclude whether suicide defined a subgroup of BP or MDD 
subjects.   
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miR-34a and miR-184’s respective regulation of NCOA1 and NCOR2—which, in turn, 
can alter the glucocorticoid receptor’s (GR) transcriptional activity (Lachize et al., 2009; 
van der Laan et al., 2008)—is intriguing for several reasons. NCOA1 has been identified 
as necessary for proper stress responses (Lachize et al., 2009; Winnay, Xu, O'Malley, & 
Hammer, 2006) while prior literature demonstrates both NCOA1 and NCOR2 modulate 
the GR-mediated transcription of corticotropin releasing hormone (CRH), a psychiatric 
risk factor linked to MDD pathology (van der Laan et al., 2008). Prior work has 
demonstrated the direct transcriptional repression of miR-184 by the psychiatric risk 
factor methyl CpG binding protein 2 (MeCP2) (Nomura et al., 2008). Additionally, the 
miR-34 family (including miR-34a) has previously been linked to stress (Haramati et al., 
2011). Chronic stress is thought to act as a precipitating environmental factor for a host 
of mental illnesses and induces chronic elevations in circulating glucocorticoids (e.g. 
hypercortisolemia). Altered HPA axis activity—particularly hypercortisolemia—is one of 
the most consistently observed pathophysiologies in MDD patients (Gibbons & Mc, 
1962) and is observed in both BP and SZ (Altamura, Boin, & Maes, 1999; Daban, Vieta, 
Mackin, & Young, 2005; Jakovljevic, Muck-Seler, Pivac, & Crncevic, 1998). As 
glucocorticoids exert powerful transcriptional effects through the GR (with GR mRNA 
level significantly reduced in MDD versus control patients in a prior study (Qi et al., 
2013)) and miR-34a exerts influence over a GR cofactor, these findings suggest a role 
for miR-34a in the transcriptional response to stress. 
The shared regulation of PDE4B by miR-34a and miR-184 is also of note given 
PDE4B’s linkage to MDD, BP, SZ and anxiety (Fatemi et al., 2008; McGirr et al., 2015; 
Millar et al., 2005; Numata et al., 2009; Padmos et al., 2008; Pickard et al., 2007; Yuan 
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et al., 2011). In addition to PDE4B binding to and being regulated by the psychiatric risk 
factor Disrupted in Schizophrenia 1 (DISC1) (Millar et al., 2005), pharmacological 
inhibitors of PDE4B activity have previously been tested as atypical antidepressants 
(Fleischhacker et al., 1992; Zeller, Stief, Pflug, & Sastre-y-Hernandez, 1984). While 
these drugs were never widely deployed (due primarily to negative side-effects at 
therapeutic dosage), the directionality suggested by this pharmacological treatment—
i.e. that increased PDE4B is correlated with MDD—is substantiated by prior work 
demonstrating an increase in levels of PDE4B protein in cingulate cortex of MDD 
patients versus controls (Yuan et al., 2011). This prior work is also consistent with our 
current data, in which decreases in miR-34a and miR-184 (Fig. 2.1)—which can 
negatively regulate PDE4B (Fig. 2.2)—should lead to an increase in PDE4B protein 
levels. While PDE4B mRNA levels were unchanged in either BP or MDD cohorts of the 
present study, it is important to note that miRNAs can exert their regulatory influence 
through translational inhibition as well as via mRNA degradation (reviewed in 
(Wilczynska & Bushell, 2015)). 
 
Finally, we note that—in addition to the work presented here—several groups have 
validated additional targets of miR-34a that are either directly dysregulated or indirectly 
implicated in biological processes thought to be disrupted in psychiatric disease (Table 
2.2). Given that mental illnesses are noted for their heterogeneity of causes, symptoms 
and treatments, it is noteworthy that miR-34a—representing the only shared miRNA 
dysregulated in MDD, BP and SZ—targets transcripts implicated in the pathology of all 
three of these illnesses (Table 2.2). Intriguingly, miR-34a has been linked to acute 
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responses to stress while another miR-34 isoform—miR-34c—was differentially 
expressed in animal models of both acute and chronic stress (Haramati et al., 2011). As 
stress-induced HPA axis dysfunction is a common precipitating event for mood and 
affective disorders—and our work presented here identifies miR-34a as a regulator of 
NCOA1, itself previously identified as a key modulator of both stress responses and 
HPA axis activity (Lachize et al., 2009; Winnay et al., 2006)—these findings suggest 
miR-34a as an attractive target for further investigation. 
In sum: due to their enrichment in the brain, regulation of key CNS processes and the 
fact one miRNA can regulate hundreds of mRNA targets, miRNAs are hypothesized to 
play a key role in mood and affective disorders. This current work sheds light on miRNA 
dysregulation in AnCg (a brain region central to the regulation of mood and cognition) 
as well as the mRNA targets of these dysregulated miRNAs, and identifies miR-34a in 
particular as a miRNA dysregulated across multiple psychiatric illnesses and across 
multiple cortical brain regions known to participate in affect and whose role in the 
molecular architecture of these disorders remains to be fully described. 
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Tables and Supplementary Information 
 
Table 2.1: Initial screen of miRNAs in AnCg of MDD and BP patients versus controls. 
  BP versus Control   MDD versus Control   
microRNA Fold Change P-Value Fold Change P-Value 
miR-124 0.83 0.21 0.92 0.69 
miR-132 0.79 0.05 0.97 0.73 
miR-133a 0.71 0.04 0.88 0.30 
miR-133b 0.73 0.13 0.80 0.17 
miR-139-5p 0.87 0.12 0.90 0.56 
miR-145* 1.03 0.90 0.90 0.55 
miR-148a 0.95 0.72 0.95 0.70 
miR-154* 1.00 1.00 0.93 0.74 
miR-181a 0.92 0.40 0.91 0.35 
miR-181b 1.01 0.94 1.09 0.69 
miR-184 0.93 0.44 0.84 0.02 
miR-195 0.87 0.10 0.87 0.09 
miR-212 0.79 0.03 1.03 0.77 
miR-219 0.99 0.94 0.91 0.56 
miR-23a 0.86 0.56 0.96 0.83 
miR-23b 0.86 0.44 1.08 0.61 
miR-342-3p 0.93 0.33 0.99 0.92 
miR-346 1.01 0.97 0.90 0.41 
miR-34a 0.69 0.02 0.77 0.03 
miR-423-3p 0.88 0.60 0.94 0.77 
miR-487a 0.77 0.11 0.83 0.39 
miR-574-3p 1.01 0.96 0.94 0.60 
miR-584 1.00 0.99 0.99 0.96 
miR-7 0.77 0.25 0.94 0.72 
miR-769-5p 0.85 0.32 0.98 0.90 
miR-889 0.84 0.19 0.85 0.16 
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Supplementary Table 2.1: Demographics and information for patients used in this 
study may be accessed at: 
https://umich.box.com/s/g395mdeivulfon1q99o7jt1i3y8nmjqu 
Supplementary Table 2.2: List of miRNAs chosen for differential expression 
analyses and rationale may be accessed at: 
https://umich.box.com/s/l8kusc748d2yn5g61105fqs5w7hi9aa7 
Supplementary Table 2.3: Gene ontology analysis of in silico predicted targets of 
miR-34a may be accessed at: 
https://umich.box.com/s/l73bay2m2f0zw3gbsma2mxk9y8tflu0w 
Table 2.2: Validated mRNA targets of miR‐34a with linkage to neuropsychiatric illness. Gene names in 
bold represent novel mRNA targets. 
Gene Gene Description Gene function Association with Disease 
GRM7 Metabotropic Glutamate Receptor 7 Synaptic transmission 
GWAS (BP): 
(Fleischhacker et al. , 1992, 
 Zhou et al. , 2009) 
ANK3 Ankyrin G Actin/spectrin adaptor protein GWAS (BP)(Bavamian et al. , 2015) 
CACNB3 
Voltage-Dependent L-
Type Clacium  Synaptic transmission GWAS (BP)(Bavamian et al. , 2015) 
Channel Subunit Beta-3 
VEGFA Vascular Endothelial Growth Factor A Growth factor signaling 
Dysregulation of mRNA and protein levels, 
linkage analysis (MDD) 
(Berent et al. , 2014, Tsai et al. , 2009) 
NCOA1 Nuclear Receptor Co-Activator 1 
Modulation of gene 
transcription via  
Dysregulation of mRNA levels (BP), modulation of 
stress responses and  
glucocorticoid receptor HPA axis activity. (Lachize et al. , 2009, Winnay et al. , 2006) 
NCOR2 Nuclear Receptor Co-Repressor 2 
Modulation of gene 
transcription  Dysregulation of mRNA levels (MDD) via glucocorticoid 
receptor 
PDE4B 
cAMP-specific 3',5'-cyclic  Regulates synaptic transmission via  
Dysregulation of protein levels (MDD), SNP (SZ 
and BP 
Phosphodiesterase 4B controlling cAMP levels (Fatemi et al. , 2008, Pickard et al. , 2007, Yuan et al. , 2011) 
SIRT1 Sirtuin 1 Histone deacetylase 
Dysregulation of mRNA levels (BP, 
MDD)(Abe, 2011) 
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Supplementary Table 2.4: Primer design and information for end-point PCR and 
site-directed mutagenesis of miR-34a targets may be accessed at: 
https://umich.box.com/s/sq4tjk93xhoe2ftf9rcnmv6j978kkdky 
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Chapter III: A chronic variable stress paradigm induces large-scale transcriptomic 
alterations in medial prefrontal cortex 
 
 
Following the completion of our prior miRNA studies (Chapter II), we recognized that 
studies in human samples are confounded by both the sheer diversity of clinical 
depressive phenotypes as well as individual patient variability (e.g. lifestyle, 
environmental and genetic variabilities). These conditions make it extraordinarily difficult 
to examine potential mechanistic hypotheses, a direction in which we wished to move 
towards. Given that animal models afford researchers the opportunity to more rigorously 
define experimental manipulations, and stress is often a major precipitating factor in the 
onset of depressive illness in humans, we elected to employ an animal model of chronic 
stress to examine stress-induced transcriptomic alterations in a brain-region-specific 
fashion. 
 
ABSTRACT 
Stress is a central feature that enables an organism’s to adapt to a variety of changing 
conditions. While acute stress is generally perceived as beneficial, chronic stress is 
often maladaptive and induces a number of physiological and genetic changes in a 
highly brain-region-dependent fashion. One of these brain regions is the medial 
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prefrontal cortex (mPFC), an extremely stress-sensitive region which is centrally 
involved in stress responses and regulation of HPA axis activity. We performed RNA 
sequencing and high-throughput qPCR analyses to query the impact of chronic stress 
on transcriptomic networks in mPFC and validated a large number of mRNA and 
miRNA transcripts as chronic-stress-regulated. Using laser capture microdissection 
(LCM), I examined infralimbic and prelimbic expression patterns in control and chronic 
stress samples, revealing subregional stress regulation in a subset of RNAs. Finally, 
given that mPFC hypofunction and shrinkage is commonly observed following chronic 
stress, we constructed a biochemical “interactome” of stress-regulated mRNAs that is 
consistent with chronic-stress-induced reductions in glutamatergic function in mPFC. 
Combined, these findings support the wide-ranging impact of stress on the mPFC 
transcriptome and is consistent with a potential mechanism for stress-induced 
glutamatergic hypofunction in mPFC. 
 
INTRODUCTION 
One of the key challenges that organisms face is maintaining homeostasis in the face of 
various environmental challenges (collectively termed ‘stress’). The hypothalamic-
pituitary-adrenal (HPA) axis--one of the primary systems underlying the central stress 
response--serves an indispensable role in the survival of an organism by orchestrating 
physiological adaptations in response to stress. While these adaptations are beneficial 
during periods of acute stress, extended and/or frequent activation of the HPA axis—
such as that induced by chronic stress—is often maladaptive. Of particular note, chronic 
stress has been linked to the precipitation of a variety of psychiatric disorders such as 
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mood and anxiety disorders (Holsboer, 2000; Kendler, Karkowski, & Prescott, 1999; 
Kessler, 1997). 
Chronic stress is also noteworthy due to its significant impact on neuronal physiology. A 
number of studies have identified robust decreases in volume, cell number, dendritic 
spine size, dendritic branching and neuronal activity in the medial prefrontal cortex 
(mPFC) following chronic stress (reviewed in (Arnsten, 2009)). The mPFC acts as a 
“brake” on amygdalar activity and, consistent with this, prior work has identified 
increased dendritic branching and neuronal activity in the amygdala following chronic 
stress (Morgan, Romanski, & LeDoux, 1993; Quirk, Likhtik, Pelletier, & Pare, 2003; 
Vyas et al., 2002). The mPFC also acts as an inhibitor of HPA axis activity, with direct 
stimulation of the prelimbic subdivision (PL) of mPFC sufficient to inhibit not only HPA 
axis activity but also responses to stress (Jones, Myers, & Herman, 2011). 
In addition to the physiological effects of chronic stress, a number of biological systems 
(particularly glutamatergic, GABAergic and monoaminergic neurotransmission) have 
been shown to be subject to regulation by stress within mPFC. Stress is capable of 
heavily modulating gene expression across nearly every organ, tissue and cell type in 
the body (Chrousos, 2009). This is particularly true in the CNS, where a multitude of 
biological processes—including cell division/cycle control, neurogenesis, synaptic 
plasticity, neurotransmitter synthesis, microRNA (miRNA) expression and glial/neuronal 
function—are regulated not only by brain region but also by individual cell type (Bak et 
al., 2008; Salta & De Strooper, 2012; Ziats & Rennert, 2014). 
These physiological and genetic observations are noteworthy in the context of relating 
mPFC dysfunction and maladaptive responses to chronic stress. The first is that the 
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mPFC exhibits a high vulnerability to stress, with morphological changes being 
observed in as little as 1-2 days in mPFC compared to >7 days in other brain regions 
(Brown, Henning, & Wellman, 2005; Izquierdo, Wellman, & Holmes, 2006). 
Furthermore, given that the primary output of the mPFC are excitatory glutamatergic 
pyramidal cells, an intriguing possibility is that this reduction in mPFC function is due to 
glutamatergic hypofunction. A growing body of prior work has provided support to this 
theory, with a number of studies revealing significant alterations of genes linked to 
glutamatergic neurotransmission, glutamate reuptake/recycling and direct reductions of 
glutamate and glutamate metabolites in the mPFC following chronic stress (Sanacora et 
al., 2012; Sanacora et al., 2008). This work is consistent with the observation that 
pyramidal neurons demonstrate significantly increased (inhibitory) adrenergic receptors 
in mPFC (particularly Adra2a, a gene with significant ties to chronic stress and 
depressive pathology (reviewed in (Cottingham & Wang, 2012)). Finally, mPFC 
pyramidal neurons receive heavy inhibition via serotonergic, epinephrinergic and 
norepinephrinergic input from the locus coeruleus (LC) (which is activated by chronic 
stress) (Mana & Grace, 1997; Pavcovich et al., 1990). Taken together, these data 
support the hypothesis that the mPFC hypofunction observed following chronic stress 
may be 1) causative of these maladaptive responses to chronic stress and the 
precipitation of depressive illness (via reducing the mPFC’s ability to negatively regulate 
HPA axis activity) and 2) the result of impaired glutamatergic neurotransmission. 
In the present study we have employed RNA sequencing and high-throughput qPCR 
methodologies to analyze gene expression (via RNA levels) in mPFC of mice subjected 
to a 14 day chronic unpredictable stress paradigm versus unstressed controls. Using 
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laser-capture microdissection methods we revealed the subregional specificity of a 
subset of these transcripts. Following the identification and validation of a large number 
of stress-regulated mRNA and miRNA transcripts we employed an in silico target 
prediction analysis of our data set. We subsequently identified several putative 
mRNA/miRNA interactions within our cohort of validated stress-regulated RNAs and 
proceeded to confirm these interactions. Finally, we generated an interactome 
comprised of stress-regulated RNAs that provides a mechanistic framework for the 
morphological changes observed following chronic stress. 
 
MATERIALS AND METHODS 
Animals 
All animal experiments were performed with adult male C57BL/6 mice (10 weeks of 
age). With the exception of exposure to the CVS paradigm (see below), mice were 
group housed on a 12:12 light/dark cycle (6:00 AM to 6:00 PM) and were provided with 
ad libitum access to food and water. All animal procedures were reviewed and approved 
by the University of Cincinnati Animal Care and Use Committee. 
 
CVS Paradigm 
We opted to employ the CVS paradigm due to the fact that 1) it is a robust and well-
characterized model of stress and 2) it induces a number of physiological, genetic and 
behavioral deficits (including HPA axis hyperactivity and anhedonia-like behavior) (Flak, 
Ostrander, Tasker, & Herman, 2009; Herman et al., 1995; Imaki, Nahan, Rivier, 
Sawchenko, & Vale, 1991). Two separate cohorts of mice were employed in the CVS 
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paradigm (n=12, Cohort A; n=10, Cohort B) with each cohort consisting of one group 
exposed to the CVS paradigm and one group of non-stressed controls (n=6/group, 
Cohort A; n=5/group, Cohort B).  
Mice employed in the CVS were subjected to the paradigm as previously described 
(Herman et al., 1995). Briefly, mice were exposed to 14 days of CVS consisting of two 
stressors per day (one AM stressor, one PM stressor). Stressors are summarized in 
Table 3.1. The morning following the final afternoon stressor mice were euthanized via 
cervical dislocation and brain tissue was extracted. 
 
Tissue Collection and RNA Extraction 
Depending on experimental utility, tissue was collected in one of two ways. 
Following cranial extraction, brains from mice in Cohort A were placed into a chilled, 
stainless steel mouse brain matrix. Using coordinates from the Paxinos 
neuroanatomical atlas, neural tissue containing medial prefrontal cortex (mPFC) was 
identified and coronal “slabs” were generated using pre-defined slice intervals in the 
brain matrix. These slabs were then placed on a chilled stainless steel block and mPFC 
was microdissected on the basis of defined landmarks, with the ventral border defined 
by the ventralmost extent of the foreceps minor, the dorsal border defined by the lateral 
deflection of the corpus callosum, and the lateral border by the corpus callosum.  The 
dissections were designed to be limited to the infralimbic (IL) and prelimbic (PL) 
cortices. mPFC tissue was then placed in a 1.5 mL microfuge tube and snap-frozen in 
liquid nitrogen. RNA was subsequently isolated via a standard TRIzol extraction 
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following manufacturer’s instructions (Life Technologies, Carlsbad, CA) and 
concentration was measured on a NanoDrop 1000 (Thermo Scientific). 
Brains from mice in Cohort B were immediately flash-frozen in liquid nitrogen and 
subsequently cut into 14µm-thick sections on a Leica CM1850 Cryostat (Leica, Wetzlar, 
Germany). Sections containing mPFC were then prepared for laser-capture 
microdissection (LCM) via ethanol dehydration (2x 75% ethanol, 1x 95% ethanol, 2x 
100% ethanol washes, 30 seconds each wash) and xylene treatment (2x xylene 
washes, 5 minutes each). IL and PL subdivisions of mPFC were separately laser 
captured using an ArcturusXT LCM System (Thermo Fisher Scientific, Waltham, MA). 
Following LCM, IL and PL RNA samples were generated using the RNAqueous Micro 
Kit (Thermo Fisher Scientific, Waltham, MA) following manufacturer's instructions. Due 
to the relatively low yield of this method, RNA concentration was quantified using the 
Quant-IT RiboGreen kit (Thermo Fisher Scientific, Waltham, MA). 
 
RNA Sequencing and Analysis 
Following extraction, RNA samples from Cohort A were subjected to RNA sequencing. 
Library construction and sequencing were performed by the University of Michigan DNA 
Sequencing Core (Director: Robert Lyons, Ph.D.). Libraries were generated from 100 ng 
of total RNA per sample using the Illumina TruSeq Sample Prep v2 kit (Illumina, San 
Diego, CA) following manufacturer's instructions. Following library construction samples 
were clustered on a cBot (Illumina, San Diego, CA), loaded with 4 samples per lane 
onto a HiSeq flow cell (Illumina, San Diego, CA), and sequenced on a HiSeq 2000 
(Illumina, San Diego, CA) using version 3 reagents according to manufacturer's 
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instructions. Reads were subsequently aligned and mapped to the mouse genome 
(UCSC version GRCm38/mm10, Dec. 2011) using TopHat and Bowtie. Individual reads 
with low transition, >3 mismatches or mapped >10 times to the genome were excluded 
from analysis, with an average read count of 34.3 million reads used in subsequent 
analyses (Supplementary Table 3.1). Read counts were generated using standard 
RPKM normalization (Mortazavi et al, 2008; Nat Methods) (Supplementary Table 3.2). 
Reads were then analyzed for differential expression between CVS and non-stressed 
control groups, with a minimum fold change of 1.3 and raw p-value < 0.05 used to 
identify candidates for qPCR validation analyses. 
 
Selection and Validation of Stress-Regulated mRNAs 
A gene ontology (GO) analysis was performed to narrow the list of prospective targets 
for validation. All transcripts identified as differentially expressed in the RNA sequencing 
results were used in this preliminary screen, and a list of top GO terms associated with 
CNS-specific phenomena was generated. Greater than 60 transcripts from these 
categories were selected for subsequent validation based upon several criteria including 
association with processes dysregulated in mPFC in chronic stress (such as spine size, 
synaptic plasticity, neurotransmission, etc), association with HPA axis function and 
response, prior association with neuropsychiatric illness and prior use as a therapeutic 
target in mood/affective disorders (Supplementary Table 3.3). 
Total RNA samples from Cohort A (15 ng/sample) were reverse transcribed using the 
High Capacity cDNA Kit and TaqMan Custom RT pool primers (Life Technologies, 
Carlsbad, CA) corresponding to the mRNA targets selected for validation. First-strand 
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cDNA was then subjected to preamplification using TaqMan Preamp Master Mix and 
TaqMan Custom PreAmp pooled primers (Life Technologies, Carlsbad, CA) 
corresponding to the aforementioned mRNA targets. Both reverse transcription and 
preamplification were performed according to manufacturer's instructions. The resulting 
preamplified material was diluted 1:8 in 0.1x TE Buffer prior to qPCR detection. 
qPCR was accomplished using custom TaqMan Low-Density Array (TLDA) cards (Life 
Technologies, Carlsbad, CA) capable of measuring 64 mRNA targets in technical 
triplicate. TLDA cards were run on a ViiA 7 (Life Technologies, Carlsbad, CA) using 
standard TaqMan thermocycler conditions: 2 minutes at 50 C, 10 minutes at 95 C (1 
repeat); 15 seconds at 95 C, 1 minute at 60 C (40 repeats). Differential expression was 
assessed using the 2-CT method (Livak & Schmittgen, 2001) with beta actin used as a 
reference control. Significance was set at p<0.05 in a Student's two-tailed T-test. 
For Cohort B, both RNA pools (PL and IL; 15 ng per sample) were separately reverse 
transcribed with the High Capacity cDNA Kit (Life Technologies, Carlsbad, CA) using 
standard random hexameric primers. TaqMan Individual mRNA Assays were used to 
measure steady-state RNA levels of putative stress-regulated transcripts in both IL- and 
PL-derived samples. qPCR, differential expression and statistical analysis were both 
performed as outlined above. Beta actin was used as a reference control. 
 
High-Throughput Screen and Validation of Stress-Regulated microRNAs 
Total RNA samples from Cohort A (15 ng/sample) were reverse transcribed using the 
TaqMan MicroRNA Reverse Transcription Kit (Life Technologies, Carlsbad, CA) with 
TaqMan MegaPlex Rodent Pool A primers (Life Technologies, Carlsbad, CA). Reverse 
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transcribed material was subsequently preamplified using TaqMan Preamp Master Mix 
(Life Technologies, Carlsbad, CA) with TaqMan Megaplex Rodent Pool A Preamp 
primers (Life Technologies, Carlsbad, CA). >350 microRNAs were initially measured 
using Rodent Pool A TLDA cards. microRNAs identified as differentially expressed in 
this initial screen were then subjected to additional qPCR validation using more 
individual miRNA assays. Thermocycling, qPCR detection, and differential expression 
were assessed as outlined above. U6 was used as a reference control. 
 
Prediction and Validation of mRNA Targets of Stress-Regulated microRNAs 
Putative mRNA targets of stress-regulated miRNAs were identified using the 
TargetScan 7.0 and miRanda (August 2010 release) algorithms. Rac1 was selected for 
validation due to 1) its shared targeting by several stress-regulated miRNAs and 2) prior 
evidence that characterized it as a direct binding partner of a our subset of validated 
stress-regulated RNAs. Following selection, Rac1 3’ UTR was amplified via end-point 
PCR and cloned into a previously described US2-Luciferase vector (Yu et al., 2008) 
using standard molecular cloning methods. Following vector construction 3' UTR 
luciferase constructs were transfected into HEK-293 cells along with MISSION miRNA 
mimic (Sigma-Aldrich, St. Louis, MO) and US2-Renilla Luciferase constructs as a 
transfection efficiency control. Following a 24-hour incubation, protein lysates were 
collected from transfected cells and luciferase assays performed using the Dual-Glo 
Luciferase Assay Reporter System (Promega, Madison, WI) following manufacturer's 
instructions. Luminescence was measured on a FluoStar Optima (BMG LabTech, 
Germany). To confirm miRNA binding specificity, putative miRNA binding sites were 
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mutated using the QuikChange Site-Directed Mutagenesis Kit (Agilent, Santa Clara, 
CA) and then subjected to a second luciferase assay as previously described. 
 
RESULTS 
Chronic stress induces widespread mRNA dysregulation in mPFC 
Our initial RNA sequencing analysis identified >15,000 individual gene IDs within each 
RNA sample from Cohort A mPFC (Supplementary Tables 3.1, 3.3). Of these 
transcripts >2,000 RNAs were identified as significantly differentially expressed in mice 
from Cohort A subjected to CVS versus non-stressed controls. In order to narrow down 
this list for subsequent qPCR validation studies we performed a gene ontology analysis 
on a list of all differentially expressed transcripts using the GoTermFinder Gene 
Ontology tool (E. I. Boyle et al., 2004). Given that stress affects nearly every cell type, 
tissue and organ system in the body, we focused our search specifically on terms 
associated with CNS-specific processes (Supplementary Table 3.4). In conjunction 
with this approach, we employed additional literature screens to identify additional 
stress-regulated targets that were either previously linked to stress (such as Rgs4, a 
previously identified risk factor for schizophrenia (Rivero et al., 2013; Volk, Eggan, & 
Lewis, 2010)) or validated binding partners of genes identified in the initial GO analysis. 
We limited our validation phase to approximately 60 mRNA targets (with additional 
negative and housekeeping RNA controls) due to limits imposed by the custom design 
of the commercial platform we employed (Taqman Low Density Array (TLDA) cards 
(Applied Biosystems, Inc.)). 
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Due to the custom design of the TLDA platform, we limited our validation phase to ~60 
mRNA targets for qPCR validation (Supplementary Table 3.3) according to our 
previously mentioned criteria. 61 of these targets were identified as differentially 
expressed in our RNA sequencing data, while 2 (Grin2b and Nr3c1) were chosen as 
negative controls. The final mRNA (beta actin, Bact) was selected as a reference 
control. Following qPCR analysis, statistical analysis of qPCR data confirmed the 
differential expression of 31 of these 60 mRNA transcripts (p<0.05) (Figure 3.1). In 
addition, a direct examination of linear fold changes revealed a robust positive 
correlation (R2 = 0.8646) between samples analyzed by deep sequencing and qPCR 
methodologies, indicating strong reproducibility of RNA sequencing data 
(Supplementary Figure 3.1). 
We note that a large number of validated transcripts have showed prior association with 
mood and affective disorders, particularly Disrupted in Schizophrenia 1 (Disc1), its well-
characterized binding partner Traf2 and Nck-interacting Kinase (Tnik) and the 
adrenergic receptor Adra2a (Burette et al., 2015; Cottingham & Wang, 2012; Q. Wang 
et al., 2011).  Furthermore, a number of our validated stress-regulated targets have also 
been targets for therapeutic interventions in a number of mental illnesses. These 
include the status of Adra2a as a target for monoaminergic therapies in mood disorders, 
inhibitors of the tachykinin receptor Tacr1 being explored as atypical antidepressants 
and, more recently, inhibitors of glycine transporter Slc6a9 (GlyT1) being examined as 
an avenue for atypical antipsychotics (Ratti et al., 2013; Singer, Dubroqua, & Yee, 
2015). Finally, while changes in steady-state levels of mRNAs are not necessarily 
indicative of changes at the protein level, we note that the directionality of these 
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changes are consistent with the proposed mechanisms of therapeutic activity for these 
drugs (e.g. we observe increased GlyT1 in CVS, while inhibition of GlyT1 is proposed to 
have a therapeutic effect). 
 
A subset of miRNAs are regulated by chronic stress in mPFC 
Given the growing body of evidence that implicates both HPA axis activity and chronic 
stress regulation of a subset of miRNAs we also performed miRNA expression analyses 
on RNA samples from Cohort A mPFC. Of note, these samples were identical to those 
used to generate RNA sequencing and mRNA qPCR expression data. 
Figure 3.1: RNA sequencing and qPCR validation reveals widespread mRNA 
dysregulation in mPFC of CVS mice versus controls. Vertical axes in represent linear fold 
change of mRNA levels in CVS mice versus non-stressed controls (n=6/group; Cohort A) with 
blue and red bars representing fold changes assessed by RNA sequencing and TLDA-based 
qPCR, respectively. All transcripts shown were initially identified as putatively differentially 
expressed via RNA sequencing (linear fold change > 1.3, raw p-value < 0.05), while those 
labeled significant in this figure were validated by qPCR as significantly differentially 
expressed (*: p<0.05, #: p<0.10). 
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Of the >500 miRNAs examined in our initial screen, 14 showed significant differential 
expression in Cohort A CVS animals compared to non-stressed controls (Figure 3.2). 
Due to technical limitations of this TLDA card format in high-throughput screens 
(specifically, each assay having only a single replicate per plate), we proceeded to 
perform individual assay qPCR validations in technical triplicate for all putative stress-
regulated miRNAs identified in our initial screen (Figure 3.2). Of these, four miRNAs 
were validated as significantly differentially expressed: miR-187-3p, miR-298-5p, miR-
320-3p, and miR-666-5p. Two additional miRNAs--miR-142-3p and 423-5p--exhibited a 
strong trend towards repression (p < 0.10), but did not validate.  
 
 
Figure 3.2: A high-throughput qPCR screen reveals altered steady-state levels of miRNAs in 
mPFC of CVS mice versus controls. Vertical axes in Fig. 3.2 represent linear fold changes of miRNA 
levels in CVS mice versus non-stressed controls (n=6/group; Cohort A). Of the >500 miRNAs tested, 14 
were identified as significant in our initial screen (blue bars). Of these, 4 (miR-187, 298, 320 and 666-5p) 
were validated as significantly differentially expressed with 2 additional miRNAs exhibiting a strong trend 
towards differential expression (miR-142-3p, p=0.07; miR-423-5p, p=0.09) following more stringent 
qPCR validation (red bars). (*: p<0.05; #: p<0.10) 
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miR-187 targets Rac1, a downstream effector of Disc1 
Following the validation of a number of stress-regulated miRNAs we sought to identify 
potential mRNA targets through in silico analyses. Based upon its targeting by multiple 
stress-regulated RNAs and role as a downstream effector of the stress-regulated Disc1, 
we identified Rac1 as a putative mRNA target of interest. Firefly luciferase vectors 
containing WT and 3’ UTR from Rac1 (US2-Luc-Rac1) were generated as previously 
described and used in subsequent luciferase assays (Yu et al., 2008). 
US2-Luc-Rac1 showed no significant change in luciferase activity when treated with the 
miR-320 mimic (Figure 3.3). In contrast, US2-Luc-Rac1 demonstrated a significant 
decrease in luciferase activity when treated with miR-187 miRNA mimic (Figure 3.3). 
Subsequent mutagenesis of the putative miR-187 binding site in WT Rac1 3’ UTR was 
Figure 3.3: Rac1 is targeted by the stress-regulated miR-187 but not miR-320. In silico target 
prediction algorithms indicated miR-187 and miR-320 as putative regulators of Rac1. Following 
treatment with miRNA mimics, WT Rac1 3’ UTR (US2-Luc-Rac1) demonstrated repression specifically 
upon miR-187 treatment. The subsequent mutagenesis of the putative miR-187 binding site (US2-
Luc-Rac1-Mut) was sufficient to relieve this repression, indicating the specificity of this interaction. 
Vertical bars represent relative luciferase expression assayed by fluorescence. (*: p<0.05; error bars 
represent S.E.M.) 
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sufficient to relieve this inhibition, demonstrating the sequence dependency of this 
mRNA/miRNA interaction (Figure 3.3).  
 
Characterization and prospective “interactome” for the impact of stress on PFC 
function 
Our initial GO analysis identified multiple genes differentially expressed by stress that 
are implicated in the regulation of neuronal morphology, dendritic spine size and/or 
synaptic plasticity (Supplementary Table 3.3). Given this finding, and the identification 
that a number of our genes of interest are neuronally enriched, we explored potential 
links between stress-induced changes in gene expression and neuronal function. By 
deploying Ingenuity Pathway Analysis, STRING Analysis software and literature 
analyses, we identified a number of protein-protein interactions between a number of 
our genes of interest and genes in pathways linked to the regulation of spine size and 
synaptic transmission. Consistent with a neuron-centric hypothesis, prior work has 
identified not only the neuronal enrichment of a large subset of these transcripts but 
their enrichment within specific cell type(s). Of particular note, several of these 
transcripts--notably Disc1 and Tnik, both risk factors for psychiatric illness—not only 
demonstrate enrichment at the glutamatergic synapse but also have empirically 
validated interactions at the protein level (Burette et al., 2015; Q. Wang et al., 2011) 
(Figure 3.4). Additionally, Gad1 and Gad2 are rate-limiting enzymes in the production of 
the GABA neurotransmitter (Asada et al., 1997; Kash et al., 1997) and, together with 
Dlx6, represent cell-type-specific markers for GABAergic cortical interneurons (Y. Wang 
et al., 2010). 
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In addition to this presumptive neuronal network, two genes of note were identified as 
being glial-enriched. Of these, the Adcyap1 receptor Adcyap1r1 has been previously 
demonstrated to be expressed in astrocytes and regulates astrocytic glutamine 
metabolism (a key role in the biosynthesis of glutamate) (Figiel & Engele, 2000; Suzuki 
et al., 2003). The glycine transporter Slc6a9 is also enriched in astrocytes and is 
noteworthy due to recent studies focusing on it as a prospective therapeutic target for 
novel antipsychotics (Aroeira, Sebastiao, & Valente, 2014; Singer et al., 2015). 
Combined, these data are consistent with 1) the convergence of multiple biological 
Figure 3.4: A mechanistic ‘interactome’ of transcripts altered by chronic stress in mPFC. Genes 
listed in green and red demonstrated increased and decreased expression, respectively, in mPFC of 
CVS mice versus non-stressed controls. Genes in blue did not change. Unidirectional arrows 
represent the action of one gene on another, with blue representing activation and red representing 
inhibition. Solid lines represent empirically validated protein-protein interactions, while faded lines 
represent indirect interactions. Yellow and purple circles represent phosphate and ubiquitin groups, 
respectively. 
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pathways across various cell types onto mPFC pyramidal cells function and 2) their 
shared dysregulation following chronic stress in mPFC. 
 
Subregion specificity of a subset of stress-regulated mRNAs 
The mPFC features two primary subdivisions—specifically, the infralimbic (IL) and 
prelimbic (PL) subregions—that exert differential regulatory effects on in stress 
responses and to HPA axis activity (Jones et al., 2011; Radley et al., 2006; Sullivan & 
Gratton, 1999; Tavares, Correa, & Resstel, 2009). To examine the potential stress 
regulation of transcripts by subregion, we isolated RNA from both IL and PL of a second 
cohort of CVS mice by employing LCM methods. We subsequently performed qPCR 
analyses on a subset of stress regulated transcripts (Adcyap1r1, Gad2, Rgs4 and Tnik) 
in an independent cohort of CVS and non-stressed control animals, with one transcript 
(Nrgn) serving as a negative control. 
3 our 4 stress-regulated transcripts validated as differentially expressed in at least one 
subregion (Figure 3.5). Consistent with our initial qPCR validation employing whole 
mPFC samples (Cohort A), Nrgn did not demonstrate differential expression in either 
subregion (Figure 3.5). Of note, 2 of our 3 validated transcripts--Gad2 and Tnik--
demonstrated differential expression specifically within the PL subregion, while Rgs4 
was significantly differentially expressed in both PL and IL subregions. Combined, this 
data demonstrates subregional specificity of the impact of chronic stress on gene 
expression and may contribute to the differential response of IL and PL in stress 
responses. 
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DISCUSSION 
Given the physiological impact of stress and its large-scale regulation of gene 
expression, understanding the molecular architecture of chronic stress may shed further 
light on the mechanistic underpinnings of its impact on neuronal physiology. This is 
particularly true in the mPFC, a brain region noted for its central regulation of mood and 
affect as well as its heavy implication in the pathophysiology of a host of mental 
illnesses (Arnsten, 2009; Cardinal, Parkinson, Hall, & Everitt, 2002; Phillips, Drevets, 
Rauch, & Lane, 2003). In our present study we performed RNA sequencing analysis 
and high-throughput qPCR screens using mPFC RNA samples to identify, respectively, 
stress-regulated mRNAs and miRNAs in CVS versus unstressed mouse controls 
(n=6/group, Cohort A). From this, we selected a subset of >60 mRNAs and 14 miRNAs 
Figure 3.5: A subset of stress-regulated targets demonstrate 
subregional specificity within mPFC. Vertical axes represent linear fold 
change of mRNA levels in whole mPFC (Cohort A, n-6/group) or IL and PL 
subregions in CVS mice versus non-stressed controls (Cohort B; 
n=5/group). Gad2, Rgs4 and Tnik all validated with directionality consistent 
with the first cohort of mice (Cohort A). While Rgs4 was significantly 
differentially expressed in both IL and PL subregions, Gad2 and Tnik 
demonstrated significant differential expression specifically within the PL 
subregion. (*: p<0.05) 
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and subjected them to further qPCR validation, with 31 mRNAs and 4 miRNAs 
validating as differentially expressed. Additionally, we identified and validated an mRNA 
target--Rac1--as being regulated by a stress-sensitive miRNA, miR-187. We 
subsequently validated the differential expression of several mRNA transcripts in an 
independent cohort of CVS and control mice (Cohort B) and demonstrated the 
subregional specificity of a subset of these stress-regulated mRNAs. Finally, by 
combining these data sets, we generated a presumptive “interactome” of genes 
identified as differentially expressed in this current study.  
Coupled with prior literature outlining specific gene functions and interactions, our data 
is consistent with a potential glutamate-centric mechanistic hypothesis underlying 
stress-induced mPFC hypofunction (Figure 3.4).  
Disc1 has been identified as a prominent risk factor for a number of mental disorders 
and plays a key role in a number of CNS processes, including synaptic spine size 
(Blackwood et al., 2001; Brandon & Sawa, 2011; Farrell et al., 2015). Prior work by 
Hayashi-Takagi et al. has demonstrated that Disc1 is also a direct negative regulator of 
glutamatergic spine size via interactions via a Kalrn7, Rac1 and Pak1 pathway 
(Hayashi-Takagi et al., 2010). In this same study, it was observed that Rac1 levels 
positively correlate with spine size. While we did not observe altered steady-state levels 
of Rac1 mRNA in our CVS animals, we did validate Rac1 as a target of the stress-
regulated miRNA miR-187 (Figure 3.3). Given the directionality of our observed 
changes (e.g. both Disc1 and miR-187 are increased in chronic stress and both 
negatively regulate Rac1 function), our findings are consistent with a mechanistic role of 
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Disc1 and miR-187 in chronic-stress-induced reductions in mPFC pyramidal cell spine 
size. 
We also validated Tnik, a Disc1 binding partner, as regulated by stress. A recent study 
demonstrated that Disc1 and Tnik are direct binding partners, with Disc1 inhibiting 
kinase activity of Tnik (Q. Wang et al., 2011). In this same study, researchers observed 
that this inhibition of Tnik’s kinase activity not only led to reductions in PSD95, GluR1 
and stargazin protein levels, but also to reductions in AMPA mEPSCs in primary 
hippocampal neurons. An additional study identified Tnik as a binding partner, and 
negative regulator, of the E3 ubiquitin ligase Nedd4 (Kawabe & Brose, 2010). Chronic-
stress-induced reductions in surface levels of multiple AMPAR and NMDAR subunits in 
mPFC were found to occur via the ubiquitinylation/proteasomal pathway (Yuen et al., 
2012). Intriguingly, these reductions in the expression of genes linked to glutamatergic 
neurotransmission are 1) dependent on Nedd4 function (Yuen et al., 2012) and 2) would 
be expected to increase ubiquitinylation (and subsequent degradation) of glutamatergic 
receptors under conditions of reduced Tnik (due to loss of inhibitory control on Nedd4). 
While we acknowledge that both Disc1 and Tnik validated as significantly increased in 
both Cohort A and Cohort B of CVS mice versus non-stressed controls, we also note 
that the magnitude of these fold changes (~1.5- and ~2-fold increase in Tnik and Disc1, 
respectively) are compatible with a proportionally greater inhibition of Tnik via Disc1. 
Combined, our data are consistent with reduced Tnik activity in chronic stress leading to 
a negative impact on glutamatergic neurotransmission in mPFC. 
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We also observed increased levels of the adrenergic α2A receptor Adra2a in chronically 
stressed animals compared to controls (Figure 3.1). Both adrenergic and noradrenergic 
systems have been linked with chronic stress and mPFC function, with stress resulting 
in enhanced (nor)adrenergic transmission onto mPFC due to increased locus coeruleus 
activity (Nakane et al., 1994). Adra2a in particular is strongly implicated in depression 
and depressive-like behavior (reviewed in (Cottingham & Wang, 2012)), with human 
and animal studies showing robust increases in Adra2a mRNA expression, protein 
levels, Adra2a receptor sensitivity, and/or reductions in Adra2a receptor levels linked to 
antidepressant efficacy in animal models of chronic stress. Keeping with our hypothesis, 
Adra2a exerts a generally inhibitory influence via inhibition of neuronal function and 
negative regulation of adenylyl cyclase activity (Valdizan et al., 2010; M. Wang et al., 
2007; Y. Wang et al., 2011; Wilson et al., 1998). Adding to this impact, the regulator of 
G-protein signaling Rgs4 has previously been shown to negatively regulate Adra2a 
activity (Cavalli, Druey, & Milligan, 2000). Finally, as we demonstrated reductions in 
Rgs4 mRNA in animals subjected to CVS, these findings are consistent with prolonged 
activation of Adra2a-mediated downstream signaling events—a hypothesis supported 
by previous observations of increased Adra2a receptor sensitivity in post-mortem 
human depressive studies (Gonzalez-Maeso, Rodriguez-Puertas, Meana, Garcia-
Sevilla, & Guimon, 2002; Valdizan et al., 2010). 
While our hypothesis focuses primarily on glutamatergic mPFC pyramidal cells, our 
findings also implicate both GABAergic interneurons and glia in stress-induced 
glutamatergic dysfunction. We observed significant increases in the GABAergic 
interneuronal marker Dlx6 (Y. Wang et al., 2010), as well as both forms of the 
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GABAergic interneuronal marker glutamic acid decarboxylase (Gad1 and Gad2). 
Intriguingly, these enzymes catalyze the rate-limiting step in the production of GABA, 
the primary inhibitory neurotransmitter in the CNS (Asada et al., 1997; Kash et al., 
1997) and a study by Gilabert-Juan et al. has demonstrated not only elevations of 
mPFC Gad1 in chronic stress but also increased dendritic complexity of Gad1-positive 
mPFC interneurons following chronic stress (Gilabert-Juan, Castillo-Gomez, Guirado, 
Molto, & Nacher, 2013), consistent with increased GABAergic inhibition following 
chronic stress. In addition to these findings, we also observed significant increases in 
both Vim and the astrocytic marker Gfap, consistent with a prior report indicating 
increased cortical Gfap protein levels following repeated restraint stress (Jang, Suh, 
Yoo, Lee, & Oh, 2008). We also validated a significant increase in the glial-enriched 
glycine transporter Slc6a9 (GlyT1) (Figure 3.2). This finding is of note given that glycine 
acts as an important NMDAR cofactor and, together with glutamate, is necessary for 
NMDAR activation (Johnson & Ascher, 1987). Additionally, the directionality of this 
change is consistent with reduced NMDAR activity: increased GlyT1 would be 
consistent with increased clearance of glycine and reduced availability at the synapse, 
which would indicate reduced NMDAR activity. Combined, our findings are consistent 
with the convergence of multiple cell types in mPFC exhibiting a negative impact on 
glutamatergic transmission and mPFC activity following chronic stress. 
Additionally, we have demonstrated the subregional specificity (e.g. PL vs IL) of stress-
regulated transcripts. While Rgs4 was significantly decreased in both PL and IL 
subregions, Gad2 and Tnik both exhibited stress-induced increases specific to PL 
(Figure 3.5). We also note that PacR1 failed to validate in either PL or IL subregion, 
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suggesting the possibility of either 1) differential expression in another mPFC subregion 
(such as cingulate cortex) or 2) contamination of our initial whole-mPFC preparation by 
adjacent brain region(s). While the mPFC has an overall effect of inhibition on HPA axis 
activity, with general mPFC hypofunction potentially serving a causative role, prior work 
indicating subregional specificity of HPA axis control adds further complexity to our 
current understanding of stress responses. Previous studies have indicated the 
necessity of mPFC IL cortex in the initial HPA axis response (Ronzoni, Anton, Mora, 
Segovia, & Del Arco, 2016). Furthermore, inactivation of the IL cortex is sufficient to 
reduce both HPA axis activity and physiological responses to psychogenic stressors 
(Radley et al., 2006; Sullivan & Gratton, 1999; Tavares et al., 2009), indicating a 
positive correlation of IL activity and HPA axis activity. In contrast, the PL cortex 
appears to inhibit HPA axis activity in response to psychogenic—but not physical—
threats (Jones et al., 2011). While additional studies will be needed to identify additional 
candidates and dissect the potential role of subregion-dependent genomic responses to 
stress, these findings are intriguing given 1) the PL specificity of several of our stress-
regulated transcripts and 2) that specific reductions in PL activity, rather than IL, would 
be expected to underlie the stress-induced increased in HPA axis activity. 
We acknowledge the potential limitations of interpreting our findings—specifically, that 
1) all observations were performed in RNA samples rather than protein and 2) the 
extraordinary difficulty in accurately overlaying “whole brain region” transcriptomic data 
on specific components of the underlying neural circuitry. We note, however, that the 
proposed cell type(s) of interest and directionality of these changes—coupled with 
observations of protein functionality and validated interactions in the literature—are 
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extremely consistent with both prior findings and our proposed hypothesis. 
In summary, given the significant effects of stress on gene networks and its impact on 
neuronal physiology, understanding the genetic impact of chronic stress will be 
instrumental in devising future treatments. Our current study illuminates the wide-
ranging impact of chronic stress on mRNA and miRNA expression in the mPFC (a brain 
region central to the regulation of mood and affect). Additionally, these changes provide 
a mechanistic framework for how gene expression changes may underlie stress-
induced glutamatergic mPFC hypofunction, a pathophysiology thought to be causative 
of several pathophysiologies observed in chronic stress and of which our knowledge of 
the underlying biology remains incomplete. 
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TABLES AND SUPPLEMENTARY INFORMATION 
Table 3.1: Schedule of stressors used for the CVS paradigm. 
Day  Timing  Stressor 
1  AM  Elevated plus maze 
   PM  Warm sim 
2  AM  Orbital shaker 
   PM  Cold room 
3  AM  Cold room 
   PM  Hypoxia and single housing (overnight) 
4  AM  Orbital shaker 
   PM  Warm swim 
5  AM  Hypoxia 
   PM  Cold room 
6  AM  Orbital shaker 
   PM  Warm swim and single housing (overnight) 
7  AM  Cold room 
   PM  Hypoxia 
8  AM  Shaker 
   PM  Warm swim and single housing (overnight) 
9  AM  Hypoxia 
   PM  Cold room and single housing (overnight) 
10  AM  Warm swim 
   PM  Hypoxia 
11  AM  Cold room 
   PM  Orbital shaker 
12  AM  Hypoxia 
   PM  Orbital shaker and single housing (overnight) 
13  AM  Orbital shaker 
   PM  Hypoxia 
14  AM  Elevated plus maze 
   PM  Warm swim 
15  AM  Novel restraint 
 
Supplementary Figure 3.1: qPCR validation correlates strongly with linear fold 
changes assessed by deep sequencing methodologies may be accessed at: 
https://umich.box.com/s/7mhd9zb36u47819j9jrz3wmeifjt0deb 
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Supplementary Table 3.1: Summary of reads obtained from each sample in 
Cohort A may be accessed at: 
https://umich.box.com/s/smfvj33k1msb2yi9l303fvsopezstvy1 
Supplementary Table 3.2: Gene read counts from RNA sequencing of Cohort A 
may be accessed at: https://umich.box.com/s/y3lth7fqs6rmgrly0cclq2tiq2sopidu 
Supplementary Table 3.3: Genes and Assay ID#'s for TaqMan Low-Density Array 
Cards may be accessed at: 
https://umich.box.com/s/85k7e2etao54z53d4c869nxh4b7rr7y5 
Supplementary Table 3.4: Gene Ontology Analysis of All Stress-Regulated 
Transcripts From RNA-Seq Data may be accessed at: 
https://umich.box.com/s/q3las77ao8mhnwyax7tiliae0v0tdhus 
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Chapter IV: Analyzing transcriptomic alterations in a cell-type-dependent fashion: 
implementation of translating ribosomal affinity purification (TRAP) methods 
 
"The brain is a monstrous, beautiful mess. Its billions of nerve cells--called neurons--lie 
in a tangled web that displays cognitive powers far exceeding any of the silicon 
machines we have built to mimic it." 
-William F. Allman 
 
INTRODUCTION 
In prior chapters this thesis posited a cell-type-specific hypothesis for the prospective 
transcriptomic events underlying a major chronic stress-induced physiological change in 
mPFC. Our current body of knowledge supports this hypothesis, with a number of prior 
studies establishing the enrichment of specific transcripts in cell type(s) of interest 
(Cahoy et al., 2008; Gong et al., 2003). However, these studies (as well as nearly all 
similar studies at the time of writing) are fundamentally constrained by an inability to 
overlay changes in gene expression onto specific components of the underlying neural 
circuitry. While a number of genes are commonly considered “markers” of either CNS 
cell type (e.g. GFAP for astrocytes, MAP2 for neurons) or subtype (e.g. parvalbumin 
and 5HT3AR, for distinct subsets of GABAergic interneurons (Markram et al., 2004; 
Rudy et al., 2011)), these markers represent a tiny minority of 
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transcripts expressed in the CNS. Rather, the majority of transcripts are expressed in 
more than one cell type ranging from reasonably specific (e.g. Gad2, which labels a 
majority of GABAergic interneurons) to the generic (such as beta actin). From a 
practical standpoint this adds a further layer of complexity to understanding the 
biological context of gene expression changes. For instance, a gene that is implicated in 
altered neuronal function would generate very different hypotheses on its prospective 
mechanism of action if it were expressed specifically in neurons as opposed to glia. 
 A major limiting factor in linking changes in gene expression to specific cell type(s) has 
been the lack of available methodologies. While a number of methodologies have been 
developed and/or adapted to enable more precise collection of relevant samples (e.g. 
laser-capture microdissection (LCM), cell sorting, cell and tissue culture methods), 
samples obtained via these methods are likely to be mechanically, temporally and/or 
physically removed from their in vivo environment which are likely to alter transcriptomic 
networks, potentially obfuscating genomic responses to various insults. As such, it 
would be ideal to identify and implement further approaches to minimize these 
variables. 
Quite recently Doyle and Heiman et al. developed a novel method, termed Translating 
Ribosome Affinity Purification (TRAP) to address this problem (Doyle et al., 2008; 
Heiman et al., 2008). The authors engineered a transgenic mouse model that 
expressed an eGFP-tagged L10a ribosomal subunit downstream of a floxed stop codon, 
enabling the expression of this construct specifically in Cre-recombinase-positive cells. 
As L10a is a ribosomal subunit and forms part of the translation complex that binds to 
actively-translated transcripts, this approach enables the immunopurification (and 
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subsequent isolation) of actively translated mRNAs from genetically targeted cell types. 
By combining these TRAP methods with traditional neuroanatomical dissections, one 
can more readily associate transcriptomic changes to cells of a defined neurochemical 
phenotype (specified by Cre driver) and, hence, components of the neural circuitry 
within brain.  
While the research outlined in this thesis has focused primarily on neuronal cell types, 
our laboratory has published several papers focused on the glucocorticoid regulation of 
transcriptomic changes in astrocytes both in vivo and in vitro (Carter, Hamilton, & 
Thompson, 2013; Carter, Meng, & Thompson, 2012). At the time we were unable to 
perform a full transcriptomic analysis of astrocytic gene expression changes in vivo. As 
TRAP 1) represented an opportunity to expand on this prior work, 2) would be 
deployable to my own neural-centric hypotheses, and 3) was consistent with funding 
opportunities at this time, our laboratory elected to focus our seminal efforts on 
deploying the TRAP methodology in astrocytes. Though astrocytes have received 
comparatively little attention, prior work has implicated them as an important set piece in 
understanding brain function in both health and disease. Astrocytes represent a large 
proportion of CNS cells and are more numerous than neurons, with ~1.4 astrocytes per 
neuron in human cortex (Bass, Hess, Pope, & Thalheimer, 1971; Nedergaard, Ransom, 
& Goldman, 2003). Astrocytes make extensive connections (averaging ~10,000 
neuronal connections for each astrocyte) and play key roles in neuronal health, 
neurotransmitter recycling/biosynthesis and may also be involved in ‘glial signaling’ via 
glutamate release (Schousboe, Scafidi, Bak, Waagepetersen, & McKenna, 2014).  
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There is also growing evidence that astrocytes are involved in the pathophysiology of 
chronic stress and depression. Recent work in our laboratory demonstrated that chronic 
glucocorticoid treatment induced widespread dysregulation of gene expression in 
astrocytes both in vitro and in vivo (Carter et al., 2013; Carter et al., 2012). In addition, a 
number of studies have revealed significant reductions in astrocyte cell density and glial 
fibrillary acidic protein (Gfap, an astrocytic marker) across numerous brain regions 
implicated in neuropsychiatric illness, including prefrontal cortex and hippocampus. A 
number of studies (including the work outlined in this thesis) has demonstrated the 
chronic-stress-induced dysregulation of glial-specific transcripts in chronic glucocorticoid 
treatment and/or chronic stress. Perhaps most convincingly, injections of glial-specific 
toxins into mPFC in animal models induced depressive-like behavior that was not 
observed when neuron-specific toxins were used (Banasr & Duman, 2008).  
In summary, astrocytes are strongly associated with multiple chronic stress and 
depressive pathologies and represent an intriguing target. While prior studies have been 
unable to directly link stress-induced gene expression changes to a specific cell type(s), 
the recently developed TRAP methodology enables us to obtain biological samples 
substantially enriched for a targeted cell type of interest. This focus of the present 
chapter will be to demonstrate the successful implementation of the TRAP method into 
our laboratory and describe preliminary data of the successful targeting of cells of a 
specific neurochemical phenotype (e.g. Gfap versus Gad2). Furthermore, we also 
describe the generation of preliminary gene expression data derived from mPFC 
astrocytes in mice subjected to a 14-day CVS paradigm versus non-stressed controls. 
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MATERIALS AND METHODS 
Animals 
All preliminary experiments were performed with adult male C57BL/6 mice between 2 
and 10 months of age. All CVS animal experiments were performed with adult male 
Rosa26L10a-eGFP mice carrying Cre recombinase under the control of either the Gfap 
(astrocytes; Gfapcre) or Gad2 (GABAergic interneuron; Gad2cre) promoter. Due to a 
deleterious phenotype arising from homozygous Gfapcre, all mice used in the CVS 
paradigm (n=12, CVS; n=12, non-stressed controls) possessed a genotype of 
Rosa26L10a-eGFP/L10a-eGFP; Gfapcre/+.  
With the exception of the 14-day CVS paradigm (see below), all animals were group 
housed with ad libitum access to food and water. With the exception of several CVS 
stressors (see below), all animals were kept on a 12:12 light:dark cycle (6:00 AM to 6:00 
PM). All animal procedures were reviewed and approved by the University of Michigan 
Animal Care and Use Office (UCUCA). 
 
CVS Paradigm 
Due to its robust and well-characterized nature, as well as our prior success in 
deploying it (Chapter III), we opted to employ a slightly modified version of the 14-day 
CVS paradigm previously described (Herman et al., 1995). Mice were divided into two 
groups, with one group subjected to the CVS paradigm and one group acting as non-
stressed controls (n=12/group). Mice in the CVS group were exposed to two stressors 
per day (one AM stressor, one PM stressor) which included cold swim (10 minutes at 18 
degrees C), warm swim (20 minutes at 31 degrees C), vibrational stress (cages placed 
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on a plate shaker at maximum speed for 15 minutes), restraint stress (1 hour restraint), 
solitary housing (overnight duration), removal of bedding (overnight duration), and 
skipping a dark cycle (lights on overnight). The morning following the final PM stressor, 
mice were rapidly euthanized via cervical dislocation and brain tissue removed (see 
Tissue Collection – CVS Animals below). 
 
Tissue Collection - Preliminary Samples 
During preliminary testing of TRAP methodologies, mice were euthanized via rapid 
decapitation following isoflurane anesthetization. Given the exploratory nature of these 
efforts we employed less precise anatomical dissections than in our subsequent CVS 
studies (see below). Brains were removed and placed on a chilled stainless steel block 
and 70 mg of brain tissue (consisting primarily of neocortex) was excised. These 
samples were then placed into a pre-chilled 2 mL glass and Teflon homogenizer 
containing 1 mL ice-cold lysis buffer (20 mM HEPES KOH (pH 7.4), 150 mM KCl, 10 
mM MgCl2) containing the equivalent of one-tenth of a cOmplete EDTA-free protease 
inhibitor tablet (Roche), 0.5 mM DTT, 100 ug/mL cycloheximide and 10 ul each RNAsin 
(Promega Inc, Madison, WI) and Superasin (Thermo Fisher Scientific, Waltham, MA). 
Samples were then subjected to TRAP purification (see below). 
 
Tissue Collection - CVS Animals 
For CVS and non-stressed control samples, following euthanasia brains were placed 
into a stainless steel mouse brain matrix that had been pre-chilled on ice. Using a 
mouse neuroanatomical atlas (Paxinos and Franklin), approximate rostral and caudal 
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boundaries of mPFC cortex were identified on dorsal surface of the mouse brain. Razor 
blades were used at these boundaries to generate a coronal “slab” containing whole 
mPFC. These slabs were then placed on a chilled stainless steel block and further 
dissected via the removal of dorsal (to prelimbic cortex), ventral (to infralimbic cortex), 
and lateral (to mPFC) areas. mPFCs were then placed in a pre-chilled 2 mL glass and 
Teflon homogenizer 1 mL ice-cold lysis buffer (20 mM HEPES KOH (pH 7.4), 150 mM 
KCl, 10 mM MgCl2) containing equivalent of 1/10th one cOmplete EDTA-free protease 
inhibitor tablet (Roche), 0.5 mM DTT, 100 ug/mL cycloheximide and 10 ul each RNAsin 
(Promega Inc, Madison, WI) and Superasin (Thermo Fisher Scientific, Waltham, MA). 
Samples were then homogenized with a Teflon pestle (being careful not to introduce air 
bubbles) and subjected to TRAP purification. Due to input material requirements, mPFC 
dissections were “pooled” across mice (n=3 mice/sample), resulting in an effective 
sample size of 4 per group (n=4, CVS; n=4, control) before proceeding to TRAP 
purification. 
 
Translating Ribosome Affinity Purification (TRAP) 
TRAP methodologies were performed as previously described (Doyle et al, 2008). 
Affinity matrix was prepared by washing Dynabeads (Streptavidin MyOne T1 
Dynabeads, Thermo Fisher Scientific, Waltham, MA) with 1x PBS before incubating with 
1x PBS containing biotinylated Protein L for 35 minutes at room temperature. Beads 
were then collected on a magnet and washed 5 times with 1x PBS containing 3% (by 
weight) IgG-free bovine serum albumin (BSA) (Jackson ImmunoResearch). Following 
washes in PBS containing BSA, beads were incubated for 1 hour at room temperature 
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in 1 mL low salt buffer (20 mM HEPES KOH (pH 7.4), 150 mM KCl, 10 mM MgCl2, 1% 
NP-40 containing equivalent of 1/10th one cOmplete EDTA-free protease inhibitor tablet 
(Roche), 0.5 mM DTT, 100 ug/mL cycloheximide, 10 ul each RNAsin and Superasin) 
and 100 ug of eGFP antibody (50 ug each HtzGFP-19C8 and HtzGFP-19F7, Sloan 
Kettering MACF). After incubation, beads were collected on a magnet and washed 3 
times with low salt buffer before being resuspended in the same. 
Following tissue homogenization, an aliquot (10% of total homogenized tissue sample) 
was collected as a whole-tissue control (hereafter referred to as “Total”) and frozen at -
80 degrees C. Lysates were subsequently cleared by centrifugation (10 minutes at 
2,000 x g at 4 degrees C). Supernatant was then transferred to a new pre-chilled 1.5 mL 
Eppendorf tube and 1/9th sample volumes of 10% NP-40 and 300 mM 1,2-diheptanoyl-
sn-glycero-3-phosphocholine (DHPC) added. Supernatant was then mixed by gentle 
inversion, incubated on ice for 5 minutes, and centrifuged (10 minutes at 20,000 x g at 4 
degrees C). Final supernatant was then combined with affinity matrix and allowed to 
rotate end-over-end for at least 16 hours at 4 degrees C. Following binding, beads were 
collected on a magnet and supernatant (hereafter defined as “Depleted sample”) 
removed to a pre-chilled tube. Beads were then washed 4 times with high salt buffer (20 
mM HEPES KOH (7.4), 350 mM KCl, 10 mM MgCl2 containing equivalent of 1/10th one 
cOmplete EDTA-free protease inhibitor tablet (Roche), 0.5 mM DTT, 100 ug/mL 
cycloheximide, 10 ul each RNAsin and Superasin). After the final wash, high salt buffer 
was removed and beads were allowed to warm to room temperature. 100 ul of lysis 
solution (RNAqueous Micro Kit,Thermo Fisher Scientific, Waltham, MA) was added to 
beads and incubated for 10 minutes at room temperature.  Beads were subsequently 
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collected on a magnet, and the supernatant further purified using the RNAqueous Micro 
Kit. Immunopurified RNA yield and purity was then assayed on a NanoDrop 1000 
(Thermo Fisher Scientific, Waltham, MA). 
 
Reverse Transcription and qPCR Detection 
Total RNA (15 ng/sample) was reverse transcribed using SuperScript II (Life 
Technologies, Carlsbad, CA) with random hexameric priming following manufacturer’s 
instructions. To assay the relative enrichment of immunopurified material, we selected 
two main markers of neurochemical phenotype: glial fibrillary acidic protein (Gfap, a 
predominantly astrocyte-expressed marker) and glutamic acid decarboxylase 2 (Gad2, 
expressed exclusively within GABAergic interneurons in the CNS). qPCR analyses were 
subsequently performed using ABsolute Blue qPCR master mix (Thermo Fisher 
Scientific, Waltham, MA) on a ViiA 7 thermocycler (Life Technologies, Carlsbad, CA). 
Due to the potential bias for housekeeping genes of interest by individual cell type 
versus whole brain, fold enrichment was assayed by directly comparing CT values of 
genes of interest between total lysate and immunopurified material. 
 
Next-Generation RNA Sequencing and Analysis 
Immunopurified material was subsequently subjected to next-generation sequencing. 
Library construction and sequencing were performed by the University of Michigan DNA 
Sequencing Core (Director: Robert Lyons, Ph.D.). Libraries were generated from 100 ng 
of immunopurified RNA per sample using the Illumina TruSeq Sample Prep v2 kit 
(Illumina, San Diego, CA) following manufacturer’s instructions. Following library 
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construction samples were clustered on a cBot (Illumina, San Diego, CA), loaded with 4 
samples per lane onto a HiSeq flow cell (Illumina, San Diego, CA), and sequenced on a 
HiSeq 2000 (Illumina, San Diego, CA) using version 3 reagents according to 
manufacturer's instructions. 
Reads were subsequently aligned and mapped to the mouse genome (UCSC version 
GRCm38/mm10, Dec. 2011) using TopHat and Bowtie. Individual reads with low 
transition, >3 mismatches or mapped >10 times to the genome were excluded from 
analysis. Read counts were generated using standard RPKM normalization (Mortazavi, 
Williams, McCue, Schaeffer, & Wold, 2008). 
 
Immunohistochemistry 
To verify the specific expression of the Rosa26L10a-eGFP construct in our targeted cell 
type(s) of interest, brains were collected for immunohistochemical staining from 
Rosa26L10a-eGFP/L10a-eGFP; Gfapcre/+ mice. Mice were deeply anesthetized with sodium 
pentobarbital then subjected to thoracotamy and transcardial perfusion with 4% 
paraformaldehyde. Brains were subsequently removed and further fixed for 12 hours in 
4% paraformaldehyde at 4C.  Following this post-fix treatment, 70 um thick brain 
sections were cut on a Leica VT 1000 S vibratome and tissue sections collected. 
Sections containing the mPFC were washed 3x with 1x PBS and blocked for 1 hour in 
blocking solution (1x PBS containing 3% normal goat serum (Invitrogen) and 0.3% 
Triton X-100 (Invitrogen) detergent) in 6 well microtiter dishes. Sections were then 
washed in 1x PBS and incubated overnight at 4 degrees C in blocking solution 
containing a 1:10,000 dilution of eGFP antibody (AbCam ab13970, AbCam, Cambridge, 
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United Kingdom) and a 1:1,000 dilution of Gfap antibody (Astro6, Thermo Fisher 
Scientific, Waltham, MA). After incubation, sections were washed 3x in 1x PBS and 
blocked for 1 hour in block solution containing a 1:1,000 dilution of Alexa Fluor488 
(AbCam ab150169, AbCam, Cambridge, United Kingdom) and a 1:1,000 dilution of 
AlexaFluor 647 secondary (AbCam ab150079, AbCam, Cambridge, United Kingdom). 
Following incubation, sections were washed in 1x PBS and subsequently mounted onto 
SuperFrost microscope slides (ThermoFisher Scientific). Sections were imaged on an 
Olympus Fluoview FV 1000 confocal microscope. 
 
RESULTS 
Neuroanatomical expression of L10a-eGFP is dependent on cre recombinase 
To ensure our mouse model expressed the L10a-eGFP reporter in our cell type of 
interest (as defined by the Cre driver), we performed dual fluorescent 
immunohistochemistry with antibodies against eGFP and Gfap in Rosa26L10a-eGFP; 
Gfapcre/+ and Rosa26L10a-eGFP mice. We subsequently examined mPFC (our area of 
interest) for colocalization of our markers and observed significant overlap in 
Rosa26L10a-eGFP; Gfapcre (Figure 4.1), indicating the specific expression of eGFP in 
Gfap-positive cells. While we observed significant Gfap signal in Rosa26L10a-eGFP (e.g. 
wild-type) mice we observed no eGFP signal (data not shown), indicating the cre-
dependency of eGFP expression. 
 
TRAP purification of RNA is dependent on Cre recombinase 
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To test both the quantity of immunopurified RNA obtained, as well as further ensure the 
cre-dependency of L10a-eGFP expression, we initially performed immunoprecipitations 
on three different genotypes of mice: Rosa26L10a-eGFP; Gfapcre/+, Rosa26L10a-
eGFP;Gad2cre/+, and Rosa26L10a-eGFP mice. All mice yielded total RNA in line with 
expectations (with a general rule of thumb indicating a yield of 1 ug of RNA for each mg 
of wet brain tissue) (Table 4.1). While material immunopurified from Rosa26L10a-eGFP 
mice yielded extremely low quantities of RNA (7.4 ng total, or ~0.1 ng RNA per 1 mg of 
wet tissue), mice expressing cre produced significantly greater quantities of RNA with 
Figure 4.1: Co-localization of eGFP within astrocytes in Rosa26L10a-eGFP; 
Gfapcre/+ mouse. Images represent eGFP signal(A), Gfap signal (B) signal, and 
merged signal (C).   
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Rosa26L10a-eGFP; Gad2cre/+ and Rosa26L10a-eGFP; Gfapcre/+ mice yielding 762 ng and 540 
ng of immunopurified RNA, respectively (Table 4.1). Collectively, these data indicate 1) 
background levels of immunopurified RNA in mice negative for Cre recombinase and 2) 
>50-fold increases in immunopurified RNA from mice positive for Cre recombinase. 
 
qPCR analysis reveals Cre-driver-specific enrichment of RNA in immunopurified 
cell types 
To test whether the immunopurified RNA samples obtained were consistent with the 
cre-driver utilized, we measured the expression of Gad2 and Gfap and mRNAs in total 
RNA versus immunopurified material in both Rosa26L10a-eGFP;Gad2cre/+ and Rosa26L10a-
eGFP;Gfapcre/+. Consistent with genotyping results, Rosa26L10a-eGFP;Gfapcre demonstrated 
an immunopurified enrichment (~4 fold) in Gfap  expression compared to total RNA 
while Gad2 expression was extremely depleted (<20% that of total RNA) (Figure 4.2). 
Additionally, qPCR analysis of another astrocyte-enriched mRNA (Aldh1l1) 
demonstrated nearly identical cell-type enrichment data as Gfap in Rosa26L10a-
eGFP;Gfapcre/+ mice (data not shown). Similarly, Rosa26L10a-eGFP;Gad2cre exhibited a ~4-
fold enrichment in Gad2 expression from immunopurified material compared to total 
Table 4.1: RNA yield from TRAP immunopurification is Cre recombinase-
dependent. Total RNA yield was genotype-independent and followed expected yield 
(e.g. 1 µg total RNA per 1 mg wet tissue). In contrast immunopurified RNA yield was 
Cre-dependent, with both Gad2cre/+ and Gfapcre/+ yielding a >70-fold increase in 
recovered material. 
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RNA, while Gfap expression was only ~4% that of total RNA. These data are consistent 
with a cre-driver-specific expression of L10a-eGFP in, and subsequent sample 
enrichment for, our targeted cell types of interest. 
 
Preliminary analysis of RNA sequencing results demonstrates robust expression 
of astrocyte-specific genes 
After demonstrating the technical feasibility of the TRAP methodology I proceeded to 
subject 12 Rosa26L10a-eGFP; Gfapcre mice to the CVS paradigm. An additional 12 
Rosa26L10a-eGFP; Gfapcre mice served as non-stressed controls. CVS treatments 
occurred as previously described (see Chapter III). Following CVS treatments, mPFC 
dissections were subsequently “pooled” before processing (3 mouse mPFC samples 
per pool), giving us an effective sample size of n=4/group. Two of these pooled samples 
(one CVS, one control) yielded quantities of RNA below that ideally useful for next 
generation sequencing.  As a result, we submitted a total of 6 samples to the UM DNA 
sequencing core for RNAseq library construction and sequencing (n=3/group).  
Sequencing analysis identified >14,000 individual gene IDs in each sample. Consistent 
with our expectations, a number of genes previously confirmed to be enriched in 
astrocytes—particularly glutamine ligase (GluL), Gfap, and the glial excitatory amino 
acid transporter 2 (Slc1a2)—were among the most robustly expressed of any transcripts 
identified (Table 4.2). Collectively, this data demonstrates a significant enrichment for 
astrocyte-specific transcripts in our immunopurified material and paves the way for the 
 
 
143 
 
 identification and analysis of gene expression differences specifically within astrocytes. 
 
DISCUSSION 
Chronic stress induces a number of physiological alterations and profoundly impacts 
gene expression. Given the cellular heterogeneity of the brain, understanding the 
specific impact of chronic stress on gene expression within specific cell types may shed 
light on the mechanism by which chronic stress induces its maladaptive effects while 
providing unique insights into how chronic stress impacts specific neural circuits. In the 
present chapter I present data implementing TRAP methodology, a technique that 
enables the analysis of gene expression that leverages cre-dependent cell-type driver 
mice. Further, I have generated preliminary data indicating the successful deployment 
Figure 4.2: Relative proportions of Gfap and Gad2 mRNA in 
immunopurified material versus total RNA are Cre recombinase-
dependent. Both Gad2 and Gfap mRNA levels were enriched ~4-fold in 
Gad2cre/+ and Gfapcre/+ animals, respectively (Y-axis represents linear fold 
enrichment in immunopurified material versus total RNA). In contrast, Gad2 
mRNA levels were depleted in Gfapcre/+ mice, while Gfap levels were highly 
depleted in Gad2cre/+ (both in immunopurified material versus total RNA). 
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of this TRAP methodology to examine stress-induced gene expression changes within 
Gfap-positive cells (e.g. astrocytes) derived from mPFC, positioning me to expand this 
TRAP methodology to other cell types of interest (such as pyramidal glutamatergic cells 
and various GABAergic interneurons in mPFC, identified as cell types of interest in 
earlier chapters). While these initial results are promising there are several limitations to 
bear in mind going forward. The first is that relatively small sample size used in my RNA 
sequencing (CVS versus control, n=3/group) may negatively impact our ability to 
validate prospective genes of interest. Furthermore, while the TRAP methodology is a 
vast improvement on prior methods, it still exhibits collection artifacts (evidenced by the 
presence, albeit depleted, of Gad2 and Gfap mRNA in mice expressing Gfap-cre and 
Gad2-cre, respectively). It is possible, however, that these artifacts may be further 
minimized by additional optimization within our laboratory. Efforts to improve yield and 
minimize potential artifacts in the TRAP methodology are ongoing. 
In spite of these limitations, these preliminary findings represent a significant step 
forward in understanding the transcriptional dynamics of chronic stress within a specific 
cell type of interest. For example, this preliminary data identifies multiple mRNAs as 
downregulated following chronic stress but it currently remains unknown whether these 
mRNA changes are unique to astrocytes in vivo.  In an attempt to address this question, 
future studies could compare and contrast my astrocyte gene expression to previously 
published TRAP results from both astrocytes as well as neurons to identify mRNAs 
whose expression changes due to chronic stress but are enriched in astrocytes 
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Gene ID 
Expression 
Rank 
Rn18s‐
rs5  1 
Gm12896 2 
Glul  3 
Gm12895 4 
Fam107a  5 
Aldoc  6 
Slc1a2  7 
Ckb  8 
Lars2  9 
Gm15564 10 
Actb  11 
Ndrg2  12 
Kalrn  13 
Ubc  14 
Gfap  15 
 
compared to neurons. Such analyses could tentatively identify candidate RNAs that, 
upon in situ hybridization analyses, would reveal both enrichment in astrocytes and 
stress-dependent expression differences. Future work based on these questions, as 
well as others raised in this thesis, will make extensive use of these TRAP methods 
(see Chapter V). Combined with data generated from this present work, these studies 
are expected to shed light on gene expression within several major cell types in mPFC. 
 
 
 
 
 
Table 4.2: Rank-ordering of sequencing data reveals astrocyte-enriched transcripts 
in immunopurified material. Astrocyte-enriched transcripts are amongst the most 
robustly expressed in material immunopurified from Rosa26L10a-eGFP/L10a-eGFP;Gfapcre/+ mice. 
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Chapter V: Thesis Summary and Conclusions 
 
The major goals of the research conducted in this dissertation were to shed light on how 
the miRNA regulatory network may be altered in AnCg of BP and MDD patients 
compared to controls and to characterize the impact of chronic stress on transcriptomic 
networks of mPFC in an animal CVS model. In addition, I have shown preliminary 
evidence demonstrating the successful deployment of a previously described 
methodology (e.g. TRAP) that enables analyses of the transcriptomic impact of chronic 
stress in a cell-type-dependent fashion. The purpose of this final chapter is to 
summarize the major findings of this work, examine questions raised by these findings 
and to explore potential next steps for the work described. 
 
Summary of the Major Findings of this Dissertation 
 
An overarching aim of this thesis has been to identify transcriptomic links to depression 
and chronic stress. The introductory chapter of this thesis began with an overview of 
bipolar (BP) and major (MDD) depressive illness (Chapter 1.1) and included a section 
devoted specifically to miRNAs within psychiatric illness (Chapter 1.4). Both BP and 
MDD are highly prevalent with significant heritability (Craddock & Jones, 1999; Kessler 
et al., 2005), but our understanding of their underlying genetics is still limited. In recent 
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years, miRNAs have been strongly implicated in neuropsychiatric illnesses due to their 
CNS enrichment, direct dysregulation in multiple neuropsychiatric illnesses and the 
capability of one miRNA to target multiple mRNA species (Selbach et al., 2008). Unlike 
my study, few prior studies had examined the dysregulation of miRNAs in MDD. 
Furthermore, the majority of studies examining miRNAs in psychiatric illness within the 
brain focused on the dorsolateral prefrontal cortex and cerebellum (Bavamian et al., 
2015; A. H. Kim et al., 2010; Miller et al., 2012; Moreau et al., 2011; Perkins et al., 
2007). Prior to the studies outlined in this thesis no work had examined the miRNA 
network within the anterior cingulate cortex, a brain region centrally involved in the 
regulation of mood, emotion and affect (Drevets et al., 2008; Ebert & Ebmeier, 1996; 
Mayberg et al., 1999; Posner & DiGirolamo, 1998). Given the relevance of both AnCg 
and miRNAs to mental illness I wanted to query whether miRNAs might be dysregulated 
in AnCg in BP and/or MDD patients and, furthermore, what mRNA targets they may 
regulate. As such, I formulated and tested the following hypothesis: 
MicroRNAs are dysregulated in various brain regions of patients with various mental 
illnesses, including MDD and BP. Given its central role in the regulation of mood and 
affect, miRNAs are likely to a) be differentially expressed in the AnCg of patients with 
MDD and BP and b) target genes of relevance to pathophysiological processes. 
In order to test this hypothesis I measured miRNA expression levels in AnCg from a 
cohort of BP, MDD and control patients (Chapter II). I initially selected 29 miRNAs 
based upon prior published association with psychiatric illness, prior literature indicating 
targeting of mRNAs previously implicated in mental illness, shared dysregulation across 
multiple psychiatric illnesses and/or robust expression. Following qPCR analysis of 
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these miRNA transcripts I identified 5 miRNAs with raw p-values < 0.05 (though none 
passed multiple correction testing, e.g. FDR < 0.15). miR-132, miR-133a and miR-212 
were differentially expressed specifically in BP vs control patients, miR-184 was 
differentially expressed specifically in MDD vs control, while miR-34a was differentially 
expressed in both illnesses. To minimize the possibility of false positives I performed 
further qPCR validations with individual miRNA-specific qPCR assays and validated the 
differential expression of these miRNAs with directionality, magnitude of fold change, 
and disease specificity mirroring those observed in the initial screen. 
 
Given that miRNAs are thought to largely exert their biological effects via the regulation 
of target mRNAs I next sought to query potential mRNA targets of miRNAs dysregulated 
in disease. A particular emphasis was placed on miR-34a given its shared dysregulation 
across both BP and MDD cohorts. I subsequently performed gene ontology and 
clustering analyses of all in silico predicted mRNA targets of miR-34a. Based on the two 
highest associations provided from this analysis—‘Synapse’ (Cluster 1) and 
‘Transcription Regulator Activity’ (Cluster 2) (see Supp. Table 2.3, p. 94)—three mRNA 
candidates were chosen for subsequent validations: PDE4B, NCOA1 and NCOR2. Prior 
work has shown that PDE4B is a genetic risk factor for mental illness (Fatemi et al., 
2008; Millar et al., 2005; Numata et al., 2009; Pickard et al., 2007), and the protein 
product is enriched at the synapse (Bradshaw et al., 2008; Millar et al., 2005). NCOA1 
and NCOR2 have previously been demonstrated to be glucocorticoid receptor co-
factors and modulate its transcriptional activity (van der Laan et al., 2008). For example, 
NCOA1 is necessary for regulating stress-induced corticotropin releasing hormone (a 
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major component of the HPA axis stress response, see Chapter I) (Lachize et al., 
2009). Additionally, mice not expressing NCOA1 exhibited increased HPA axis 
sensitivity (Winnay et al., 2006). Finally, both NCOR2 and PDE4B were predicted to be 
targeted by miR-184, a miRNA differentially expressed in the MDD cohort as compared 
to controls. 
 
To further query whether these mRNA/miRNA interactions occur directly, I constructed 
reporter constructs consisting of firefly luciferase upstream of the 3’ UTR of these genes 
of interest (NCOA1, NCOR2, and PDE4B) and transfected them into HEK293 cells with 
either miRNA mimics or saline solution (negative control). Constructs that showed initial 
repression of luciferase activity upon treatment with miRNA mimic compared to saline 
were then mutagenized at their prospective miRNA binding site(s) and employed in 
luciferase assays to assess the sequence specific dependency of miRNA/mRNA 
interactions. From these analyses I validated NCOA1 as regulated by miR-34a, NCOR2 
as regulated by miR-184, and PDE4B as regulated by both miR-34a and miR-184 (see 
Figure 2.2, Chapter II). Combined, these data indicated the convergence of miRNAs 
dysregulated in illness on both an individual gene (e.g. PDE4B) and on a biological 
process linked to both chronic stress and depression (e.g. glucocorticoid signaling, via 
NCOA1 and NCOR2). 
As I identified several miRNAs that varied in MDD and/or BP cohorts compared to 
control patients, and in combination with prior research suggesting that miRNAs act 
primarily via modulation of mRNA levels and/or translational repression, I sought to 
determine if the steady-state levels of these validated mRNA targets were altered in 
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MDD and BP patient cohorts. Employing the same cohort of samples used in my 
miRNA expression analyses, I examined the steady-state levels of NCOA1, NCOR2 
and PDE4B mRNAs using TaqMan-based qPCR. I observed a significant decrease in 
NCOR2 mRNA levels specifically in our MDD cohort, whereas I observed no significant 
change in steady-state PDE4B mRNA levels in either BP or MDD patients. In contrast, 
and consistent with canonical miRNA-induced repression of gene expression, I 
observed a significant increase in NCOA1 mRNA expression specific to the BP cohort.  
While I am encouraged by these miRNA and mRNA findings, my work is not without 
caveats. Though I have validated several miRNA/mRNA interactions, there is no 
present evidence demonstrating co-expression of miRNAs dysregulated in disease with 
their validated mRNA targets. Future human neuroanatomical studies will be required to 
examine the cellular localization of these microRNAs and their mRNA targets. 
Additionally, while I have demonstrated the differential expression of several mRNA 
transcripts, I do not have protein expression data within this cohort of patients (though 
prior literature has demonstrated increased PDE4B protein levels in the cingulate cortex 
of MDD patients (Yuan et al., 2011). As such, while future studies will be needed to 
address both of these limitations, the results of the present study are consistent with the 
miRNA regulation of several transcripts implicated in neuropsychiatric illness. 
To summarize: a majority of miRNAs are expressed within brain regulate key CNS 
processes, have a “one-to-many” relationship with their mRNA targets, and are 
hypothesized to play a key role in mood and affective disorders. While we note several 
caveats in our findings, the work performed in this thesis sheds light on miRNA 
dysregulation in AnCg (a brain region centrally involved in mood and cognition) as well 
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as mRNA targets of these dysregulated miRNAs. Additionally, this work identifies miR-
34a as a miRNA of particular interest given 1) its dysregulation across multiple 
psychiatric illnesses, 2) its dysregulation in multiple cortical regions linked to psychiatric 
illness, and 3) its regulation of a large number of mRNA targets implicated in these 
disorders. 
As these initial human studies progressed I recognized that studies in human samples 
are often confounded by both the diversity of clinical depressive phenotypes and 
individual (e.g. patient-to-patient) variability. As we wished to move towards examining 
more mechanistic hypotheses, and this variability makes probing mechanistic questions 
difficult, we elected to employ an animal model of chronic stress to examine stress-
induced transcriptomic alterations in a brain-region-specific fashion. Chronic stress is a 
major precipitating factor for neuropsychiatric illness. Chronic stress also induces 
persistent hypercortisolemia (increased circulating glucocorticoids) and, as 
glucocorticoids are powerful mediators of gene transcription, influences widespread 
changes in gene expression. Additionally, there is a growing consensus in the field that 
human depression, as well as depressive-like behavior in animal models of chronic 
stress, may represent the summation of (mal)adaptive responses to chronic stress. One 
such maladaptive response is reduced activity and function in the mPFC, a brain region 
central to regulating HPA axis activity, stress responses and emotionality (Arnsten, 
2009; Joormann & Gotlib, 2010). Given that gene expression changes likely underlie 
maladaptive responses to chronic stress (including mPFC hypofunction) I wished to test 
the following hypothesis: 
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Chronic stress is a major precipitant of mental illness and is a powerful modulator of 
gene expression. Given the mPFC is a central regulator of stress responses (and is a 
particularly stress-sensitive brain region), chronic stress will result in widespread gene 
expression changes consistent with inhibited mPFC function. 
 
To test this hypothesis I employed RNA sequencing analyses of RNA samples 
generated from mPFC of mice subjected to a chronic variable stress protocol as well as 
non-stressed controls (Chapter III). I identified >15,000 unique gene IDs per sample, 
with a substantial number (~1,800) of these identified as putatively differentially 
regulated in CVS mice versus non-stressed controls (linear fold-change > 1.3, raw p-
value < 0.05). I subsequently performed gene ontology and clustering analyses of 
differentially expressed transcripts and focused on CNS-specific categories (specifically, 
‘Neuron development,’ ‘Neuron projection development,’ and, ‘Synaptic Transmission’). 
Based on these criteria I chose ~60 mRNA targets to validate using high-throughput 
qPCR methodologies and, following expression analyses, validated 31 targets as 
differentially expressed in CVS versus control animals. Additionally, given growing 
evidence that miRNAs play a role in regulating HPA axis activity, stress responses, 
mood and anxiety (Bahi et al., 2014; Haramati et al., 2011; Honda et al., 2013; Katsuura 
et al., 2012; Muinos-Gimeno et al., 2011; Vreugdenhil et al., 2009), I examined miRNA 
expression in the mPFC of this same cohort of mice. I performed an initial screen of 
>300 miRNAs using high-throughput qPCR methodologies and identified 14 miRNAs as 
putatively differentially expressed (see Figure 3.2, Chapter III). Following more stringent 
validations employing individual assays, 4 miRNAs validated as regulated by stress: 
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miR-187, 298, 320 and 666-5p (see Figure 3.2, Chapter III). Combined, these data 
indicate the dysregulation of a large number of mRNA and microRNA transcripts as a 
function of chronic stress with many validated transcripts linked to neuronal processes. 
Given the large number of transcripts that validated as stress-regulated, I next sought to 
contextualize these changes within the impact of chronic stress on mPFC physiology. 
Prior findings have demonstrated a large number of neuronal- and synaptic related 
pathologies, with the glutamatergic system gaining increasing prominence as a key 
player in maladaptive responses to stress (Sanacora et al., 2012). By employing 
bioinformatics pathway analysis tools and literature syntheses I characterized a 
prospective ‘interactome’ of our stress-regulated mRNA transcripts with an eye towards 
their impact on mPFC function (see Figure 3.4, Chapter III). From this analysis, the 
oncogene Rac1 (a regulator of glutamatergic spine size and a downstream effector of 
the stress-regulated psychiatric risk factor Disc1 (Hayashi-Takagi et al., 2010)) emerged 
as a putative target of the stress-regulated miR-187. I subsequently validated this 
miRNA/mRNA interaction in vitro and integrated it as a component of our mechanistic 
hypothesis 
While the results of these transcriptomic and “interactomic” studies  are intriguing, I urge 
caution and note that a number of future studies (see below) will be necessary to 
further assess the prospective cellular, biological and functional impact(s) of stress-
induced transcriptomic alterations. Specifically, I note that these changes were 
observed at the RNA level and—as protein levels may not correlate with RNA levels—
commensurate alterations at the protein level may not be observed. Furthermore I note 
that, even if protein levels were observed to change commensurate with my hypothesis, 
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further experiments would be required to determine whether these were accompanied 
by a functional response. In spite of these caveats, I note that this “interactome” is 
consistent with both my findings and current literature. Taken together, my hypothesis 
presents a starting point for examining the underlying genomic mechanisms that may 
influence hypofunction in mPFC in a cell-type-dependent fashion. 
Finally, prior literature has established that two mPFC subregions—the IL and PL 
subdivisions—have previously been linked to regulation of stress responses and HPA 
axis activity (Jones et al., 2011; Radley et al., 2006; Sullivan & Gratton, 1999; Tavares 
et al., 2009). Of particular note, IL and PL cortices appear to have roughly opposite 
effects on HPA axis function: IL cortical activity appears to be necessary for the initiation 
of HPA axis responses, while stimulation of PL cortex inhibits HPA axis response 
specifically to psychogenic (but not physical) insults (Jones et al., 2011). Given these 
prior observations I sought to identify whether a subset of my validated mRNA 
transcripts demonstrated subregional-specific differential expression. To address this 
question, I performed laser-capture microdissection of IL and PL subregions in an 
independent cohort of mice subjected to 14 days of CVS and non-stressed control mice. 
Following qPCR expression analyses of 4 examined transcripts, 3 validated (Gad2, 
Rgs4 and Tnik) with directionality and magnitude of fold expression consistent with the 
initial cohort. While Rgs4 demonstrated differential expression in both PL and IL, Gad2 
and Tnik were differentially expressed specifically within PL cortex. While Adcyap1r1 did 
not validate in either brain region it is possible that it may 1) be regulated in another 
brain region or 2) its initial significance was due to contamination of mPFC by unrelated 
brain regions. While the number of transcripts examined is relatively small, these 
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findings do indicate the subregion-specific dysregulation of several stress-regulated 
transcripts and are consistent with differential impacts of chronic stress on IL and PL 
regions. 
Combined, these data indicate widespread gene expression changes in mPFC following 
chronic stress. Additionally, integrating these findings with bioinformatics analyses and 
prior literature indicates these changes may be part of a mechanistic framework for how 
gene expression changes could underlie stress-induced glutamatergic mPFC 
hypofunction (Chapter III). Finally, this work provides the first large-scale analysis of the 
transcriptional impacts of chronic stress in mPFC as well as the first empirical evidence 
of differential gene expression by subregion in a mouse CVS model.  
 
Further Questions Prompted By This Work and Future Directions 
The findings obtained from this dissertation research shed further light on transcriptomic 
alterations in both human neuropsychiatric illness and animal models of chronic stress. 
This thesis research hypothesizes a cell-type-specific basis for a subset of stress-
regulated transcripts. Finally, this work outlines preliminary work employing an 
immunopurification model that will enable the acquisition of relevant biological samples 
from targeted cell type(s) of interest that is expected to be instrumental in assessing the 
cell-type-specific stress-regulated mPFC model hypothesized. While our group’s focus 
on overlaying stress-induced gene expression changes on specific components of the 
neural circuitry has had preliminary success, it raises a number of intriguing questions 
that will need to be addressed by future studies. A subset of prospective future 
directions are discussed below: 
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What component(s) of the neural circuitry (e.g. cell type) drive dysregulation of 
miRNAs with altered expression in disease and disease-like states? 
As we have noted elsewhere the brain is extremely heterogeneous in both function and 
in its multitude of cell types. mRNA expression can vary widely from one brain region to 
another and this heterogeneity is known to extend to specific cell types. While cell-type 
“markers” are commonly employed to identify a specific cell (sub)type, identifying the 
relative expression of RNA transcripts not confined to a single cell type has proven 
more challenging. Similarly, a recent article demonstrated the enrichment of a large 
number of miRNAs by neuronal cell type using a technique similar to the TRAP 
methodology for miRNAs (He et al., 2012).  While results in this thesis implicate specific 
miRNAs as regulators of a subset of miRNA targets, these studies were conducted in 
an in vitro model system (e.g. HEK293 cells) engineered to express both miRNAs and 
mRNA targets together. At present, we lack in vivo evidence attesting to the co-
expression of miRNAs with their validated mRNA targets (a necessary prerequisite for 
these interactions to impact cellular physiology). 
A potential way to address this would be to employ dual in situ hybridization (ISH) 
approaches using radioactively tagged nucleic acid probes directed against miRNAs of 
interest and colorimetric nucleic acid probes directed against mRNA targets. These 
methods have the advantage of providing relative quantification of their targets via 
silver-grain counting (e.g. autoradiographic) methods and would provide strong 
evidence of co-expression within the same cell type. Similar methods have been 
previously employed (though only via colocalization of mRNAs, not mRNAs and 
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miRNAs) (Curran & Watson, 1995), although several technical considerations 
compromise an effort to deploy this method (specifically, the relatively low signal 
strength and half-life of the gamma-P33 labeled probes combined with the relative lack 
of abundance of our targeted miRNAs). To address these concerns I attempted to 
leverage in vitro transcription (IVT) methods and S35-labeled UTP to generate our 
radioactive nucleic acid probes for miRNAs (which would, in theory, give us greater 
signal strength (e.g. greater specific activity) with a much longer half-life). This method, 
however, proved less than satisfactory: while I was able to demonstrate similar 
expression profiles for a number of well-characterized miRNAs using our IVT method, 
negative controls consistently exhibited extremely high and non-specific background 
signal. Despite multiple attempts to optimize this protocol I was unable to reduce 
nonspecific signal to an acceptable level. 
Another way I might approach this question is to use fluorescent in situ hybridization 
(FISH) methodologies, with one probe directed against the miRNA of interest and the 
other directed against the mRNA target. Subsequent imaging analyses would be 
sufficient to identify whether the miRNA/mRNA pair colocalize and similar methods have 
been successfully employed in prior work (Deo, Yu, Chung, Tippens, & Turner, 2006; 
Wu, Piccini, & Singh, 2014). While these methods do not provide the quantification 
abilities of radioactive ISH approaches they do provide an effective method to query the 
neuroanatomy of miRNA expression and assay whether miRNAs of interest and their 
mRNA targets overlap. This would enable us to make stronger hypothesis on the 
particular function of an individual miRNA and avoid potential “false positive” 
interactions when attempting to ascertain biologically relevant miRNA functions (e.g. 
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when a miRNA may regulate an mRNA target in vitro, but this interaction is not 
biologically applicable). 
An additional way we might query the specific cell type(s) driving miRNA dysregulation 
in disease- and disease-like states is to employ the miRNA tagging and affinity 
purification (miRAP) methodology established by He et al. (He et al., 2012). By 
employing mice carrying a cre-inducible argonaute 2 construct (Ago2, a core protein in 
the RNA-induced silencing complex (J. Liu et al., 2004)) fused to a Myc and eGFP tag, 
this methodology enables the immunopurification of miRNAs from specific cell types 
(specified by Cre driver). These studies leverage our laboratory’s current expertise with 
RNA immunopurification methodologies and would serve to complement both the 
aforementioned in situ hybridization studies and TRAP methodologies. 
 
How does chronic stress impact gene expression in neuronal (as opposed to 
glial) cell types? 
As mentioned in Chapter I, stress affects gene expression in nearly every organ system, 
tissue and cell type. This is particularly true in the CNS, where significant morphological 
and physiological changes have been observed across the brain in both neurons and 
glia following both chronic stress and glucocorticoid treatment. Prior work in our 
laboratory has demonstrated both the in vitro and in vivo regulation of multiple 
astrocyte-enriched transcripts by chronic glucocorticoid treatment (Carter et al., 2013; 
Carter et al., 2012). Furthermore, preliminary data performed as part of this dissertation 
(Chapter IV) has indicated the stress regulation of numerous mRNA transcripts 
specifically within astrocytes that were NOT identified as stress regulated in our whole-
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mPFC data. Together, this data indicates a cell-type-dependent impact of chronic stress 
on gene expression. This observation, then, prompts a major question: how does 
chronic stress impact gene expression in neuronal cell types? 
One possible way to examine this would be to employ the previously described TRAP 
methodology ((Doyle et al., 2008; Heiman et al., 2008); see Chapter IV) using mice that 
express Cre recombinase under the control of neuron-specific promoters. We would be 
particularly interested in examining the transcriptomic impact of chronic stress in mPFC 
within the context of glutamatergic pyramidal cells (labeled by Camk2a) and GABAergic 
interneurons (labeled predominantly by Gad2) as these cell types have 1) been 
implicated in both maladaptive responses to chronic stress and human neuropsychiatric 
illness and 2) represent the predominant drivers of excitatory and inhibitory tone within 
mPFC. Furthermore, this approach would allow us to further test our ‘glutamate-centric’ 
hypothesis for the transcriptomic changes we observed in whole-mPFC analyses (see 
Chapter 3). These experiments would also provide us with unbiased gene expression 
analyses of basal expression and stress-regulation from each cell type (astrocyte, 
glutamatergic neuron and GABAergic neuron) of the canonical “tripartite synapse” within 
mPFC. We note that recent work by Tasic et al. focused on single-cell transcriptomics 
and has indicated there are likely many different glutamatergic neurons (Tasic et al., 
2016) in addition to the established heterogeneity of GABAergic interneurons (Rudy et 
al., 2011). As such, whether all—or only a subset—of these neuronal subtypes regulate 
mPFC function in stress remains in open question. In spite of these challenges, 
however, these proposed studies would provide a potentially valuable ‘atlas’ of gene 
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expression changes at the RNA level that could guide future functional and mechanistic 
studies. 
 
What are the functional consequences of stimulation and/or inhibition of specific 
cell types within the mPFC? 
The overarching theme of this dissertation has been to examine large-scale 
transcriptomic events occurring in either human neuropsychiatric disorders or animal 
models of chronic stress. In the course of this latter aim we have described our rationale 
for investigating the mPFC and the potential relevance of its hypofunction following 
chronic stress. Missing from this work, however, has been the functional assessment of 
the impact of mPFC hypofunction on depressive-like behavior. 
Several prior studies have suggested that this may be a profitable line of inquiry. A high-
impact paper published in 2005 from Mayberg et al. (Mayberg et al., 2005) revealed that 
deep brain stimulation of subgenual cingulate cortex yielded therapeutic responses for 
treatment-resistant depression, indicating that modulation of activity in a specific brain 
region may be sufficient to relieve many symptoms of depression. A recent study by 
Covington et al.  observed the reduction of multiple immediate early genes (IEGs) 
following chronic social defeat stress (CSDS) and demonstrated that optogenetic 
stimulation of whole mPFC was sufficient to not only restore expression of these IEGs 
but also induce a robust antidepressant-like effect in mice subjected to CSDS 
(Covington et al., 2010). A more recent study by Kumar et al. revealed that the specific 
optogenetic stimulation of layer-V PL pyramidal cells was sufficient to induce an 
antidepressant-like phenotype in mice subjected to a forced swim test as well as having 
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anxiolytic effects (though no antidepressant-like effects of optogenetic stimulation of PL 
pyramidal cells following CSDS were observed) (Kumar et al., 2013). 
A logical extension of this published work, as well as my own, would be to employ the 
CVS paradigm with optogenetic stimulation specifically within pyramidal neurons (not 
only layer-V) in PL and IL subregions. This approach would allow me to assess whether 
activation of either subregion following chronic stress is sufficient to induce an 
antidepressant-like phenotype. An alternate (although potentially less clear) approach 
may be to perform optogenetic stimulation concurrent with the CVS paradigm, the 
rationale being to identify whether preventing the acquisition of mPFC hypofunction via 
optogenetic stimulation is sufficient to prevent the occurrence of CVS-induced 
depressive like behavior. Another way to approach this question would be to employ 
optogenetic inhibition of PL and IL function within mPFC. By using halorhodopsin, rather 
than channelrhodopsin, I would be able to induce mPFC hypofunction in the absence of 
stress and assay whether mPFC hypofunction is sufficient to induce (or render mice 
more susceptible to developing) depressive-like behavior. 
A major benefit to these approaches is that they are theoretically capable of generating 
both transcriptomic and functional data from the same cohort of mice. It would be 
possible to generate mice carrying 1) Cre recombinase under the control of the Camk2a 
promoter and 2) the Cre-inducible L10a-eGFP ribosomal fusion protein, restricting the 
expression of this construct to pyramidal cells. We would then be able to inject these 
same mice with a virus expressing a Cre-inducible channelrhodopsin injected into PL or 
IL. Following optogenetic stimulation (or inhibition), we could then perform behavioral 
assays and subsequently identify transcripts regulated by stimulation/inhibition 
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specifically from mPFC subregion. While we note the need for feasibility studies 
(particularly to ensure that targeting a specific cell type in a specific subregion with 
several genetic manipulations does not affect baseline behavior), we have begun 
implementing optogenetics methodologies into our laboratory in pursuit of these 
questions. At present, we are currently collecting preliminary data on the co-expression 
of eGFP and mCherry-tagged channelrhodopsin in mPFC of Rosa26L10a-eGFP/L10a-eGFP; 
Gad2cre/cre mice in preparation for undertaking of these experiments. While currently 
speculative, these findings may have clinical relevance for human depressive patients 
given the strong shared pathologies (e.g. HPA axis dysfunction, glutamatergic 
dysfunction and mPFC hypofunction) between chronic stress and mood disorders and 
may enable the identification of prospective therapeutic targets. 
 
Synopsis of Dissertation Findings 
 3 miRNAs in a bipolar disorder (BP) cohort (miR-132, miR-133a and miR-212), 1 
in a major depressive disorder (MDD) cohort (miR-184) and 1 in both BP and MDD 
cohorts (miR-34a) are significantly repressed compared to control patients. 
 Several mRNAs linked to psychiatric illness are regulated by these microRNAs in 
an in vitro assay: miR-34a regulates NCOA1, miR-184 regulates NCOR2, while both 
miR-184 and miR-34a regulate PDE4B. 
 The steady state levels of NCOA1 and NCOR2 mRNA are altered in BP and 
MDD cohorts, respectively. 
 Exposure to the chronic variable stress (CVS) paradigm results in the differential 
expression of a large number of mRNA transcripts (assayed by RNA sequencing). 
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 Identified 4 miRNA and >30 mRNA transcripts as CVS-regulated with a subset of 
mRNA transcripts being regulated in a prelimbic cortex (PL)-specific manner. 
 Identified Rac1 as regulated by the stress-regulated miR-187. 
 Generated a mechanistic hypothesis/“interactome” of CVS-regulated transcripts 
consistent with glutamatergic hypofunction in mPFC (based on bioinformatics analyses 
and literature analysis). 
 Performed feasibility analysis of using translating ribosomal affinity purification 
(TRAP) methods to immunopurify RNA specifically from astrocytes and GABAergic 
interneurons. 
 Employed TRAP methods to immunopurify RNA specifically from mPFC 
astrocytes in mice subjected to CVS versus non-stressed controls. 
 
 
 
 
 
 
 
 
 
 
 
 
166 
 
Chapter V References 
Agarwal, V., Bell, G. W., Nam, J. W., & Bartel, D. P. (2015). Predicting effective 
microRNA target sites in mammalian mRNAs. Elife, 4. doi:10.7554/eLife.05005 
Akiskal, H. S., Bourgeois, M. L., Angst, J., Post, R., Moller, H., & Hirschfeld, R. (2000). 
Re-evaluating the prevalence of and diagnostic composition within the broad 
clinical spectrum of bipolar disorders. J Affect Disord, 59 Suppl 1, S5-s30.  
Aksoy-Aksel, A., Zampa, F., & Schratt, G. (2014). MicroRNAs and synaptic plasticity--a 
mutual relationship. Philos Trans R Soc Lond B Biol Sci, 369(1652). 
doi:10.1098/rstb.2013.0515 
Altamura, A. C., Boin, F., & Maes, M. (1999). HPA axis and cytokines dysregulation in 
schizophrenia: potential implications for the antipsychotic treatment. Eur 
Neuropsychopharmacol, 10(1), 1-4.  
Amann, B., Born, C., Crespo, J. M., Pomarol-Clotet, E., & McKenna, P. (2011). 
Lamotrigine: when and where does it act in affective disorders? A systematic 
review. J Psychopharmacol, 25(10), 1289-1294. doi:10.1177/0269881110376695 
American Psychiatric, A., American Psychiatric, A., & Force, D. S. M. T. (2013). 
Diagnostic and statistical manual of mental disorders : DSM-5.  Retrieved from 
http://dsm.psychiatryonline.org/book.aspx?bookid=556 
Andero, R., Choi, D. C., & Ressler, K. J. (2014). BDNF-TrkB receptor regulation of 
distributed adult neural plasticity, memory formation, and psychiatric disorders. 
Prog Mol Biol Transl Sci, 122, 169-192. doi:10.1016/b978-0-12-420170-5.00006-
4 
Arnow, B. A., Hunkeler, E. M., Blasey, C. M., Lee, J., Constantino, M. J., Fireman, B., . . 
. Hayward, C. (2006). Comorbid depression, chronic pain, and disability in 
primary care. Psychosom Med, 68(2), 262-268. 
doi:10.1097/01.psy.0000204851.15499.fc 
Arnsten, A. F. (2009). Stress signalling pathways that impair prefrontal cortex structure 
and function. Nat Rev Neurosci, 10(6), 410-422. doi:10.1038/nrn2648 
Aroeira, R. I., Sebastiao, A. M., & Valente, C. A. (2014). GlyT1 and GlyT2 in brain 
astrocytes: expression, distribution and function. Brain Struct Funct, 219(3), 817-
830. doi:10.1007/s00429-013-0537-3 
Asada, H., Kawamura, Y., Maruyama, K., Kume, H., Ding, R. G., Kanbara, N., . . . 
Obata, K. (1997). Cleft palate and decreased brain gamma-aminobutyric acid in 
mice lacking the 67-kDa isoform of glutamic acid decarboxylase. Proc Natl Acad 
Sci U S A, 94(12), 6496-6499.  
Auer, D. P., Putz, B., Kraft, E., Lipinski, B., Schill, J., & Holsboer, F. (2000). Reduced 
glutamate in the anterior cingulate cortex in depression: an in vivo proton 
magnetic resonance spectroscopy study. Biol Psychiatry, 47(4), 305-313.  
Axelson, D. A., Doraiswamy, P. M., McDonald, W. M., Boyko, O. B., Tupler, L. A., 
Patterson, L. J., . . . Krishnan, K. R. (1993). Hypercortisolemia and hippocampal 
changes in depression. Psychiatry Res, 47(2), 163-173.  
Bahi, A., Chandrasekar, V., & Dreyer, J. L. (2014). Selective lentiviral-mediated 
suppression of microRNA124a in the hippocampus evokes antidepressants-like 
effects in rats. Psychoneuroendocrinology, 46, 78-87. 
doi:10.1016/j.psyneuen.2014.04.009 
167 
 
Bak, M., Silahtaroglu, A., Moller, M., Christensen, M., Rath, M. F., Skryabin, B., . . . 
Kauppinen, S. (2008). MicroRNA expression in the adult mouse central nervous 
system. RNA, 14(3), 432-444. doi:10.1261/rna.783108 
Banasr, M., Chowdhury, G. M., Terwilliger, R., Newton, S. S., Duman, R. S., Behar, K. 
L., & Sanacora, G. (2010). Glial pathology in an animal model of depression: 
reversal of stress-induced cellular, metabolic and behavioral deficits by the 
glutamate-modulating drug riluzole. Mol Psychiatry, 15(5), 501-511. 
doi:10.1038/mp.2008.106 
Banasr, M., & Duman, R. S. (2008). Glial loss in the prefrontal cortex is sufficient to 
induce depressive-like behaviors. Biol Psychiatry, 64(10), 863-870. 
doi:10.1016/j.biopsych.2008.06.008 
Barlow, S. M., Morrison, P. J., & Sullivan, F. M. (1975). Effects of acute and chronic 
stress on plasma corticosterone levels in the pregnant and non-pregnant mouse. 
J Endocrinol, 66(1), 9o-9.  
Basowitz, H., Chevalier, J. A., Grinker, R. R., Hamburg, D. A., Korchin, S. J., Persky, H., 
& Sabshin, M. A. (1956). Adrenal cortical function in anxious human subjects; 
plasma level and urinary excretion of hydrocortisone. AMA Arch Neurol 
Psychiatry, 76(5), 549-558.  
Bass, N. H., Hess, H. H., Pope, A., & Thalheimer, C. (1971). Quantitative 
cytoarchitectonic distribution of neurons, glia, and DNa in rat cerebral cortex. J 
Comp Neurol, 143(4), 481-490. doi:10.1002/cne.901430405 
Bassett, A. S., & Chow, E. W. (1999). 22q11 deletion syndrome: a genetic subtype of 
schizophrenia. Biol Psychiatry, 46(7), 882-891.  
Bavamian, S., Mellios, N., Lalonde, J., Fass, D. M., Wang, J., Sheridan, S. D., . . . 
Haggarty, S. J. (2015). Dysregulation of miR-34a links neuronal development to 
genetic risk factors for bipolar disorder. Mol Psychiatry. doi:10.1038/mp.2014.176 
Belanoff, J. K., Flores, B. H., Kalezhan, M., Sund, B., & Schatzberg, A. F. (2001). Rapid 
reversal of psychotic depression using mifepristone. J Clin Psychopharmacol, 
21(5), 516-521.  
Bernstein, E., Kim, S. Y., Carmell, M. A., Murchison, E. P., Alcorn, H., Li, M. Z., . . . 
Hannon, G. J. (2003). Dicer is essential for mouse development. Nat Genet, 
35(3), 215-217. doi:10.1038/ng1253 
Berrettini, W. (2003). Evidence for shared susceptibility in bipolar disorder and 
schizophrenia. Am J Med Genet C Semin Med Genet, 123C(1), 59-64. 
doi:10.1002/ajmg.c.20014 
Betel, D., Koppal, A., Agius, P., Sander, C., & Leslie, C. (2010). Comprehensive 
modeling of microRNA targets predicts functional non-conserved and non-
canonical sites. Genome Biol, 11(8), R90. doi:10.1186/gb-2010-11-8-r90 
Beveridge, N. J., Gardiner, E., Carroll, A. P., Tooney, P. A., & Cairns, M. J. (2010). 
Schizophrenia is associated with an increase in cortical microRNA biogenesis. 
Mol Psychiatry, 15(12), 1176-1189. doi:10.1038/mp.2009.84 
Beveridge, N. J., Tooney, P. A., Carroll, A. P., Gardiner, E., Bowden, N., Scott, R. J., . . 
. Cairns, M. J. (2008). Dysregulation of miRNA 181b in the temporal cortex in 
schizophrenia. Hum Mol Genet, 17(8), 1156-1168. doi:10.1093/hmg/ddn005 
Bhagwagar, Z., Wylezinska, M., Jezzard, P., Evans, J., Ashworth, F., Sule, A., . . . 
Cowen, P. J. (2007). Reduction in occipital cortex gamma-aminobutyric acid 
168 
 
concentrations in medication-free recovered unipolar depressed and bipolar 
subjects. Biol Psychiatry, 61(6), 806-812. doi:10.1016/j.biopsych.2006.08.048 
Bicker, S., Lackinger, M., Weiss, K., & Schratt, G. (2014). MicroRNA-132, -134, and -
138: a microRNA troika rules in neuronal dendrites. Cell Mol Life Sci, 71(20), 
3987-4005. doi:10.1007/s00018-014-1671-7 
Bierut, L. J., Heath, A. C., Bucholz, K. K., Dinwiddie, S. H., Madden, P. A., Statham, D. 
J., . . . Martin, N. G. (1999). Major depressive disorder in a community-based 
twin sample: are there different genetic and environmental contributions for men 
and women? Arch Gen Psychiatry, 56(6), 557-563.  
Blackwood, D. H., Fordyce, A., Walker, M. T., St Clair, D. M., Porteous, D. J., & Muir, 
W. J. (2001). Schizophrenia and affective disorders--cosegregation with a 
translocation at chromosome 1q42 that directly disrupts brain-expressed genes: 
clinical and P300 findings in a family. Am J Hum Genet, 69(2), 428-433.  
Bliss, E. L., Migeon, C. J., Branch, C. H., & Samuels, L. T. (1956). Reaction of the 
adrenal cortex to emotional stress. Psychosom Med, 18(1), 56-76.  
Board, F., Persky, H., & Hamburg, D. A. (1956). Psychological stress and endocrine 
functions; blood levels of adrenocortical and thyroid hormones in acutely 
disturbed patients. Psychosom Med, 18(4), 324-333.  
Board, F., Wadeson, R., & Persky, H. (1957). Depressive affect and endocrine 
functions; blood levels of adrenal cortex and thyroid hormones in patients 
suffering from depressive reactions. AMA Arch Neurol Psychiatry, 78(6), 612-
620.  
Boyle, E. I., Weng, S., Gollub, J., Jin, H., Botstein, D., Cherry, J. M., & Sherlock, G. 
(2004). GO::TermFinder--open source software for accessing Gene Ontology 
information and finding significantly enriched Gene Ontology terms associated 
with a list of genes. Bioinformatics, 20(18), 3710-3715. 
doi:10.1093/bioinformatics/bth456 
Boyle, M. P., Brewer, J. A., Funatsu, M., Wozniak, D. F., Tsien, J. Z., Izumi, Y., & 
Muglia, L. J. (2005). Acquired deficit of forebrain glucocorticoid receptor 
produces depression-like changes in adrenal axis regulation and behavior. Proc 
Natl Acad Sci U S A, 102(2), 473-478. doi:10.1073/pnas.0406458102 
Bradshaw, N. J., Ogawa, F., Antolin-Fontes, B., Chubb, J. E., Carlyle, B. C., Christie, S., 
. . . Millar, J. K. (2008). DISC1, PDE4B, and NDE1 at the centrosome and 
synapse. Biochem Biophys Res Commun, 377(4), 1091-1096. 
doi:10.1016/j.bbrc.2008.10.120 
Brandon, N. J., & Sawa, A. (2011). Linking neurodevelopmental and synaptic theories of 
mental illness through DISC1. Nat Rev Neurosci, 12(12), 707-722. 
doi:10.1038/nrn3120 
Breslau, N., & Davis, G. C. (1986). Chronic stress and major depression. Arch Gen 
Psychiatry, 43(4), 309-314.  
Broderick, J. A., Salomon, W. E., Ryder, S. P., Aronin, N., & Zamore, P. D. (2011). 
Argonaute protein identity and pairing geometry determine cooperativity in 
mammalian RNA silencing. RNA, 17(10), 1858-1869. doi:10.1261/rna.2778911 
Brown, S. M., Henning, S., & Wellman, C. L. (2005). Mild, short-term stress alters 
dendritic morphology in rat medial prefrontal cortex. Cereb Cortex, 15(11), 1714-
1722. doi:10.1093/cercor/bhi048 
169 
 
Bunney, B. G., & Bunney, W. E. (2013). Mechanisms of rapid antidepressant effects of 
sleep deprivation therapy: clock genes and circadian rhythms. Biol Psychiatry, 
73(12), 1164-1171. doi:10.1016/j.biopsych.2012.07.020 
Bunney, B. G., Li, J. Z., Walsh, D. M., Stein, R., Vawter, M. P., Cartagena, P., . . . 
Bunney, W. E. (2015). Circadian dysregulation of clock genes: clues to rapid 
treatments in major depressive disorder. Mol Psychiatry, 20(1), 48-55. 
doi:10.1038/mp.2014.138 
Burcusa, S. L., & Iacono, W. G. (2007). Risk for recurrence in depression. Clin Psychol 
Rev, 27(8), 959-985. doi:10.1016/j.cpr.2007.02.005 
Burette, A. C., Phend, K. D., Burette, S., Lin, Q., Liang, M., Foltz, G., . . . Weinberg, R. 
J. (2015). Organization of TNIK in dendritic spines. J Comp Neurol, 523(13), 
1913-1924. doi:10.1002/cne.23770 
Cahoy, J. D., Emery, B., Kaushal, A., Foo, L. C., Zamanian, J. L., Christopherson, K. S., 
. . . Barres, B. A. (2008). A transcriptome database for astrocytes, neurons, and 
oligodendrocytes: a new resource for understanding brain development and 
function. J Neurosci, 28(1), 264-278. doi:10.1523/jneurosci.4178-07.2008 
Cao, X., Yeo, G., Muotri, A. R., Kuwabara, T., & Gage, F. H. (2006). Noncoding RNAs 
in the mammalian central nervous system. Annu Rev Neurosci, 29, 77-103. 
doi:10.1146/annurev.neuro.29.051605.112839 
Cardinal, R. N., Parkinson, J. A., Hall, J., & Everitt, B. J. (2002). Emotion and 
motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. 
Neurosci Biobehav Rev, 26(3), 321-352.  
Carter, B. S., Hamilton, D. E., & Thompson, R. C. (2013). Acute and chronic 
glucocorticoid treatments regulate astrocyte-enriched mRNAs in multiple brain 
regions in vivo. Front Neurosci, 7, 139. doi:10.3389/fnins.2013.00139 
Carter, B. S., Meng, F., & Thompson, R. C. (2012). Glucocorticoid treatment of 
astrocytes results in temporally dynamic transcriptome regulation and astrocyte-
enriched mRNA changes in vitro. Physiol Genomics, 44(24), 1188-1200. 
doi:10.1152/physiolgenomics.00097.2012 
Cassidy, F., Ahearn, E. P., & Carroll, B. J. (2001). Substance abuse in bipolar disorder. 
Bipolar Disord, 3(4), 181-188.  
Cavalli, A., Druey, K. M., & Milligan, G. (2000). The regulator of G protein signaling 
RGS4 selectively enhances alpha 2A-adreoreceptor stimulation of the GTPase 
activity of Go1alpha and Gi2alpha. J Biol Chem, 275(31), 23693-23699. 
doi:10.1074/jbc.M910395199 
Cheng, H. Y., Papp, J. W., Varlamova, O., Dziema, H., Russell, B., Curfman, J. P., . . . 
Obrietan, K. (2007). microRNA modulation of circadian-clock period and 
entrainment. Neuron, 54(5), 813-829. doi:10.1016/j.neuron.2007.05.017 
Chiba, S., Numakawa, T., Ninomiya, M., Richards, M. C., Wakabayashi, C., & Kunugi, 
H. (2012). Chronic restraint stress causes anxiety- and depression-like 
behaviors, downregulates glucocorticoid receptor expression, and attenuates 
glutamate release induced by brain-derived neurotrophic factor in the prefrontal 
cortex. Prog Neuropsychopharmacol Biol Psychiatry, 39(1), 112-119. 
doi:10.1016/j.pnpbp.2012.05.018 
Choudary, P. V., Molnar, M., Evans, S. J., Tomita, H., Li, J. Z., Vawter, M. P., . . . Jones, 
E. G. (2005). Altered cortical glutamatergic and GABAergic signal transmission 
170 
 
with glial involvement in depression. Proc Natl Acad Sci U S A, 102(43), 15653-
15658. doi:10.1073/pnas.0507901102 
Chrousos, G. P. (2009). Stress and disorders of the stress system. Nat Rev Endocrinol, 
5(7), 374-381. doi:10.1038/nrendo.2009.106 
Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., . . . Richards, C. 
A. (2008). Identification of miRNA changes in Alzheimer's disease brain and CSF 
yields putative biomarkers and insights into disease pathways. J Alzheimers Dis, 
14(1), 27-41.  
Cook, S. C., & Wellman, C. L. (2004). Chronic stress alters dendritic morphology in rat 
medial prefrontal cortex. J Neurobiol, 60(2), 236-248. doi:10.1002/neu.20025 
Cottingham, C., Chen, Y., Jiao, K., & Wang, Q. (2011). The antidepressant desipramine 
is an arrestin-biased ligand at the alpha(2A)-adrenergic receptor driving receptor 
down-regulation in vitro and in vivo. J Biol Chem, 286(41), 36063-36075. 
doi:10.1074/jbc.M111.261578 
Cottingham, C., & Wang, Q. (2012). alpha2 adrenergic receptor dysregulation in 
depressive disorders: implications for the neurobiology of depression and 
antidepressant therapy. Neurosci Biobehav Rev, 36(10), 2214-2225. 
doi:10.1016/j.neubiorev.2012.07.011 
Covington, H. E., 3rd, Lobo, M. K., Maze, I., Vialou, V., Hyman, J. M., Zaman, S., . . . 
Nestler, E. J. (2010). Antidepressant effect of optogenetic stimulation of the 
medial prefrontal cortex. J Neurosci, 30(48), 16082-16090. 
doi:10.1523/jneurosci.1731-10.2010 
Craddock, N., & Jones, I. (1999). Genetics of bipolar disorder. J Med Genet, 36(8), 585-
594.  
Crick, F. (1970). Central dogma of molecular biology. Nature, 227(5258), 561-563.  
Cui, Y., Xiao, Z., Han, J., Sun, J., Ding, W., Zhao, Y., . . . Dai, J. (2012). MiR-125b 
orchestrates cell proliferation, differentiation and migration in neural 
stem/progenitor cells by targeting Nestin. BMC Neurosci, 13, 116. 
doi:10.1186/1471-2202-13-116 
Curran, E. J., & Watson, S. J., Jr. (1995). Dopamine receptor mRNA expression 
patterns by opioid peptide cells in the nucleus accumbens of the rat: a double in 
situ hybridization study. J Comp Neurol, 361(1), 57-76. 
doi:10.1002/cne.903610106 
Daban, C., Vieta, E., Mackin, P., & Young, A. H. (2005). Hypothalamic-pituitary-adrenal 
axis and bipolar disorder. Psychiatr Clin North Am, 28(2), 469-480. 
doi:10.1016/j.psc.2005.01.005 
Datson, N. A., van der Perk, J., de Kloet, E. R., & Vreugdenhil, E. (2001). Identification 
of corticosteroid-responsive genes in rat hippocampus using serial analysis of 
gene expression. Eur J Neurosci, 14(4), 675-689.  
Davanzo, P., Yue, K., Thomas, M. A., Belin, T., Mintz, J., Venkatraman, T. N., . . . 
McCracken, J. (2003). Proton magnetic resonance spectroscopy of bipolar 
disorder versus intermittent explosive disorder in children and adolescents. Am J 
Psychiatry, 160(8), 1442-1452. doi:10.1176/appi.ajp.160.8.1442 
de Kloet, E. R., Fitzsimons, C. P., Datson, N. A., Meijer, O. C., & Vreugdenhil, E. 
(2009). Glucocorticoid signaling and stress-related limbic susceptibility pathway: 
171 
 
about receptors, transcription machinery and microRNA. Brain Res, 1293, 129-
141. doi:10.1016/j.brainres.2009.03.039 
Delgado, P. L. (2000). Depression: the case for a monoamine deficiency. J Clin 
Psychiatry, 61 Suppl 6, 7-11.  
Demyttenaere, K. (2001). Compliance and acceptance in antidepressant treatment. Int J 
Psychiatry Clin Pract, 5(1), 29-35. doi:10.1080/13651500152048423 
Deo, M., Yu, J. Y., Chung, K. H., Tippens, M., & Turner, D. L. (2006). Detection of 
mammalian microRNA expression by in situ hybridization with RNA 
oligonucleotides. Dev Dyn, 235(9), 2538-2548. doi:10.1002/dvdy.20847 
Diler, R. S., Pan, L. A., Segreti, A., Ladouceur, C. D., Forbes, E., Cela, S. R., . . . 
Phillips, M. L. (2014). Differential Anterior Cingulate Activity during Response 
Inhibition in Depressed Adolescents with Bipolar and Unipolar Major Depressive 
Disorder. J Can Acad Child Adolesc Psychiatry, 23(1), 10-19.  
Doyle, J. P., Dougherty, J. D., Heiman, M., Schmidt, E. F., Stevens, T. R., Ma, G., . . . 
Heintz, N. (2008). Application of a translational profiling approach for the 
comparative analysis of CNS cell types. Cell, 135(4), 749-762. 
doi:10.1016/j.cell.2008.10.029 
Drevets, W. C., Savitz, J., & Trimble, M. (2008). The subgenual anterior cingulate cortex 
in mood disorders. CNS Spectr, 13(8), 663-681.  
Dutta, A., McKie, S., & Deakin, J. F. (2015). Ketamine and other potential glutamate 
antidepressants. Psychiatry Res, 225(1-2), 1-13. 
doi:10.1016/j.psychres.2014.10.028 
Ebert, D., & Ebmeier, K. P. (1996). The role of the cingulate gyrus in depression: from 
functional anatomy to neurochemistry. Biol Psychiatry, 39(12), 1044-1050. 
doi:10.1016/0006-3223(95)00320-7 
Edgar, N., & McClung, C. A. (2013). Major depressive disorder: a loss of circadian 
synchrony? Bioessays, 35(11), 940-944. doi:10.1002/bies.201300086 
Edwards, C. R., Stewart, P. M., Burt, D., Brett, L., McIntyre, M. A., Sutanto, W. S., . . . 
Monder, C. (1988). Localisation of 11 beta-hydroxysteroid dehydrogenase--tissue 
specific protector of the mineralocorticoid receptor. Lancet, 2(8618), 986-989.  
Eulalio, A., Huntzinger, E., & Izaurralde, E. (2008). Getting to the root of miRNA-
mediated gene silencing. Cell, 132(1), 9-14. doi:10.1016/j.cell.2007.12.024 
Evans, S. J., Choudary, P. V., Neal, C. R., Li, J. Z., Vawter, M. P., Tomita, H., . . . Akil, 
H. (2004). Dysregulation of the fibroblast growth factor system in major 
depression. Proc Natl Acad Sci U S A, 101(43), 15506-15511. 
doi:10.1073/pnas.0406788101 
Evans, S. J., Choudary, P. V., Vawter, M. P., Li, J., Meador-Woodruff, J. H., Lopez, J. 
F., . . . Akil, H. (2003). DNA microarray analysis of functionally discrete human 
brain regions reveals divergent transcriptional profiles. Neurobiol Dis, 14(2), 240-
250.  
Fan, H. M., Sun, X. Y., Guo, W., Zhong, A. F., Niu, W., Zhao, L., . . . Lu, J. (2014). 
Differential expression of microRNA in peripheral blood mononuclear cells as 
specific biomarker for major depressive disorder patients. J Psychiatr Res, 59, 
45-52. doi:10.1016/j.jpsychires.2014.08.007 
172 
 
Farrell, M. S., Werge, T., Sklar, P., Owen, M. J., Ophoff, R. A., O'Donovan, M. C., . . . 
Sullivan, P. F. (2015). Evaluating historical candidate genes for schizophrenia. 
Mol Psychiatry, 20(5), 555-562. doi:10.1038/mp.2015.16 
Fatemi, S. H., King, D. P., Reutiman, T. J., Folsom, T. D., Laurence, J. A., Lee, S., . . . 
Menniti, F. S. (2008). PDE4B polymorphisms and decreased PDE4B expression 
are associated with schizophrenia. Schizophr Res, 101(1-3), 36-49. 
doi:10.1016/j.schres.2008.01.029 
Ferrari, A. J., Charlson, F. J., Norman, R. E., Patten, S. B., Freedman, G., Murray, C. J., 
. . . Whiteford, H. A. (2013). Burden of depressive disorders by country, sex, age, 
and year: findings from the global burden of disease study 2010. PLoS Med, 
10(11), e1001547. doi:10.1371/journal.pmed.1001547 
Feyissa, A. M., Chandran, A., Stockmeier, C. A., & Karolewicz, B. (2009). Reduced 
levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the 
prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol 
Psychiatry, 33(1), 70-75. doi:10.1016/j.pnpbp.2008.10.005 
Figiel, M., & Engele, J. (2000). Pituitary adenylate cyclase-activating polypeptide 
(PACAP), a neuron-derived peptide regulating glial glutamate transport and 
metabolism. J Neurosci, 20(10), 3596-3605.  
Flak, J. N., Ostrander, M. M., Tasker, J. G., & Herman, J. P. (2009). Chronic stress-
induced neurotransmitter plasticity in the PVN. J Comp Neurol, 517(2), 156-165. 
doi:10.1002/cne.22142 
Fleischhacker, W. W., Hinterhuber, H., Bauer, H., Pflug, B., Berner, P., Simhandl, C., . . 
. et al. (1992). A multicenter double-blind study of three different doses of the 
new cAMP-phosphodiesterase inhibitor rolipram in patients with major 
depressive disorder. Neuropsychobiology, 26(1-2), 59-64. doi:118897 
Friedman, R. C., Farh, K. K., Burge, C. B., & Bartel, D. P. (2009). Most mammalian 
mRNAs are conserved targets of microRNAs. Genome Res, 19(1), 92-105. 
doi:10.1101/gr.082701.108 
Fujino, J., Yamasaki, N., Miyata, J., Sasaki, H., Matsukawa, N., Takemura, A., . . . 
Murai, T. (2015). Anterior cingulate volume predicts response to cognitive 
behavioral therapy in major depressive disorder. J Affect Disord, 174, 397-399. 
doi:10.1016/j.jad.2014.12.009 
Geddes, J. R., Calabrese, J. R., & Goodwin, G. M. (2009). Lamotrigine for treatment of 
bipolar depression: independent meta-analysis and meta-regression of individual 
patient data from five randomised trials. Br J Psychiatry, 194(1), 4-9. 
doi:10.1192/bjp.bp.107.048504 
Gibbons, J. L., & Mc, H. P. (1962). Plasma cortisol in depressive illness. J Psychiatr 
Res, 1, 162-171.  
Gilabert-Juan, J., Castillo-Gomez, E., Guirado, R., Molto, M. D., & Nacher, J. (2013). 
Chronic stress alters inhibitory networks in the medial prefrontal cortex of adult 
mice. Brain Struct Funct, 218(6), 1591-1605. doi:10.1007/s00429-012-0479-1 
Gilsbach, R., Faron-Gorecka, A., Rogoz, Z., Bruss, M., Caron, M. G., Dziedzicka-
Wasylewska, M., & Bonisch, H. (2006). Norepinephrine transporter knockout-
induced up-regulation of brain alpha2A/C-adrenergic receptors. J Neurochem, 
96(4), 1111-1120. doi:10.1111/j.1471-4159.2005.03598.x 
173 
 
Giraldez, A. J., Cinalli, R. M., Glasner, M. E., Enright, A. J., Thomson, J. M., Baskerville, 
S., . . . Schier, A. F. (2005). MicroRNAs regulate brain morphogenesis in 
zebrafish. Science, 308(5723), 833-838. doi:10.1126/science.1109020 
Gitlin, M. J., Swendsen, J., Heller, T. L., & Hammen, C. (1995). Relapse and impairment 
in bipolar disorder. Am J Psychiatry, 152(11), 1635-1640. 
doi:10.1176/ajp.152.11.1635 
Gold, P. W. (2015). The organization of the stress system and its dysregulation in 
depressive illness. Mol Psychiatry, 20(1), 32-47. doi:10.1038/mp.2014.163 
Gong, S., Zheng, C., Doughty, M. L., Losos, K., Didkovsky, N., Schambra, U. B., . . . 
Heintz, N. (2003). A gene expression atlas of the central nervous system based 
on bacterial artificial chromosomes. Nature, 425(6961), 917-925. 
doi:10.1038/nature02033 
Gonzalez-Maeso, J., Rodriguez-Puertas, R., Meana, J. J., Garcia-Sevilla, J. A., & 
Guimon, J. (2002). Neurotransmitter receptor-mediated activation of G-proteins 
in brains of suicide victims with mood disorders: selective supersensitivity of 
alpha(2A)-adrenoceptors. Mol Psychiatry, 7(7), 755-767. 
doi:10.1038/sj.mp.4001067 
Grant, B. F. (1995). Comorbidity between DSM-IV drug use disorders and major 
depression: results of a national survey of adults. J Subst Abuse, 7(4), 481-497.  
Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, 
P. A., & Corey-Lisle, P. K. (2003). The economic burden of depression in the 
United States: how did it change between 1990 and 2000? J Clin Psychiatry, 
64(12), 1465-1475.  
Gregory, R. I., Yan, K. P., Amuthan, G., Chendrimada, T., Doratotaj, B., Cooch, N., & 
Shiekhattar, R. (2004). The Microprocessor complex mediates the genesis of 
microRNAs. Nature, 432(7014), 235-240. doi:10.1038/nature03120 
Grieve, S. M., Korgaonkar, M. S., Koslow, S. H., Gordon, E., & Williams, L. M. (2013). 
Widespread reductions in gray matter volume in depression. Neuroimage Clin, 3, 
332-339. doi:10.1016/j.nicl.2013.08.016 
Guidotti, G., Calabrese, F., Anacker, C., Racagni, G., Pariante, C. M., & Riva, M. A. 
(2013). Glucocorticoid receptor and FKBP5 expression is altered following 
exposure to chronic stress: modulation by antidepressant treatment. 
Neuropsychopharmacology, 38(4), 616-627. doi:10.1038/npp.2012.225 
Ha, M., & Kim, V. N. (2014). Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol, 
15(8), 509-524. doi:10.1038/nrm3838 
Haramati, S., Navon, I., Issler, O., Ezra-Nevo, G., Gil, S., Zwang, R., . . . Chen, A. 
(2011). MicroRNA as repressors of stress-induced anxiety: the case of 
amygdalar miR-34. J Neurosci, 31(40), 14191-14203. 
doi:10.1523/jneurosci.1673-11.2011 
Hasler, B. P., Buysse, D. J., Kupfer, D. J., & Germain, A. (2010). Phase relationships 
between core body temperature, melatonin, and sleep are associated with 
depression severity: further evidence for circadian misalignment in non-seasonal 
depression. Psychiatry Res, 178(1), 205-207. 
doi:10.1016/j.psychres.2010.04.027 
Hasler, G., van der Veen, J. W., Tumonis, T., Meyers, N., Shen, J., & Drevets, W. C. 
(2007). Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid 
174 
 
levels in major depression determined using proton magnetic resonance 
spectroscopy. Arch Gen Psychiatry, 64(2), 193-200. 
doi:10.1001/archpsyc.64.2.193 
Hayashi-Takagi, A., Takaki, M., Graziane, N., Seshadri, S., Murdoch, H., Dunlop, A. J., . 
. . Sawa, A. (2010). Disrupted-in-Schizophrenia 1 (DISC1) regulates spines of the 
glutamate synapse via Rac1. Nat Neurosci, 13(3), 327-332. doi:10.1038/nn.2487 
He, M., Liu, Y., Wang, X., Zhang, M. Q., Hannon, G. J., & Huang, Z. J. (2012). Cell-
type-based analysis of microRNA profiles in the mouse brain. Neuron, 73(1), 35-
48. doi:10.1016/j.neuron.2011.11.010 
Health Policy Brief: Mental Health Parity. (2014).  
Heiman, M., Schaefer, A., Gong, S., Peterson, J. D., Day, M., Ramsey, K. E., . . . 
Heintz, N. (2008). A translational profiling approach for the molecular 
characterization of CNS cell types. Cell, 135(4), 738-748. 
doi:10.1016/j.cell.2008.10.028 
Henry, C., Sorbara, F., Lacoste, J., Gindre, C., & Leboyer, M. (2001). Antidepressant-
induced mania in bipolar patients: identification of risk factors. J Clin Psychiatry, 
62(4), 249-255.  
Herman, J. P., Adams, D., & Prewitt, C. (1995). Regulatory changes in neuroendocrine 
stress-integrative circuitry produced by a variable stress paradigm. 
Neuroendocrinology, 61(2), 180-190.  
Hidaka, B. H. (2012). Depression as a disease of modernity: explanations for increasing 
prevalence. J Affect Disord, 140(3), 205-214. doi:10.1016/j.jad.2011.12.036 
Hirschfeld, R. M. (2001). The Comorbidity of Major Depression and Anxiety Disorders: 
Recognition and Management in Primary Care. Prim Care Companion J Clin 
Psychiatry, 3(6), 244-254.  
Holsboer, F. (2000). The corticosteroid receptor hypothesis of depression. 
Neuropsychopharmacology, 23(5), 477-501. doi:10.1016/s0893-133x(00)00159-
7 
Holsboer, F., & Ising, M. (2008). Central CRH system in depression and anxiety--
evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol, 
583(2-3), 350-357. doi:10.1016/j.ejphar.2007.12.032 
Honda, M., Kuwano, Y., Katsuura-Kamano, S., Kamezaki, Y., Fujita, K., Akaike, Y., . . . 
Rokutan, K. (2013). Chronic academic stress increases a group of microRNAs in 
peripheral blood. PLoS One, 8(10), e75960. doi:10.1371/journal.pone.0075960 
Horrobin, D. F., & Bennett, C. N. (1999). Depression and bipolar disorder: relationships 
to impaired fatty acid and phospholipid metabolism and to diabetes, 
cardiovascular disease, immunological abnormalities, cancer, ageing and 
osteoporosis. Possible candidate genes. Prostaglandins Leukot Essent Fatty 
Acids, 60(4), 217-234. doi:10.1054/plef.1999.0037 
Huang da, W., Sherman, B. T., & Lempicki, R. A. (2009a). Bioinformatics enrichment 
tools: paths toward the comprehensive functional analysis of large gene lists. 
Nucleic Acids Res, 37(1), 1-13. doi:10.1093/nar/gkn923 
Huang da, W., Sherman, B. T., & Lempicki, R. A. (2009b). Systematic and integrative 
analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 
4(1), 44-57. doi:10.1038/nprot.2008.211 
175 
 
Ilgen, M. A., & Hutchison, K. E. (2005). A history of major depressive disorder and the 
response to stress. J Affect Disord, 86(2-3), 143-150. 
doi:10.1016/j.jad.2005.01.010 
Imaki, T., Nahan, J. L., Rivier, C., Sawchenko, P. E., & Vale, W. (1991). Differential 
regulation of corticotropin-releasing factor mRNA in rat brain regions by 
glucocorticoids and stress. J Neurosci, 11(3), 585-599.  
Ito, K., Barnes, P. J., & Adcock, I. M. (2000). Glucocorticoid receptor recruitment of 
histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation 
on lysines 8 and 12. Mol Cell Biol, 20(18), 6891-6903.  
Izquierdo, A., Wellman, C. L., & Holmes, A. (2006). Brief uncontrollable stress causes 
dendritic retraction in infralimbic cortex and resistance to fear extinction in mice. J 
Neurosci, 26(21), 5733-5738. doi:10.1523/jneurosci.0474-06.2006 
Jacobsen, A., Wen, J., Marks, D. S., & Krogh, A. (2010). Signatures of RNA binding 
proteins globally coupled to effective microRNA target sites. Genome Res, 20(8), 
1010-1019. doi:10.1101/gr.103259.109 
Jakovljevic, M., Muck-Seler, D., Pivac, N., & Crncevic, Z. (1998). Platelet 5-HT and 
plasma cortisol concentrations after dexamethasone suppression test in patients 
with different time course of schizophrenia. Neuropsychobiology, 37(3), 142-145.  
Jang, S., Suh, S. H., Yoo, H. S., Lee, Y. M., & Oh, S. (2008). Changes in iNOS, GFAP 
and NR1 expression in various brain regions and elevation of sphingosine-1-
phosphate in serum after immobilized stress. Neurochem Res, 33(5), 842-851. 
doi:10.1007/s11064-007-9523-6 
Jansson, M. D., & Lund, A. H. (2012). MicroRNA and cancer. Mol Oncol, 6(6), 590-610. 
doi:10.1016/j.molonc.2012.09.006 
Johnson, J. W., & Ascher, P. (1987). Glycine potentiates the NMDA response in 
cultured mouse brain neurons. Nature, 325(6104), 529-531. 
doi:10.1038/325529a0 
Jones, K. R., Myers, B., & Herman, J. P. (2011). Stimulation of the prelimbic cortex 
differentially modulates neuroendocrine responses to psychogenic and systemic 
stressors. Physiol Behav, 104(2), 266-271. doi:10.1016/j.physbeh.2011.03.021 
Joormann, J., & Gotlib, I. H. (2010). Emotion regulation in depression: relation to 
cognitive inhibition. Cogn Emot, 24(2), 281-298. 
doi:10.1080/02699930903407948 
Jovicic, A., Roshan, R., Moisoi, N., Pradervand, S., Moser, R., Pillai, B., & Luthi-Carter, 
R. (2013). Comprehensive expression analyses of neural cell-type-specific 
miRNAs identify new determinants of the specification and maintenance of 
neuronal phenotypes. J Neurosci, 33(12), 5127-5137. 
doi:10.1523/jneurosci.0600-12.2013 
Kash, S. F., Johnson, R. S., Tecott, L. H., Noebels, J. L., Mayfield, R. D., Hanahan, D., 
& Baekkeskov, S. (1997). Epilepsy in mice deficient in the 65-kDa isoform of 
glutamic acid decarboxylase. Proc Natl Acad Sci U S A, 94(25), 14060-14065.  
Katsuura, S., Kuwano, Y., Yamagishi, N., Kurokawa, K., Kajita, K., Akaike, Y., . . . 
Rokutan, K. (2012). MicroRNAs miR-144/144* and miR-16 in peripheral blood 
are potential biomarkers for naturalistic stress in healthy Japanese medical 
students. Neurosci Lett, 516(1), 79-84. doi:10.1016/j.neulet.2012.03.062 
176 
 
Kawabe, H., & Brose, N. (2010). The ubiquitin E3 ligase Nedd4-1 controls neurite 
development. Cell Cycle, 9(13), 2477-2478.  
Kawase-Koga, Y., Otaegi, G., & Sun, T. (2009). Different timings of Dicer deletion affect 
neurogenesis and gliogenesis in the developing mouse central nervous system. 
Dev Dyn, 238(11), 2800-2812. doi:10.1002/dvdy.22109 
Keller, M. B. (2006). Prevalence and impact of comorbid anxiety and bipolar disorder. J 
Clin Psychiatry, 67 Suppl 1, 5-7.  
Kendler, K. S., Karkowski, L. M., & Prescott, C. A. (1999). Causal relationship between 
stressful life events and the onset of major depression. Am J Psychiatry, 156(6), 
837-841. doi:10.1176/ajp.156.6.837 
Kessler, R. C. (1997). The effects of stressful life events on depression. Annu Rev 
Psychol, 48, 191-214. doi:10.1146/annurev.psych.48.1.191 
Kessler, R. C., Avenevoli, S., & Ries Merikangas, K. (2001). Mood disorders in children 
and adolescents: an epidemiologic perspective. Biol Psychiatry, 49(12), 1002-
1014.  
Kessler, R. C., Barber, C., Birnbaum, H. G., Frank, R. G., Greenberg, P. E., Rose, R. 
M., . . . Wang, P. (1999). Depression in the workplace: effects on short-term 
disability. Health Aff (Millwood), 18(5), 163-171.  
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. 
(2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in 
the National Comorbidity Survey Replication. Arch Gen Psychiatry, 62(6), 593-
602. doi:10.1001/archpsyc.62.6.593 
Kessler, R. C., & Walters, E. E. (1998). Epidemiology of DSM-III-R major depression 
and minor depression among adolescents and young adults in the National 
Comorbidity Survey. Depress Anxiety, 7(1), 3-14.  
Kim, A. H., Reimers, M., Maher, B., Williamson, V., McMichael, O., McClay, J. L., . . . 
Vladimirov, V. I. (2010). MicroRNA expression profiling in the prefrontal cortex of 
individuals affected with schizophrenia and bipolar disorders. Schizophr Res, 
124(1-3), 183-191. doi:10.1016/j.schres.2010.07.002 
Kim, D., Kim, J. W., Koo, T. H., Yun, H. R., & Won, S. H. (2015). Shared and distinct 
neurocognitive endophenotypes of schizophrenia and psychotic bipolar disorder. 
Clin Psychopharmacol Neurosci, 13(1), 94-102. doi:10.9758/cpn.2015.13.1.94 
Klein, M. E., Lioy, D. T., Ma, L., Impey, S., Mandel, G., & Goodman, R. H. (2007). 
Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. 
Nat Neurosci, 10(12), 1513-1514. doi:10.1038/nn2010 
Kosik, K. S., & Krichevsky, A. M. (2005). The Elegance of the MicroRNAs: A Neuronal 
Perspective. Neuron, 47(6), 779-782. doi:10.1016/j.neuron.2005.08.019 
Kramer, P. D. (2006). Against Depression: Penguin Books. 
Krichevsky, A. M., King, K. S., Donahue, C. P., Khrapko, K., & Kosik, K. S. (2003). A 
microRNA array reveals extensive regulation of microRNAs during brain 
development. RNA, 9(10), 1274-1281.  
Krishnan, K. R., Delong, M., Kraemer, H., Carney, R., Spiegel, D., Gordon, C., . . . 
Wainscott, C. (2002). Comorbidity of depression with other medical diseases in 
the elderly. Biol Psychiatry, 52(6), 559-588.  
177 
 
Kudryavtseva, N. N., Bakshtanovskaya, I. V., & Koryakina, L. A. (1991). Social model of 
depression in mice of C57BL/6J strain. Pharmacol Biochem Behav, 38(2), 315-
320.  
Kumar, S., Black, S. J., Hultman, R., Szabo, S. T., DeMaio, K. D., Du, J., . . . Dzirasa, K. 
(2013). Cortical control of affective networks. J Neurosci, 33(3), 1116-1129. 
doi:10.1523/jneurosci.0092-12.2013 
Lachize, S., Apostolakis, E. M., van der Laan, S., Tijssen, A. M., Xu, J., de Kloet, E. R., 
& Meijer, O. C. (2009). Steroid receptor coactivator-1 is necessary for regulation 
of corticotropin-releasing hormone by chronic stress and glucocorticoids. Proc 
Natl Acad Sci U S A, 106(19), 8038-8042. doi:10.1073/pnas.0812062106 
Lagos-Quintana, M., Rauhut, R., Lendeckel, W., & Tuschl, T. (2001). Identification of 
novel genes coding for small expressed RNAs. Science, 294(5543), 853-858. 
doi:10.1126/science.1064921 
Large-scale genome-wide association analysis of bipolar disorder identifies a new 
susceptibility locus near ODZ4. (2011). Nat Genet, 43(10), 977-983. 
doi:10.1038/ng.943 
Larrauri, J., & Schmajuk, N. (2006). Prepulse inhibition mechanisms and cognitive 
processes: a review and model. Exs, 98, 245-278.  
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993). The C. elegans heterochronic gene 
lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75(5), 
843-854.  
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005). Conserved seed pairing, often flanked 
by adenosines, indicates that thousands of human genes are microRNA targets. 
Cell, 120(1), 15-20. doi:10.1016/j.cell.2004.12.035 
Li, J. Z., Vawter, M. P., Walsh, D. M., Tomita, H., Evans, S. J., Choudary, P. V., . . . 
Myers, R. M. (2004). Systematic changes in gene expression in postmortem 
human brains associated with tissue pH and terminal medical conditions. Hum 
Mol Genet, 13(6), 609-616. doi:10.1093/hmg/ddh065 
Liu, C., Zhao, L., Han, S., Li, J., & Li, D. (2015). Identification and Functional Analysis of 
MicroRNAs in Mice following Focal Cerebral Ischemia Injury. Int J Mol Sci, 
16(10), 24302-24318. doi:10.3390/ijms161024302 
Liu, J., Carmell, M. A., Rivas, F. V., Marsden, C. G., Thomson, J. M., Song, J. J., . . . 
Hannon, G. J. (2004). Argonaute2 is the catalytic engine of mammalian RNAi. 
Science, 305(5689), 1437-1441. doi:10.1126/science.1102513 
Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using 
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25(4), 
402-408. doi:10.1006/meth.2001.1262 
Lobban, F., Taylor, L., Chandler, C., Tyler, E., Kinderman, P., Kolamunnage-Dona, R., . 
. . Morriss, R. K. (2010). Enhanced relapse prevention for bipolar disorder by 
community mental health teams: cluster feasibility randomised trial. Br J 
Psychiatry, 196(1), 59-63. doi:10.1192/bjp.bp.109.065524 
Lohoff, F. W. (2010). Overview of the genetics of major depressive disorder. Curr 
Psychiatry Rep, 12(6), 539-546. doi:10.1007/s11920-010-0150-6 
Luscher, B., Shen, Q., & Sahir, N. (2011). The GABAergic deficit hypothesis of major 
depressive disorder. Mol Psychiatry, 16(4), 383-406. doi:10.1038/mp.2010.120 
178 
 
Maciotta, S., Meregalli, M., & Torrente, Y. (2013). The involvement of microRNAs in 
neurodegenerative diseases. Front Cell Neurosci, 7, 265. 
doi:10.3389/fncel.2013.00265 
Makeyev, E. V., Zhang, J., Carrasco, M. A., & Maniatis, T. (2007). The MicroRNA miR-
124 promotes neuronal differentiation by triggering brain-specific alternative pre-
mRNA splicing. Mol Cell, 27(3), 435-448. doi:10.1016/j.molcel.2007.07.015 
Mana, M. J., & Grace, A. A. (1997). Chronic cold stress alters the basal and evoked 
electrophysiological activity of rat locus coeruleus neurons. Neuroscience, 81(4), 
1055-1064.  
Markram, H., Toledo-Rodriguez, M., Wang, Y., Gupta, A., Silberberg, G., & Wu, C. 
(2004). Interneurons of the neocortical inhibitory system. Nat Rev Neurosci, 
5(10), 793-807. doi:10.1038/nrn1519 
Mayberg, H. S., Liotti, M., Brannan, S. K., McGinnis, S., Mahurin, R. K., Jerabek, P. A., . 
. . Fox, P. T. (1999). Reciprocal limbic-cortical function and negative mood: 
converging PET findings in depression and normal sadness. Am J Psychiatry, 
156(5), 675-682. doi:10.1176/ajp.156.5.675 
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C., . 
. . Kennedy, S. H. (2005). Deep brain stimulation for treatment-resistant 
depression. Neuron, 45(5), 651-660. doi:10.1016/j.neuron.2005.02.014 
McEwen, B. S. (2000). Stress, definition and concepts of. Encyclopedia of stress, 3, 
508-509.  
McGirr, A., Lipina, T. V., Mun, H. S., Georgiou, J., Al-Amri, A. H., Ng, E., . . . Roder, J. 
C. (2015). Specific Inhibition of Phosphodiesterase-4B Results in Anxiolysis and 
Facilitates Memory Acquisition. Neuropsychopharmacology. 
doi:10.1038/npp.2015.240 
McGuffin, P., Rijsdijk, F., Andrew, M., Sham, P., Katz, R., & Cardno, A. (2003). The 
heritability of bipolar affective disorder and the genetic relationship to unipolar 
depression. Arch Gen Psychiatry, 60(5), 497-502. doi:10.1001/archpsyc.60.5.497 
McKlveen, J. M., Myers, B., & Herman, J. P. (2015). The medial prefrontal cortex: 
coordinator of autonomic, neuroendocrine and behavioural responses to stress. J 
Neuroendocrinol, 27(6), 446-456. doi:10.1111/jne.12272 
Mellios, N., Huang, H. S., Grigorenko, A., Rogaev, E., & Akbarian, S. (2008). A set of 
differentially expressed miRNAs, including miR-30a-5p, act as post-
transcriptional inhibitors of BDNF in prefrontal cortex. Hum Mol Genet, 17(19), 
3030-3042. doi:10.1093/hmg/ddn201 
Merikangas, K. R., & Stevens, D. E. (1997). Comorbidity of migraine and psychiatric 
disorders. Neurol Clin, 15(1), 115-123.  
Michael, N., Erfurth, A., Ohrmann, P., Arolt, V., Heindel, W., & Pfleiderer, B. (2003). 
Metabolic changes within the left dorsolateral prefrontal cortex occurring with 
electroconvulsive therapy in patients with treatment resistant unipolar 
depression. Psychol Med, 33(7), 1277-1284.  
Miguel-Hidalgo, J. J., Waltzer, R., Whittom, A. A., Austin, M. C., Rajkowska, G., & 
Stockmeier, C. A. (2010). Glial and glutamatergic markers in depression, 
alcoholism, and their comorbidity. J Affect Disord, 127(1-3), 230-240. 
doi:10.1016/j.jad.2010.06.003 
179 
 
Millar, J. K., Pickard, B. S., Mackie, S., James, R., Christie, S., Buchanan, S. R., . . . 
Porteous, D. J. (2005). DISC1 and PDE4B are interacting genetic factors in 
schizophrenia that regulate cAMP signaling. Science, 310(5751), 1187-1191. 
doi:10.1126/science.1112915 
Miller, B. H., Zeier, Z., Xi, L., Lanz, T. A., Deng, S., Strathmann, J., . . . Wahlestedt, C. 
(2012). MicroRNA-132 dysregulation in schizophrenia has implications for both 
neurodevelopment and adult brain function. Proc Natl Acad Sci U S A, 109(8), 
3125-3130. doi:10.1073/pnas.1113793109 
Mirza, Y., Tang, J., Russell, A., Banerjee, S. P., Bhandari, R., Ivey, J., . . . Rosenberg, 
D. R. (2004). Reduced anterior cingulate cortex glutamatergic concentrations in 
childhood major depression. J Am Acad Child Adolesc Psychiatry, 43(3), 341-
348. doi:10.1097/00004583-200403000-00017 
Mombereau, C., Kaupmann, K., Froestl, W., Sansig, G., van der Putten, H., & Cryan, J. 
F. (2004). Genetic and pharmacological evidence of a role for GABA(B) 
receptors in the modulation of anxiety- and antidepressant-like behavior. 
Neuropsychopharmacology, 29(6), 1050-1062. doi:10.1038/sj.npp.1300413 
Mombereau, C., Kaupmann, K., Gassmann, M., Bettler, B., van der Putten, H., & Cryan, 
J. F. (2005). Altered anxiety and depression-related behaviour in mice lacking 
GABAB(2) receptor subunits. Neuroreport, 16(3), 307-310.  
Moreau, M. P., Bruse, S. E., David-Rus, R., Buyske, S., & Brzustowicz, L. M. (2011). 
Altered microRNA expression profiles in postmortem brain samples from 
individuals with schizophrenia and bipolar disorder. Biol Psychiatry, 69(2), 188-
193. doi:10.1016/j.biopsych.2010.09.039 
Moreno, C., Laje, G., Blanco, C., Jiang, H., Schmidt, A. B., & Olfson, M. (2007). 
National trends in the outpatient diagnosis and treatment of bipolar disorder in 
youth. Arch Gen Psychiatry, 64(9), 1032-1039. doi:10.1001/archpsyc.64.9.1032 
Morgado, A. L., Xavier, J. M., Dionisio, P. A., Ribeiro, M. F., Dias, R. B., Sebastiao, A. 
M., . . . Rodrigues, C. M. (2014). MicroRNA-34a Modulates Neural Stem Cell 
Differentiation by Regulating Expression of Synaptic and Autophagic Proteins. 
Mol Neurobiol. doi:10.1007/s12035-014-8794-6 
Morgan, M. A., Romanski, L. M., & LeDoux, J. E. (1993). Extinction of emotional 
learning: contribution of medial prefrontal cortex. Neurosci Lett, 163(1), 109-113.  
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008). Mapping 
and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods, 5(7), 
621-628. doi:10.1038/nmeth.1226 
Muinos-Gimeno, M., Espinosa-Parrilla, Y., Guidi, M., Kagerbauer, B., Sipila, T., Maron, 
E., . . . Estivill, X. (2011). Human microRNAs miR-22, miR-138-2, miR-148a, and 
miR-488 are associated with panic disorder and regulate several anxiety 
candidate genes and related pathways. Biol Psychiatry, 69(6), 526-533. 
doi:10.1016/j.biopsych.2010.10.010 
Mukherji, S., Ebert, M. S., Zheng, G. X., Tsang, J. S., Sharp, P. A., & van Oudenaarden, 
A. (2011). MicroRNAs can generate thresholds in target gene expression. Nat 
Genet, 43(9), 854-859. doi:10.1038/ng.905 
Mulert, C., Juckel, G., Brunnmeier, M., Karch, S., Leicht, G., Mergl, R., . . . Pogarell, O. 
(2007). Rostral anterior cingulate cortex activity in the theta band predicts 
response to antidepressive medication. Clin EEG Neurosci, 38(2), 78-81.  
180 
 
Murase, S., Grenhoff, J., Chouvet, G., Gonon, F. G., & Svensson, T. H. (1993). 
Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic 
dopamine neurons studied in vivo. Neurosci Lett, 157(1), 53-56.  
Nakane, H., Shimizu, N., & Hori, T. (1994). Stress-induced norepinephrine release in 
the rat prefrontal cortex measured by microdialysis. Am J Physiol, 267(6 Pt 2), 
R1559-1566.  
Nedergaard, M., Ransom, B., & Goldman, S. A. (2003). New roles for astrocytes: 
redefining the functional architecture of the brain. Trends Neurosci, 26(10), 523-
530. doi:10.1016/j.tins.2003.08.008 
Nomura, T., Kimura, M., Horii, T., Morita, S., Soejima, H., Kudo, S., & Hatada, I. (2008). 
MeCP2-dependent repression of an imprinted miR-184 released by 
depolarization. Hum Mol Genet, 17(8), 1192-1199. doi:10.1093/hmg/ddn011 
Numata, S., Iga, J., Nakataki, M., Tayoshi, S., Taniguchi, K., Sumitani, S., . . . Ohmori, 
T. (2009). Gene expression and association analyses of the phosphodiesterase 
4B (PDE4B) gene in major depressive disorder in the Japanese population. Am J 
Med Genet B Neuropsychiatr Genet, 150B(4), 527-534. 
doi:10.1002/ajmg.b.30852 
Olfson, M., Fireman, B., Weissman, M. M., Leon, A. C., Sheehan, D. V., Kathol, R. G., . 
. . Farber, L. (1997). Mental disorders and disability among patients in a primary 
care group practice. Am J Psychiatry, 154(12), 1734-1740. 
doi:10.1176/ajp.154.12.1734 
Ongur, D., Jensen, J. E., Prescot, A. P., Stork, C., Lundy, M., Cohen, B. M., & 
Renshaw, P. F. (2008). Abnormal glutamatergic neurotransmission and 
neuronal-glial interactions in acute mania. Biol Psychiatry, 64(8), 718-726. 
doi:10.1016/j.biopsych.2008.05.014 
Ormel, J., VonKorff, M., Ustun, T. B., Pini, S., Korten, A., & Oldehinkel, T. (1994). 
Common mental disorders and disability across cultures. Results from the WHO 
Collaborative Study on Psychological Problems in General Health Care. Jama, 
272(22), 1741-1748.  
Orrego, F., & Villanueva, S. (1993). The chemical nature of the main central excitatory 
transmitter: a critical appraisal based upon release studies and synaptic vesicle 
localization. Neuroscience, 56(3), 539-555.  
Padmos, R. C., Hillegers, M. H., Knijff, E. M., Vonk, R., Bouvy, A., Staal, F. J., . . . 
Drexhage, H. A. (2008). A discriminating messenger RNA signature for bipolar 
disorder formed by an aberrant expression of inflammatory genes in monocytes. 
Arch Gen Psychiatry, 65(4), 395-407. doi:10.1001/archpsyc.65.4.395 
Park, M., Niciu, M. J., & Zarate, C. A., Jr. (2015). Novel Glutamatergic Treatments for 
Severe Mood Disorders. Curr Behav Neurosci Rep, 2(4), 198-208. 
doi:10.1007/s40473-015-0050-5 
Patel, P. D., Lopez, J. F., Lyons, D. M., Burke, S., Wallace, M., & Schatzberg, A. F. 
(2000). Glucocorticoid and mineralocorticoid receptor mRNA expression in 
squirrel monkey brain. J Psychiatr Res, 34(6), 383-392.  
Pavcovich, L. A., Cancela, L. M., Volosin, M., Molina, V. A., & Ramirez, O. A. (1990). 
Chronic stress-induced changes in locus coeruleus neuronal activity. Brain Res 
Bull, 24(2), 293-296.  
181 
 
Perkins, D. O., Jeffries, C. D., Jarskog, L. F., Thomson, J. M., Woods, K., Newman, M. 
A., . . . Hammond, S. M. (2007). microRNA expression in the prefrontal cortex of 
individuals with schizophrenia and schizoaffective disorder. Genome Biol, 8(2), 
R27. doi:10.1186/gb-2007-8-2-r27 
Perrine, S. A., Ghoddoussi, F., Michaels, M. S., Sheikh, I. S., McKelvey, G., & 
Galloway, M. P. (2014). Ketamine reverses stress-induced depression-like 
behavior and increased GABA levels in the anterior cingulate: an 11.7 T 1H-MRS 
study in rats. Prog Neuropsychopharmacol Biol Psychiatry, 51, 9-15. 
doi:10.1016/j.pnpbp.2013.11.003 
Petri, R., Malmevik, J., Fasching, L., Akerblom, M., & Jakobsson, J. (2014). miRNAs in 
brain development. Exp Cell Res, 321(1), 84-89. doi:10.1016/j.yexcr.2013.09.022 
Phillips, M. L., Drevets, W. C., Rauch, S. L., & Lane, R. (2003). Neurobiology of emotion 
perception II: Implications for major psychiatric disorders. Biol Psychiatry, 54(5), 
515-528.  
Pickard, B. S., Thomson, P. A., Christoforou, A., Evans, K. L., Morris, S. W., Porteous, 
D. J., . . . Muir, W. J. (2007). The PDE4B gene confers sex-specific protection 
against schizophrenia. Psychiatr Genet, 17(3), 129-133. 
doi:10.1097/YPG.0b013e328014492b 
Pizzagalli, D., Pascual-Marqui, R. D., Nitschke, J. B., Oakes, T. R., Larson, C. L., 
Abercrombie, H. C., . . . Davidson, R. J. (2001). Anterior cingulate activity as a 
predictor of degree of treatment response in major depression: evidence from 
brain electrical tomography analysis. Am J Psychiatry, 158(3), 405-415.  
Port, J. D., Unal, S. S., Mrazek, D. A., & Marcus, S. M. (2008). Metabolic alterations in 
medication-free patients with bipolar disorder: a 3T CSF-corrected magnetic 
resonance spectroscopic imaging study. Psychiatry Res, 162(2), 113-121. 
doi:10.1016/j.pscychresns.2007.08.004 
Posner, M., & DiGirolamo, G. (1998). Executive attention: Conflict, target detection, and 
cognitive control; R. Parasuraman (Ed.), The Attentive Brain: MIT Press. 
Preda, A., MacLean, R. W., Mazure, C. M., & Bowers, M. B., Jr. (2001). Antidepressant-
associated mania and psychosis resulting in psychiatric admissions. J Clin 
Psychiatry, 62(1), 30-33.  
Purcell, S. M., Wray, N. R., Stone, J. L., Visscher, P. M., O'Donovan, M. C., Sullivan, P. 
F., & Sklar, P. (2009). Common polygenic variation contributes to risk of 
schizophrenia and bipolar disorder. Nature, 460(7256), 748-752. 
doi:10.1038/nature08185 
Qi, X. R., Kamphuis, W., Wang, S., Wang, Q., Lucassen, P. J., Zhou, J. N., & Swaab, D. 
F. (2013). Aberrant stress hormone receptor balance in the human prefrontal 
cortex and hypothalamic paraventricular nucleus of depressed patients. 
Psychoneuroendocrinology, 38(6), 863-870. doi:10.1016/j.psyneuen.2012.09.014 
Quirk, G. J., Likhtik, E., Pelletier, J. G., & Pare, D. (2003). Stimulation of medial 
prefrontal cortex decreases the responsiveness of central amygdala output 
neurons. J Neurosci, 23(25), 8800-8807.  
Radley, J. J., Arias, C. M., & Sawchenko, P. E. (2006). Regional differentiation of the 
medial prefrontal cortex in regulating adaptive responses to acute emotional 
stress. J Neurosci, 26(50), 12967-12976. doi:10.1523/jneurosci.4297-06.2006 
182 
 
Radley, J. J., Gosselink, K. L., & Sawchenko, P. E. (2009). A discrete GABAergic relay 
mediates medial prefrontal cortical inhibition of the neuroendocrine stress 
response. J Neurosci, 29(22), 7330-7340. doi:10.1523/jneurosci.5924-08.2009 
Radley, J. J., Sisti, H. M., Hao, J., Rocher, A. B., McCall, T., Hof, P. R., . . . Morrison, J. 
H. (2004). Chronic behavioral stress induces apical dendritic reorganization in 
pyramidal neurons of the medial prefrontal cortex. Neuroscience, 125(1), 1-6. 
doi:10.1016/j.neuroscience.2004.01.006 
Ratti, E., Bettica, P., Alexander, R., Archer, G., Carpenter, D., Evoniuk, G., . . . Fava, M. 
(2013). Full central neurokinin-1 receptor blockade is required for efficacy in 
depression: evidence from orvepitant clinical studies. J Psychopharmacol, 27(5), 
424-434. doi:10.1177/0269881113480990 
Reddy, M. S. (2010). Depression: the disorder and the burden. Indian J Psychol Med, 
32(1), 1-2. doi:10.4103/0253-7176.70510 
Reid, J. G., Gitlin, M. J., & Altshuler, L. L. (2013). Lamotrigine in psychiatric disorders. J 
Clin Psychiatry, 74(7), 675-684. doi:10.4088/JCP.12r08046 
Reinhart, B. J., Slack, F. J., Basson, M., Pasquinelli, A. E., Bettinger, J. C., Rougvie, A. 
E., . . . Ruvkun, G. (2000). The 21-nucleotide let-7 RNA regulates developmental 
timing in Caenorhabditis elegans. Nature, 403(6772), 901-906. 
doi:10.1038/35002607 
Ren, Z., Sahir, N., Murakami, S., Luellen, B. A., Earnheart, J. C., Lal, R., . . . Luscher, B. 
(2015). Defects in dendrite and spine maturation and synaptogenesis associated 
with an anxious-depressive-like phenotype of GABAA receptor-deficient mice. 
Neuropharmacology, 88, 171-179. doi:10.1016/j.neuropharm.2014.07.019 
Rinaldi, A., Vincenti, S., De Vito, F., Bozzoni, I., Oliverio, A., Presutti, C., . . . Mele, A. 
(2010). Stress induces region specific alterations in microRNAs expression in 
mice. Behav Brain Res, 208(1), 265-269. doi:10.1016/j.bbr.2009.11.012 
Ripke, S., Wray, N. R., Lewis, C. M., Hamilton, S. P., Weissman, M. M., Breen, G., . . . 
Sullivan, P. F. (2013). A mega-analysis of genome-wide association studies for 
major depressive disorder. Mol Psychiatry, 18(4), 497-511. 
doi:10.1038/mp.2012.21 
Rivero, G., Gabilondo, A. M., Garcia-Sevilla, J. A., Callado, L. F., La Harpe, R., 
Morentin, B., & Meana, J. J. (2013). Brain RGS4 and RGS10 protein expression 
in schizophrenia and depression. Effect of drug treatment. Psychopharmacology 
(Berl), 226(1), 177-188. doi:10.1007/s00213-012-2888-5 
Ronzoni, G., Anton, M., Mora, F., Segovia, G., & Del Arco, A. (2016). Infralimbic cortex 
controls the activity of the hypothalamus-pituitary-adrenal axis and the formation 
of aversive memory: Effects of environmental enrichment. Behav Brain Res, 297, 
338-344. doi:10.1016/j.bbr.2015.10.037 
Rosenberg, D. R., Mirza, Y., Russell, A., Tang, J., Smith, J. M., Banerjee, S. P., . . . 
Moore, G. J. (2004). Reduced anterior cingulate glutamatergic concentrations in 
childhood OCD and major depression versus healthy controls. J Am Acad Child 
Adolesc Psychiatry, 43(9), 1146-1153. doi:10.1097/01.chi.0000132812.44664.2d 
Rosenfeld, M. G., & Glass, C. K. (2001). Coregulator codes of transcriptional regulation 
by nuclear receptors. J Biol Chem, 276(40), 36865-36868. 
doi:10.1074/jbc.R100041200 
183 
 
Rudy, B., Fishell, G., Lee, S., & Hjerling-Leffler, J. (2011). Three groups of interneurons 
account for nearly 100% of neocortical GABAergic neurons. Dev Neurobiol, 
71(1), 45-61. doi:10.1002/dneu.20853 
Rupprecht, R., Reul, J. M., van Steensel, B., Spengler, D., Soder, M., Berning, B., . . . 
Damm, K. (1993). Pharmacological and functional characterization of human 
mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol, 247(2), 
145-154.  
Salaria, S., Chana, G., Caldara, F., Feltrin, E., Altieri, M., Faggioni, F., . . . Everall, I. P. 
(2006). Microarray analysis of cultured human brain aggregates following cortisol 
exposure: implications for cellular functions relevant to mood disorders. 
Neurobiol Dis, 23(3), 630-636. doi:10.1016/j.nbd.2006.05.003 
Salta, E., & De Strooper, B. (2012). Non-coding RNAs with essential roles in 
neurodegenerative disorders. Lancet Neurol, 11(2), 189-200. doi:10.1016/s1474-
4422(11)70286-1 
Salvadore, G., Cornwell, B. R., Colon-Rosario, V., Coppola, R., Grillon, C., Zarate, C. 
A., Jr., & Manji, H. K. (2009). Increased anterior cingulate cortical activity in 
response to fearful faces: a neurophysiological biomarker that predicts rapid 
antidepressant response to ketamine. Biol Psychiatry, 65(4), 289-295. 
doi:10.1016/j.biopsych.2008.08.014 
Sanacora, G., Treccani, G., & Popoli, M. (2012). Towards a glutamate hypothesis of 
depression: an emerging frontier of neuropsychopharmacology for mood 
disorders. Neuropharmacology, 62(1), 63-77. 
doi:10.1016/j.neuropharm.2011.07.036 
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008). Targeting the 
glutamatergic system to develop novel, improved therapeutics for mood 
disorders. Nat Rev Drug Discov, 7(5), 426-437. doi:10.1038/nrd2462 
Santarelli, D. M., Beveridge, N. J., Tooney, P. A., & Cairns, M. J. (2011). Upregulation 
of dicer and microRNA expression in the dorsolateral prefrontal cortex Brodmann 
area 46 in schizophrenia. Biol Psychiatry, 69(2), 180-187. 
doi:10.1016/j.biopsych.2010.09.030 
Scharnholz, B., Lederbogen, F., Feuerhack, A., Bach, A., Kopf, D., Frankhauser, P., . . . 
Deuschle, M. (2010). Does night-time cortisol excretion normalize in the long-
term course of depression? Pharmacopsychiatry, 43(5), 161-165. doi:10.1055/s-
0030-1248316 
Schousboe, A., Scafidi, S., Bak, L. K., Waagepetersen, H. S., & McKenna, M. C. (2014). 
Glutamate metabolism in the brain focusing on astrocytes. Adv Neurobiol, 11, 13-
30. doi:10.1007/978-3-319-08894-5_2 
Schratt, G. M., Tuebing, F., Nigh, E. A., Kane, C. G., Sabatini, M. E., Kiebler, M., & 
Greenberg, M. E. (2006). A brain-specific microRNA regulates dendritic spine 
development. Nature, 439(7074), 283-289. doi:10.1038/nature04367 
Selbach, M., Schwanhausser, B., Thierfelder, N., Fang, Z., Khanin, R., & Rajewsky, N. 
(2008). Widespread changes in protein synthesis induced by microRNAs. Nature, 
455(7209), 58-63. doi:10.1038/nature07228 
Sempere, L. F., Freemantle, S., Pitha-Rowe, I., Moss, E., Dmitrovsky, E., & Ambros, V. 
(2004). Expression profiling of mammalian microRNAs uncovers a subset of 
184 
 
brain-expressed microRNAs with possible roles in murine and human neuronal 
differentiation. Genome Biol, 5(3), R13. doi:10.1186/gb-2004-5-3-r13 
Shaltiel, G., Hanan, M., Wolf, Y., Barbash, S., Kovalev, E., Shoham, S., & Soreq, H. 
(2013). Hippocampal microRNA-132 mediates stress-inducible cognitive deficits 
through its acetylcholinesterase target. Brain Struct Funct, 218(1), 59-72. 
doi:10.1007/s00429-011-0376-z 
Shepherd, A. M., Quide, Y., Laurens, K. R., O'Reilly, N., Rowland, J. E., Mitchell, P. B., . 
. . Green, M. J. (2015). Shared intermediate phenotypes for schizophrenia and 
bipolar disorder: neuroanatomical features of subtypes distinguished by 
executive dysfunction. J Psychiatry Neurosci, 40(1), 58-68.  
Shi, W., Du, J., Qi, Y., Liang, G., Wang, T., Li, S., . . . Xiao, Z. (2012). Aberrant 
expression of serum miRNAs in schizophrenia. J Psychiatr Res, 46(2), 198-204. 
doi:10.1016/j.jpsychires.2011.09.010 
Sim, S. E., Bakes, J., & Kaang, B. K. (2014). Neuronal activity-dependent regulation of 
MicroRNAs. Mol Cells, 37(7), 511-517. doi:10.14348/molcells.2014.0132 
Simon, G. E., & Unutzer, J. (1999). Health care utilization and costs among patients 
treated for bipolar disorder in an insured population. Psychiatr Serv, 50(10), 
1303-1308. doi:10.1176/ps.50.10.1303 
Simon, G. E., VonKorff, M., & Barlow, W. (1995). Health care costs of primary care 
patients with recognized depression. Arch Gen Psychiatry, 52(10), 850-856.  
Singer, P., Dubroqua, S., & Yee, B. K. (2015). Inhibition of glycine transporter 1: The 
yellow brick road to new schizophrenia therapy? Curr Pharm Des, 21(26), 3771-
3787.  
Skynner, H. A., Amos, D. P., Murray, F., Salim, K., Knowles, M. R., Munoz-Sanjuan, I., . 
. . Guest, P. C. (2006). Proteomic analysis identifies alterations in cellular 
morphology and cell death pathways in mouse brain after chronic corticosterone 
treatment. Brain Res, 1102(1), 12-26. doi:10.1016/j.brainres.2006.04.112 
Smalheiser, N. R., Lugli, G., Zhang, H., Rizavi, H., Cook, E. H., & Dwivedi, Y. (2014). 
Expression of microRNAs and other small RNAs in prefrontal cortex in 
schizophrenia, bipolar disorder and depressed subjects. PLoS One, 9(1), 
e86469. doi:10.1371/journal.pone.0086469 
Smoller, J. W., & Finn, C. T. (2003). Family, twin, and adoption studies of bipolar 
disorder. Am J Med Genet C Semin Med Genet, 123C(1), 48-58. 
doi:10.1002/ajmg.c.20013 
Soreca, I. (2014). Circadian rhythms and sleep in bipolar disorder: implications for 
pathophysiology and treatment. Curr Opin Psychiatry, 27(6), 467-471. 
doi:10.1097/yco.0000000000000108 
Stark, K. L., Xu, B., Bagchi, A., Lai, W. S., Liu, H., Hsu, R., . . . Gogos, J. A. (2008). 
Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-
deletion mouse model. Nat Genet, 40(6), 751-760. doi:10.1038/ng.138 
Sullivan, R. M., & Gratton, A. (1999). Lateralized effects of medial prefrontal cortex 
lesions on neuroendocrine and autonomic stress responses in rats. J Neurosci, 
19(7), 2834-2840.  
Sun, X. Y., Zhang, J., Niu, W., Guo, W., Song, H. T., Li, H. Y., . . . Zhang, Q. L. (2015). 
A preliminary analysis of microRNA as potential clinical biomarker for 
185 
 
schizophrenia. Am J Med Genet B Neuropsychiatr Genet, 168(3), 170-178. 
doi:10.1002/ajmg.b.32292 
Suzuki, R., Arata, S., Nakajo, S., Ikenaka, K., Kikuyama, S., & Shioda, S. (2003). 
Expression of the receptor for pituitary adenylate cyclase-activating polypeptide 
(PAC1-R) in reactive astrocytes. Brain Res Mol Brain Res, 115(1), 10-20.  
Tal, T. L., Franzosa, J. A., Tilton, S. C., Philbrick, K. A., Iwaniec, U. T., Turner, R. T., . . . 
Tanguay, R. L. (2012). MicroRNAs control neurobehavioral development and 
function in zebrafish. Faseb j, 26(4), 1452-1461. doi:10.1096/fj.11-194464 
Tan, L. P., Seinen, E., Duns, G., de Jong, D., Sibon, O. C., Poppema, S., . . . van den 
Berg, A. (2009). A high throughput experimental approach to identify miRNA 
targets in human cells. Nucleic Acids Res, 37(20), e137. doi:10.1093/nar/gkp715 
Tavares, R. F., Correa, F. M., & Resstel, L. B. (2009). Opposite role of infralimbic and 
prelimbic cortex in the tachycardiac response evoked by acute restraint stress in 
rats. J Neurosci Res, 87(11), 2601-2607. doi:10.1002/jnr.22070 
Thase, M. E., Greenhouse, J. B., Frank, E., Reynolds, C. F., 3rd, Pilkonis, P. A., Hurley, 
K., . . . Kupfer, D. J. (1997). Treatment of major depression with psychotherapy 
or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry, 54(11), 
1009-1015.  
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., . . 
. Fava, M. (2006). Evaluation of outcomes with citalopram for depression using 
measurement-based care in STAR*D: implications for clinical practice. Am J 
Psychiatry, 163(1), 28-40. doi:10.1176/appi.ajp.163.1.28 
Uchida, S., Nishida, A., Hara, K., Kamemoto, T., Suetsugi, M., Fujimoto, M., . . . 
Watanabe, Y. (2008). Characterization of the vulnerability to repeated stress in 
Fischer 344 rats: possible involvement of microRNA-mediated down-regulation of 
the glucocorticoid receptor. Eur J Neurosci, 27(9), 2250-2261. 
doi:10.1111/j.1460-9568.2008.06218.x 
Ulrich-Lai, Y. M., & Herman, J. P. (2009). Neural regulation of endocrine and autonomic 
stress responses. Nat Rev Neurosci, 10(6), 397-409. doi:10.1038/nrn2647 
Unutzer, J., Patrick, D. L., Simon, G., Grembowski, D., Walker, E., Rutter, C., & Katon, 
W. (1997). Depressive symptoms and the cost of health services in HMO 
patients aged 65 years and older. A 4-year prospective study. Jama, 277(20), 
1618-1623.  
Valdizan, E. M., Diez-Alarcia, R., Gonzalez-Maeso, J., Pilar-Cuellar, F., Garcia-Sevilla, 
J. A., Meana, J. J., & Pazos, A. (2010). alpha(2)-Adrenoceptor functionality in 
postmortem frontal cortex of depressed suicide victims. Biol Psychiatry, 68(9), 
869-872. doi:10.1016/j.biopsych.2010.07.023 
Van der Kooy, K., van Hout, H., Marwijk, H., Marten, H., Stehouwer, C., & Beekman, A. 
(2007). Depression and the risk for cardiovascular diseases: systematic review 
and meta analysis. Int J Geriatr Psychiatry, 22(7), 613-626. 
doi:10.1002/gps.1723 
van der Laan, S., Lachize, S. B., Vreugdenhil, E., de Kloet, E. R., & Meijer, O. C. 
(2008). Nuclear receptor coregulators differentially modulate induction and 
glucocorticoid receptor-mediated repression of the corticotropin-releasing 
hormone gene. Endocrinology, 149(2), 725-732. doi:10.1210/en.2007-1234 
186 
 
Venzala, E., Garcia-Garcia, A. L., Elizalde, N., & Tordera, R. M. (2013). Social vs. 
environmental stress models of depression from a behavioural and 
neurochemical approach. Eur Neuropsychopharmacol, 23(7), 697-708. 
doi:10.1016/j.euroneuro.2012.05.010 
Volk, D. W., Eggan, S. M., & Lewis, D. A. (2010). Alterations in metabotropic glutamate 
receptor 1alpha and regulator of G protein signaling 4 in the prefrontal cortex in 
schizophrenia. Am J Psychiatry, 167(12), 1489-1498. 
doi:10.1176/appi.ajp.2010.10030318 
Vreugdenhil, E., Verissimo, C. S., Mariman, R., Kamphorst, J. T., Barbosa, J. S., 
Zweers, T., . . . Fitzsimons, C. P. (2009). MicroRNA 18 and 124a down-regulate 
the glucocorticoid receptor: implications for glucocorticoid responsiveness in the 
brain. Endocrinology, 150(5), 2220-2228. doi:10.1210/en.2008-1335 
Vyas, A., Mitra, R., Shankaranarayana Rao, B. S., & Chattarji, S. (2002). Chronic stress 
induces contrasting patterns of dendritic remodeling in hippocampal and 
amygdaloid neurons. J Neurosci, 22(15), 6810-6818. doi:20026655 
Vythilingam, M., Vermetten, E., Anderson, G. M., Luckenbaugh, D., Anderson, E. R., 
Snow, J., . . . Bremner, J. D. (2004). Hippocampal volume, memory, and cortisol 
status in major depressive disorder: effects of treatment. Biol Psychiatry, 56(2), 
101-112. doi:10.1016/j.biopsych.2004.04.002 
Walker, R. M., Rybka, J., Anderson, S. M., Torrance, H. S., Boxall, R., Sussmann, J. E., 
. . . Evans, K. L. (2015). Preliminary investigation of miRNA expression in 
individuals at high familial risk of bipolar disorder. J Psychiatr Res, 62, 48-55. 
doi:10.1016/j.jpsychires.2015.01.006 
Wan, Y., Liu, Y., Wang, X., Wu, J., Liu, K., Zhou, J., . . . Zhang, C. (2015). Identification 
of differential microRNAs in cerebrospinal fluid and serum of patients with major 
depressive disorder. PLoS One, 10(3), e0121975. 
doi:10.1371/journal.pone.0121975 
Wang, C., Feng, T., Wan, Q., Kong, Y., & Yuan, L. (2014). miR-124 controls Drosophila 
behavior and is required for neural development. Int J Dev Neurosci, 38, 105-
112. doi:10.1016/j.ijdevneu.2014.08.006 
Wang, M., Ramos, B. P., Paspalas, C. D., Shu, Y., Simen, A., Duque, A., . . . Arnsten, 
A. F. (2007). Alpha2A-adrenoceptors strengthen working memory networks by 
inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell, 129(2), 397-
410. doi:10.1016/j.cell.2007.03.015 
Wang, Q., Charych, E. I., Pulito, V. L., Lee, J. B., Graziane, N. M., Crozier, R. A., . . . 
Brandon, N. J. (2011). The psychiatric disease risk factors DISC1 and TNIK 
interact to regulate synapse composition and function. Mol Psychiatry, 16(10), 
1006-1023. doi:10.1038/mp.2010.87 
Wang, Y., Dye, C. A., Sohal, V., Long, J. E., Estrada, R. C., Roztocil, T., . . . 
Rubenstein, J. L. (2010). Dlx5 and Dlx6 regulate the development of 
parvalbumin-expressing cortical interneurons. J Neurosci, 30(15), 5334-5345. 
doi:10.1523/jneurosci.5963-09.2010 
Wang, Y., Liu, J., Gui, Z. H., Ali, U., Fan, L. L., Hou, C., . . . Li, Q. (2011). alpha2-
Adrenoceptor regulates the spontaneous and the GABA/glutamate modulated 
firing activity of the rat medial prefrontal cortex pyramidal neurons. Neuroscience, 
182, 193-202. doi:10.1016/j.neuroscience.2011.03.016 
187 
 
Warner, M. D., Peabody, C. A., Whiteford, H. A., & Hollister, L. E. (1988). Alprazolam as 
an antidepressant. J Clin Psychiatry, 49(4), 148-150.  
Webster, M. J., Knable, M. B., O'Grady, J., Orthmann, J., & Weickert, C. S. (2002). 
Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects 
with schizophrenia and mood disorders. Mol Psychiatry, 7(9), 985-994, 924. 
doi:10.1038/sj.mp.4001139 
Wei, Q., Lu, X. Y., Liu, L., Schafer, G., Shieh, K. R., Burke, S., . . . Akil, H. (2004). 
Glucocorticoid receptor overexpression in forebrain: a mouse model of increased 
emotional lability. Proc Natl Acad Sci U S A, 101(32), 11851-11856. 
doi:10.1073/pnas.0402208101 
Wilczynska, A., & Bushell, M. (2015). The complexity of miRNA-mediated repression. 
Cell Death Differ, 22(1), 22-33. doi:10.1038/cdd.2014.112 
Willner, P., Muscat, R., & Papp, M. (1992). Chronic mild stress-induced anhedonia: a 
realistic animal model of depression. Neurosci Biobehav Rev, 16(4), 525-534.  
Wilson, M. H., Puranam, R. S., Ottman, R., Gilliam, C., Limbird, L. E., George, A. L., Jr., 
& McNamara, J. O. (1998). Evaluation of the alpha(2A)-adrenergic receptor gene 
in a heritable form of temporal lobe epilepsy. Neurology, 51(6), 1730-1731.  
Winnay, J. N., Xu, J., O'Malley, B. W., & Hammer, G. D. (2006). Steroid receptor 
coactivator-1-deficient mice exhibit altered hypothalamic-pituitary-adrenal axis 
function. Endocrinology, 147(3), 1322-1332. doi:10.1210/en.2005-0751 
Winter, J., Jung, S., Keller, S., Gregory, R. I., & Diederichs, S. (2009). Many roads to 
maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol, 
11(3), 228-234. doi:10.1038/ncb0309-228 
Wirz-Justice, A. (2008). Diurnal variation of depressive symptoms. Dialogues Clin 
Neurosci, 10(3), 337-343.  
Wu, M., Piccini, M. E., & Singh, A. K. (2014). MiRNA detection at single-cell resolution 
using microfluidic LNA flow-FISH. Methods Mol Biol, 1211, 245-260. 
doi:10.1007/978-1-4939-1459-3_20 
Xie, X., Lu, J., Kulbokas, E. J., Golub, T. R., Mootha, V., Lindblad-Toh, K., . . . Kellis, M. 
(2005). Systematic discovery of regulatory motifs in human promoters and 3' 
UTRs by comparison of several mammals. Nature, 434(7031), 338-345. 
doi:10.1038/nature03441 
Yildiz, A., & Sachs, G. S. (2003). Do antidepressants induce rapid cycling? A gender-
specific association. J Clin Psychiatry, 64(7), 814-818.  
Yu, J. Y., Chung, K. H., Deo, M., Thompson, R. C., & Turner, D. L. (2008). MicroRNA 
miR-124 regulates neurite outgrowth during neuronal differentiation. Exp Cell 
Res, 314(14), 2618-2633. doi:10.1016/j.yexcr.2008.06.002 
Yuan, P., Tragon, T., Xia, M., Leclair, C. A., Skoumbourdis, A. P., Zheng, W., . . . 
Guitart, X. (2011). Phosphodiesterase 4 inhibitors enhance sexual pleasure-
seeking activity in rodents. Pharmacol Biochem Behav, 98(3), 349-355. 
doi:10.1016/j.pbb.2011.02.001 
Yuen, E. Y., Wei, J., Liu, W., Zhong, P., Li, X., & Yan, Z. (2012). Repeated stress 
causes cognitive impairment by suppressing glutamate receptor expression and 
function in prefrontal cortex. Neuron, 73(5), 962-977. 
doi:10.1016/j.neuron.2011.12.033 
188 
 
Zalachoras, I., Houtman, R., & Meijer, O. C. (2013). Understanding stress-effects in the 
brain via transcriptional signal transduction pathways. Neuroscience, 242, 97-
109. doi:10.1016/j.neuroscience.2013.03.038 
Zeller, E., Stief, H. J., Pflug, B., & Sastre-y-Hernandez, M. (1984). Results of a phase II 
study of the antidepressant effect of rolipram. Pharmacopsychiatry, 17(6), 188-
190. doi:10.1055/s-2007-1017435 
Zentner, G. E., & Henikoff, S. (2013). Regulation of nucleosome dynamics by histone 
modifications. Nat Struct Mol Biol, 20(3), 259-266. doi:10.1038/nsmb.2470 
Zhou, R., Yuan, P., Wang, Y., Hunsberger, J. G., Elkahloun, A., Wei, Y., . . . Manji, H. K. 
(2009). Evidence for selective microRNAs and their effectors as common long-
term targets for the actions of mood stabilizers. Neuropsychopharmacology, 
34(6), 1395-1405. doi:10.1038/npp.2008.131 
Zhu, Y., Kalbfleisch, T., Brennan, M. D., & Li, Y. (2009). A MicroRNA gene is hosted in 
an intron of a schizophrenia-susceptibility gene. Schizophr Res, 109(1-3), 86-89. 
doi:10.1016/j.schres.2009.01.022 
Ziats, M. N., & Rennert, O. M. (2014). Identification of differentially expressed 
microRNAs across the developing human brain. Mol Psychiatry, 19(7), 848-852. 
doi:10.1038/mp.2013.93 
Zwerling, C., Whitten, P. S., Sprince, N. L., Davis, C. S., Wallace, R. B., Blanck, P. D., & 
Heeringa, S. G. (2002). Workforce participation by persons with disabilities: the 
National Health Interview Survey Disability Supplement, 1994 to 1995. J Occup 
Environ Med, 44(4), 358-364.  
 
